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ABSTRAK 
Insiden kecederaan lutut "non-contact" dilaporkan lebih tinggi pada wanita 
berbanding lelaki. Bagi wanita, insiden ini adalah berkaitan dengan fasa kitaran haid. 
Memandangkan ini, kami menyiasat perkara berikut: (i) perubahan dalam kelalaian lutut 
dalam model tikus di bawah pengaruh seks-steroids yang berbeza; (ii ) Mekanisme 
perubahan dalam kelalaian lutut yang melibatkan ungkapan pembezaan reseptor relaxin dan 
( iii ) antara lutut asas kelalaian dan serum tahap hormon seks - steroids dan relaxin di fasa 
kitaran haid. Dalam bahagian pertama kajian, tikus ovariectomized WKY telah dibahagikan 
kepada kumpulan rawatan yang berbeza (n = 6 bagi setiap kumpulan): dos berbeza 17 β-
oestradiol, progesteron dan testosteron (125 & 250 µg/kg). Hormon telah disuntik 
subcutaneously selama 3 hari berturut-turut. Pada masa yang sama, steroid hormon 
penghalang reseptor dan penghalang enzim (ICI 182780, PHTPP, MPP, mifepristone, 
Flutamide, dan Finasteride) juga telah disuntik dengan rawatan agonist steroid masing-
masing. Pada masa yang sama, tikus-tikus utuh telah dikumpulkan berdasarkan peringkat 
kitaran oestrous mereka: proestrus , estrus, metestrous dan diestrus. Dalam ovariectomized 
steroid tikus dirawat dan utuh, pelbagai lutut gerakan (ROM) telah diukur dengan 
menggunakan goniometer kecil digital. Tikus-tikus telah dikorbankan dan ungkapan 
isoforms relaxin reseptor, RXFP1 dan RXFP2 mRNAs dan protein dalam ligamen lutut dan 
tendon ditentukan.Sementara itu, pada manusia, perubahan dalam kelalaian lutut di fasa 
kitaran haid diperhatikan dalam atlet wanita.Varus lutut dan valgus sudut telah ditentukan 
dalam atlet dan bukan atlet fasa kitaran haid mereka dengan menggunakan goniometer 
pemerintah ortopedik.Tahap serum oestrogen, progesteron dan relaxin telah ditentukan 
dalam subjek manusia di pelbagai fasa kitaran haid mereka.Hasil: data kami menunjukkan 
bahawa ROM lutut pada tikus telah meningkat dengan ketara berikutan rawatan oestrogen 
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dan progesteron bagaimanapun susut berikutan rawatan testosteron.Perubahan ROM lutut 
telah dihalang oleh antagonis terhadap reseptor oestrogen, progesteron dan androgen. ROM 
lutut adalah tinggi di peringkat proestrus dan diestrus kitaran oestrus. Progesteron dan 
oestrogen merangsang manakala testosteron menghalang perubahan RXFP1 dan RXFP2 
mRNA dan ungkapan protein yang dihalang oleh penghalang reseptor masing-
masing.Sementara itu, rawatan dengan relaksin meningkatkan ROM lutut oestrogen dan 
progesteron dirawat tetapi tidak testosteron dirawat ditunjukkan daripada perubahan 
pengawalaturan reseptor relaksin.Pada manusia, perbezaan yang signifikan dalam varus 
dan valgus sudut diperhatikan dalam wanita di pelbagai fasa kitaran haid dengan yang 
tertinggi pada fasa ovulasi dan haid kitaran.Kajian ini memberikan gambaran tentang kesan 
seks steroid pada ROM lutut dan RXFP1 dan ungkapan RXFP2. Dalam tikus, ungkapan 
peningkatan RXFP1 dan RXFP2 boleh menjelaskan peningkatan dalam lutut kelalaian 
bersama. Pada manusia, meningkat kelalaian di ovulasi dan fasa luteal pertengahan kitaran 
tersebut selaras dengan tahap yang tinggi oestrogen dan progesteron. Dalam kedua-dua 
tikus utuh dan manusia, korelasi yang kuat antara kelalaian lutut dan tahap serum relaksin 
telah diperhatikan. Penemuan kami boleh menjelaskan kelemahan yang mendasari dasar 
wanita terhadap kecederaan lutut bukan traumatik di fasa kitaran reproduktif mereka. 
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ABSTRACT 
The incidence of non-contact knee injury was reported higher in female than male. 
In female, the occurrence of this injury was related to different phases of the menstrual 
cycle. In view of this, we investigated the followings: (i) changes in knee laxity in rodent 
model under different sex-steroid influence; (ii) mechanisms underlying changes in knee 
laxity, which involves differential expression of relaxin receptors and (iii) correlation 
between knee laxity and serum levels of sex-steroids and relaxin at different phases of the 
menstrual cycle. In first part of the study, ovariectomized WKY rats were divided into 
different treatment groups (n=6 per group): different doses of 17 β-oestradiol, progesterone 
and testosterone were administered. The hormones were injected subcutaneously for 3 
consecutive days. In parallel, steroid hormone receptor blockers and enzyme inhibitor (ICI 
182780, PHTPP, MPP, Mifepristone, Flutamide, and Finasteride) were also injected with 
the respective agonist. In parallel, intact rats were grouped based on their oestrous cycle 
stages: proestrus, estrus, metestrus and diestrus. In ovariectomized steroid treated and intact 
rats, knee range of motion (ROM) was measured by using a digital miniature goniometer. 
The rats were sacrificed and expression of relaxin receptor isoforms, RXFP1 and RXFP2 
mRNAs and proteins in knee ligaments and tendons were determined. Meanwhile, in 
humans, changes in knee laxity were observed at different phases of the menstrual cycle in 
the female athletes.  The knee varus and valgus angles were determined at different phases 
of the menstrual cycle by using an orthopedic goniometer ruler. Blood was withdrawn and 
serum levels of oestrogen, progesterone and relaxin were determined in human at different 
phases of their menstrual cycle. Our findings showed a significant increase in knee ROM in 
rats following oestrogen and progesterone treatment however was decreased following 
testosterone treatment. Changes in knee ROM was antagonized by the concomitant 
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administration of oestrogen, progesterone and androgen receptor antagonists. Knee ROM 
was high at proestrus and diestrus stages of the oestrous cycle. Progesterone and oestrogen 
up-regulated while testosterone down-regulated RXFP1 and RXFP2 mRNA and protein 
expressions which were antagonized by the respective steroid hormone antagonist. 
Meanwhile, relaxin administration increases knee ROM in oestrogen and progesterone 
treated but not testosterone treated groups indicating relaxin receptor up-regulation. In 
humans, significant difference in knee varus and valgus angles were observed in female 
athletes and non-athletes at different phases of the menstrual cycle which was the highest in 
the ovulatory and menstrual phases. Non-athletes have higher medial and lateral knee laxity 
as compared to athletes. This study has provided an insight into the mechanism underlying 
sex-steroid control  of knee ROM via modulating the expression of RXFP1 and RXFP2 
receptors. In rodents, increased RXFP1 and RXFP2 expressions could contribute to 
increase in knee laxity. In humans, the increase in laxity at ovulatory and mid-luteal phases 
of the cycle was consistent with high level of oestrogen and progesterone. In both intact 
rats and humans, strong correlations was noted between knee laxity and serum relaxin 
levels. Our study has provided the basis underlying female susceptibility towards non-
traumatic knee injury at different phases of their reproductive cycle. 
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1.1 Introductions 
 
Musculoskeletal injuries are common problem among athletes and are not gender 
specific (Arendt et al., 1999), however, female have been reported to have higher risk of 
ligament injury as compared to male (Ireland, 2002; Myklebust et al., 1998). Sprains of the 
knee joint are common in athletes who participate in direct contact sports such as football 
or soccer, who are more likely to injure their collateral and anterior cruciate ligaments. It 
has been proposed that the incidence of knee injury in female is related to phases of the 
menstrual cycle. The softening of ligaments in the luteal phase of the cycle has long been 
attributed to an increase in collagenase enzyme activity (Qin et al., 1997). An increasing 
trend of  non-contact knee injury has also been reported in the ovulatory phase and this 
decrease during the follicular phase however due to the conflicting reports, no conclusion 
could be drawn from the previous studies on the effect of menstrual cycle phases on this 
injury in female (Wojtys et al., 1998).  
 
The amplitude of joint laxity is related to the joint movement which was limited by 
ligaments and tendons. The relationship between different phases of menstrual cycle and 
knee joint laxity is still uncertain. Some researchers demonstrated that no association 
between knee laxity and phases of the menstrual cycle (Belanger et al., 2004; Karageanes et 
al., 2000). Meanwhile, knee laxity has been reported to be high in the ovulatory phase with 
a peak in oestrogen concentration (Heitz et al., 1999; Romani et al., 2001). Studies have 
revealed that these differences could be related to the differential expression of sex-steroid 
receptors in the skeletal muscle (Dragoo et al., 2003; Lemoine et al., 2003) in both humans 
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and animals (Sciore et al., 1998), which could explain differences in the incidence of non-
contact knee injury at different phases of the cycle.  
 
Fluctuation in relaxin receptor expression in the knee was postulated based on the 
observed fluctuation in its expression in the uterus, being the lowest during the proliferative 
phase and rises sharply at the time of ovulation (Bond et al., 2004). In neonatal porcine 
uterus, oestrogen increases RXFP1mRNA expressions, while in cervix, oestrogen increases 
and relaxin decreases these receptors expression (Yan et al., 2008). During late pregnancy 
in mice, relaxin has no influence on RXFP1 expression (Siebel et al., 2003). Progesterone 
has been reported to increase the expression of RXFP1 in the pregnant rat uteri (Vodstrcil 
et al., 2010a ) while oestrogen was found to regulate RXFP1 mRNA expression in human 
cervix at term (Maseelall et al., 2009). Relaxin receptors expression may vary in the 
musculoskeletal tissues and these changes may affect joint laxity. Nonetheless, the effect of 
sex steroids on joint laxity in female remains inconclusive. 
The laxity of the knee joint could potentially be affected by relaxin. Currently, little 
is known with regards to RXFP1 and RXFP2 expressions in the knee. Relaxin levels rise in 
the second half of the menstrual cycle in parallel with an increase in progesterone level. 
Wang et al. (2009b) reported relaxin receptors were expressed in knee fibrocartilage in 
mouse. In humans relaxin receptor expression have been identified in the ACL in male and 
female knees (Faryniarz et al., 2006), with higher expression in female (Dragoo et al., 
2003). This gender specific difference suggests the influence of circulating female sex 
hormones on the expression of relaxin receptor in the knee. In view of that relaxin has been 
implicated in controlling joint laxity and relaxin receptor expression is under sex-steroid 
influence, therefore correlation between plasma levels of relaxin and sex-steroids in female 
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need to be established in order to gain insight into the possible association between these 
hormones in the pathogenesis underlying non-traumatic knee injury in female. 
 
Knee joint relies on ligaments and surrounding muscles for stability. Sex-steroids 
have been reported to influence strength and laxity of knee ligaments and possibly affecting 
the muscles. The incidence of knee injury as a result of anterior cruciate ligament (ACL) 
tear has been widely reported and this was high during the luteal phase of the menstrual 
cycle (Pehrsson et al., 2007). Relaxin receptors have been reported to be expressed in 
guinea pig ACL (Dragoo et al, 2003). Concomitant expression of relaxin and oestrogen 
receptors have also been reported in the ACL (Fairyniarz et al, 2006). Apart from ACL, the 
expression of relaxin receptors in other knee structures including patellar tendon and 
collateral ligaments is currently unknown. Together with ACL, collateral ligaments 
participate in the control of knee stability during movement. Patellar tendon is an important 
part of the extensor mechanism of the lower extremity and is also involved in preventing 
excessive knee hyperextension.  
We hypothesized that the expression of relaxin receptors, RXFP1 and RXFP2 in the 
knee collateral ligaments, patellar tendon and hamstring muscles is under the influence of 
sex-steroids (oestrogen, progesterone and testosterone), and changes in these receptors 
expression may explain changes in knee laxity under different sex-steroid effect and at 
different phases of the menstrual/ oestrous cycle. We further hypothesized that relaxin 
levels correlate with the levels of sex-steroids in plasma and this would complement the 
influence of sex-steroids on the changes in RXFP1 and RXFP2 expressions. We also 
hypothesized that there is a correlation between rotational laxity of the knee and the levels 
of circulating sex-steroids and relaxins in females which could explain changes in knee 
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laxity at different phases of the menstrual cycle which were observed in both athletes and 
non-athletes females. In this study, ACL was not investigated since the relationship 
between sex-steroids and changes in ACL laxities have been well studied previously. 
The specific objectives of this study are:  
1- to identify the effects of sex steroids (oestrogen, progesterone, and testosterone) on 
the expression of RXFP1 and RXFP2 in the patellar tendon, collateral ligament, and 
hamstring muscles in rodents. 
2- to confirm the effect of individual sex steroids on RXFP1 and RXFP2 expressions 
in the patellar tendon, collateral ligaments and hamstring muscles via concomitant 
administration of their respective antagonists. Additionally, the effect of sex-steroids 
with and without their respective antagonist on knee passive range of motion (ROM) 
will also be investigated.   
3- to observe the relationship between plasma sex-steroid and relaxin levels with the 
expression of relaxin receptor isoforms and changes in knee passive ROM at different 
phases of oestrous cycle of rats.   
4- to investigate changes in medial and lateral knee laxity during phases of the 
menstrual cycle in athletes and non-athletes and to observed the correlation between 
serum oestrogen, progesterone, testosterone and relaxin levels with knee laxity at 
different phases of menstrual cycle in both groups. 
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1.2 Significance of the study 
 
Many common non-traumatic joint injuries in females especially during sports are 
attributed to the fluctuation in the reproductive hormones profiles. Women at a specific 
period of their menstrual cycle may be more prone to some form of non-traumatic knee 
injury. This study identifies changes in knee laxity and explore mechanisms underlying 
these changes which was related to differential expression of relaxin receptor isoforms, 
RXFP1 and RXFP2 and the fluctuation of sex-steroids and realxin levels. In view of this, 
detailing the mechanism underlying sex steroid influence on knee joint laxity is important 
in order to explain the high incidence of knee-related injury of the reproductive age female 
especially during sports. This information is valuable to the athletes and trainers in 
dedicating a specific time during the menstrual cycle period to performed exercise in order 
to reduce the risk of the non-traumatic joint injuries. 
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2 CHAPTER 2  LITRATURE REVIEW 
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2.1 Introductions 
 
This chapter presents information background, which is tailored to the specific 
objectives of this study. 
2.2 Overview of non-traumatic knee injury in female 
The most common injuries related to joints have been reported to involve the ankles 
and the knees. Knee injuries which occur during sports is mostly associated to sub-luxation 
or dislocation. In view of this, a clear understanding on the injury pattern, the mechanisms 
underlying this injury and the risk factors is crucial in exercise physiology and sports 
medicine (Junge et al., 2008). Knee injuries undoubtedly affect the athlete performances. 
The most common type of injuries are the non-contact, which occurs during activities such 
as decelerating, landing, cutting, and pivoting (Traina & Bromberg, 1997). The risk factors 
for this injury could be related to the equipments, shoe-surface and internal factors 
including the anatomical and hormonal defects (Griffin et al., 2000).  
A remarkable number of non-traumatic injuries among women during sports over the 
years has led to multiple studies being performed in order to better understand the 
underlying mechanism involved. Females are known to be 2 to 9 times more vulnerable 
than males towards knee injury (Arendt et al., 1999; Dragoo et al., 2009). In female, the 
occurrence was related to different phases of the menstrual cycle (Dragoo et al, 2011a). 
Several reports indicated that high incidence of non-contact knee injury happened during 
the follicular phase of the cycle, while others reported that the incidence is the highest at 
ovulation and in the luteal phase of the cycle (Shultz et al., 2004; Shultz et al., 2005). 
These raised the possibility that female sex hormones could be involved in this injury. The 
role of sex steroids on knee injury remains poorly understood and represent an area for 
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investigation. Table 2-1 below summarizes the study related to sex-steroid influence on 
knee injury in female. 
 
Table 2-1 Previous reported data of the non-traumatic knee injury and menstrual cycle 
phases 
Author Year Target  Sampling Model Hormone Conclusion  
(Fouladi 
et al.) 
2012 Knee joint 
position 
sense (JPS) 
menstrual 
cycle phases 
healthy female 
athletes 
oestrogen/ 
progesterone 
different levels of knee 
JPS across a menstrual 
cycle 
(Ruedl et 
al.) 
2011 ACL injury questionnaire skiers female 
non-contact ACL 
injury 
NI ACL injuries in skiers 
are intrinsic / extrinsic 
risk factors 
(Dragoo 
et al.) 
2011 ACL injury mid-luteal 
phase/ 
questionnaire 
female athletes Relaxin/proge
sterone 
correlation progesterone 
/relaxin with ACL injury 
(Montgo
mery & 
Shultz) 
2010 knee flexors 
and 
extensors 
menstrual 
cycle phases 
active women oestradiol/ 
progesterone 
/testosterone 
no change from time of 
menses Isometric knee-
extension /flexion torque 
(Cesar et 
al.) 
2011 knee valgus 
angles 
menstrual 
cycle phases 
non-athletic 
females 
progesterone valgus angles were less 
in the luteal phase 
compared to both 
follicular phases 
(Bell et 
al.) 
2009 hamstring 
muscle 
properties 
change 
across 
menstrual 
cycle 
menstrual 
cycle phases 
Normal women oestrogen hamstring muscle 
stiffness not changed in 
menstrual cycle/ 
extensibility increased at 
ovulation with oestrogen 
increases 
(Park et 
al.) 
2009 knee laxity 
and stiffness 
menstrual 
cycle phases 
healthy female Oestradiol/ 
progesterone 
increased knee joint 
laxity at ovulation 
(Kerksic
k et al.) 
2008 muscle 
injury, in 
eccentric 
exercise 
NI healthy men and 
eight women 
Oestradiol/ 
lactate 
dehydrogenas
e 
muscle strength changes 
were similar among 
genders 
(Beynno
n et al.) 
2006 ACL injury menstrual 
cycle phases 
Female 
recreational 
alpine skiers 
progesterone preovulatory phase were 
more likely to ACL tear 
than postovulatory phase 
(Agel et 
al.) 
2006 ACL injury 
and ankle 
sprains 
menstrual 
cycle phases 
Female basketball 
and soccer 
players 
NI ACL injury /ankle 
sprains rate not linked to 
hormonal therapy 
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2.2.1 Anatomy of the knee joints 
Knee being one of the largest joint in the body is vital for movement. The anatomy 
of this joint is reflective of its function in ambulation. The knee joint is a relatively complex 
anatomical structure. Knee joint connects thigh bone (femur) to the shin bone (tibia) with 
smaller bone that runs alongside the tibia (fibula) and the knee cap (patella) that make the 
knee joint. The patella bone is located into the thin anterior wall of the knee joint capsule. 
The ligaments, tendons, and capsule are components of joints guard the joint stiffness and 
laxity (Schmitz et al., 2013). In addition, knee joint is controlled by a variety of 
surrounding connective tissues including ligaments, muscles, tendons, menisci, cartilage, 
and bursae to maintain stability.  
The ligaments surrounding the knee connect bones and provide stability by limiting 
movements and together with menisci and bursae protect the articular capsule. These 
ligaments consist of: cruciate ligaments that avoid femur from sliding forward / backward 
on the tibia and collateral ligaments that avoid femur from sliding side to side. Collateral 
ligaments provide additional stabilization of the knee and direct movement in a correct 
direction. They are divided into medial and lateral collateral ligaments that resists knee 
rotational movement. The suprapatellar bursae prevents the knee from being pinched during 
extension (Gill et al., 2009). Tendons connect the bones to the leg muscles that move the 
knee joint. A tendon that extends down from the quadriceps muscle incorporate the patella 
bone and attach to the tibia, providing extension at the knee joint. The patellar tendon is 
also called patellar ligament because it connects patella to the tibia (Dye et al., 1998).  
The elastic cartilage ensures knee movement and protects the bone to slide easily of 
the joint surfaces. The menisci protects the ends of bones from rubbing on each other and to 
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effectively deepen the tibial sockets into which the femur attaches. Numerous bursae, or 
fluid-filled sacs, help the knee move smoothly (Lewin, 1952). Knee joint consist of 
connective tissue with extensive collagen fibres containing cartilage-like cells. Strong 
fibres run along the menisci from one attachment to the other, while weaker radial fibres 
are interlaced with the former. The joint is bathed in synovial fluid, which is contained 
inside the joint capsule. The muscles surrounds the knee consist of the hamstrings, 
quadriceps, and calf muscles. These muscles support knee to flex, extend, stabilize, and 
work in groups to allow the body to perform important movements such as walking, 
running, kicking, and jumping (Amis et al., 2003). 
Knee is one of the most distressed joints in the physical activity due to large extreme 
of activities and its principal movements (flexion/extension/abduction/adduction). This 
joint was mainly designed to support locomotion movement and weight stability of the 
body posture. However, it is especially unstable medially and sideways. The knee traumatic 
and non-traumatic injuries caused by ligamentous instability can be evaluated to determine 
any differences in their stability. Ligamentous instability can be classified as either straight 
or rotatory instability (Granchi et al., 2008). Special tests for ligaments assessment exists to 
disclose of knee joint function instability. Lachman drawer and pivot-shift test are 
performed to elicit cruciate ligaments laxity, while varus/valgus stress test for assessment 
of collateral ligaments integrity. These tests are usually performed with the knee in 
extension at 90 and 30 degrees (Devan et al., 2004). 
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Figure 2-1 Knee anatomical perspective (www.webmd.com) 
 
There are evidences to suggest that knee laxities are gender specific and the effect 
on female knee are greater than male (Hsu et al., 2006; Wojtys et al., 2003). 
Additionally, greater knee and ankle laxities have been reported in women as compared 
to men (Beynnon et al., 2005). Range of motion (ROM) is defined as a movement 
potential of a joint from full flexion to full extension. Many reports have suggested that 
hormonal fluctuation could affect knee laxity and subsequently knee range of motion 
(ROM). Overuse, age and traumatic injuries can cause structural damage to the knee 
that may limit its function. Therefore, a thorough understanding of the anatomy of the 
knee is essential to properly diagnose and treat disorders related to knee joint 
movements (Herrmann et al., 2013).  
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2.2.2 Physiological control of knee joint movement 
The knee joint is an organ, which simultaneously guarantees stability and 
movement. The tissues surrounding this joint are highly vascularised and the joint cavity 
contains fluid that have important roles in many physiological function and metabolism of 
the joint. The fluid or exudates produced by the synovial layer of the tissues distribute 
mineral and nutrients to the different parts of the joint. The decrease in synovial blood flow 
may cause reduced joint irrigation and may contribute to tissue injury during trauma, where 
this may also be related to vasoconstriction (Ar'Rajab et al., 1996).Adequate blood supply 
is also important to deliver hormones to their specific receptors in different parts of the 
joints which regulates laxity, thus its movement(Junqueira et al., 1986). Knee stability is 
also controlled by the nerve innervating the knee joint. Proprioceptors are found in the knee 
which sense changes in joint position and the information is relayed via the spinal nerve to 
the higher centre in the cerebelum (Marieb, 2009). Input from the higher centre is sent to 
the muscles that control knee joint stability which is achieved via varying degree of 
contraction of different groups of muscles (Marieb, 2009). Female is more susceptible to 
various knee disorders such as arthritis (Kumar et al., 2012). Pathophysiological changes 
including degenerative disorders could affect joint metabolism and can cause joint 
inflammation. In addition, collagen content of the knee could also be affected therefore 
may interfere with knee laxity and joint movements. 
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Figure 2-2 Motion degrees of human 
kneehttp://www.jointinjury.com/knee 
Figure 2-3 Knee rotational movement 
www.faculty.utpa.edu/rafree/res/biomechanics 
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2.2.3 Knee movement and its connective tissue mechanism 
 
Tendons and ligaments are elastic connective tissue surrounding the knee joint that 
give support and are vital for knee movements. Knee ligaments connect the thigh to lower 
leg bones(Marieb & Hoehn, 2013). Sprains or tears of these ligaments are common in 
sports injury. Athletes who participate in direct contact sports such as football or soccer are 
more likely to injure their collateral ligaments and anterior cruciate ligament (Dragoo et al., 
2011b). Knee joint relies on these ligaments and the surrounding muscles for stability. 
Cruciate ligaments are found inside and collateral ligaments (medial and lateral) are found 
on the sides of the knee (Snell, 2011). The cruciate ligaments control back and forth motion 
while collateral ligaments control sideway motion of the knee. Tendons are stiff cords of 
tissue that connect muscles to bones. The patellar tendon is an important part of the 
extensor mechanism of the lower extremity (Snell, 2011). Meanwhile, the role of the 
hamstring muscles as a dynamic stabilizer of the knee joint rests in its importance as a joint 
compressor and restraining mechanism for anterior motion of the tibia on the femur. These 
complexes of connective tissues participate in the control of knee stability during 
movement and support it against unusual movement (Marieb, 2009). Cruciate and collateral 
ligaments prevent knee anterior-posterior and lateral/medial dislocation respectively. Basic 
movement of the knee joint is shown in Figure 2-2 and 2-3 while Figure 2-4 shows the 
location of the collateral ligament and patella tendon.  
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Figure 2-4 Knee patellar tendon and collateral ligament 
(Dehghan et al., 2013b) 
2.3 Menstrual cycle 
Menstrual cycle is the changing phase that happens in the uterus and ovary for sexual 
reproduction purposes and occurs only in parturient female and other female primates. This 
necessary period need to produce oocytes and prepare the uterus for pregnancy (Johnson & 
Martin, 2012). The length of the cycle varies greatly among women and fluctuates 25 to 35 
days, with 28 days nominated as an average length. Based on the events in the ovary, each 
cycle can be divided into three phases; the follicular phase, ovulation, and luteal phase, 
which are controlled by normal hypothalamic-pituitary-ovarian axis (Klump et al., 2013). 
The menstrual cycle begins from the first day of bleeding and is associated with increasing 
amounts of oestrogen in the follicular phase. Approximately mid-cycle, 24–36 hours after 
the luteinizing hormone (LH) surges, the dominant follicle releases an egg in an event 
called ovulation(Johnson & Martin, 2012). The corpus luteum which is formed post-
ovulation produced large amount of progesterone where under progesterone influence, the 
endometrium undergoes changes to the receptive state in preparation for embryo 
implantation and the establishment of pregnancy (Marieb, 2009). In an event of no 
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implantation, the corpus luteum degenerates which causes a sharp drop in both oestrogen 
and progesterone levels that precede the onset of the next cycle (Sherwood, 2011). Figure 
2-5 shows changes in the hormonal profiles (LH, FSH, oestrogen and progesterone), ovary 
and endometrium throughout the menstrual cycle.  
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Figure 2-5 Changing hormone levels, ovarian and uterine events during the menstrual cycle 
dentistryandmedicine.blogspot.com 
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2.4 Oestrous cycle 
Non-primate mammals such as rodents do not display menstrual bleed or menstrual 
cycle. In these animals, the reproductive cycle is known as oestrous cycle. In rodent, 
oestrous cycle occurs 4 to 5 days, which can be divided into proestrous, oestrus, metestrous 
and diestrous (Staley & Scharfman, 2005). Proestrous occurs in the first 12 hours of the 
cycle where oestrogen levels peak and was confirmed from the presence of a predominantly 
nucleated epithelial cells. Oestrus phase occurs 12 hours following proestrous and is 
indicated by the presence of cornified cells in the vaginal smear. Ovulation occurs at the 
beginning of oestrus and the end of proestrus phases. Meanwhile, a combined of leucocyte, 
cornified and nucleated epithelial cells in the vaginal smear indicate metestrous phase. This 
phase occurs for 21-hour period following oestrus. The diestrous phase has the longest 
interval time of 57 hours and during this phase, vaginal cells displays predominantly 
leucocytes. Corpus luteum activity occur in metestrous and diestrous phases associated with 
high progesterone secretion. Due to its short cycle length, rat is a perfect animal model for 
investigating changes that occur during the reproductive cycle (Marcondes et al., 2002).  
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Figure 2-6 Human and rat reproductive menstrual cycle 
pubs.niaaa.nih.gov 
 
2.5 Overview of Sex-Steroid Biochemistry and Physiology 
In females, sex-steroids are produced from the adrenal glands, ovaries and regulate 
wide range of physiological functions. The major female sex-steroids are oestrogen and 
progesterone, testosterone are also produced in a small amount by the ovary and adrenal 
glands. Steroid hormones bind to steroid hormone binding globulin (SHBG) where it is 
transported to the target organs through the circulatory system to the specific site of actions. 
The binding of sex hormones to SHBG are of different affinity. The free hormones can 
leave the circulation and enter into the target cells where they can bind to specific 
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intracellular receptors to initiate the biochemical expression of specific genes (Devlin, 
2011).  
Free sex hormones, being lipophilic can readily cross the cell membranes and bind to 
the intracellular receptors. Steroid receptors are markedly different from gonadotropin 
receptors, where the latter are localized in the cell membrane and have several second-
messenger systems as mediators of receptor binding (Marieb, 2009). Following receptor 
binding, steroid-receptor complex crosses the nuclear membrane to bind to the nuclear 
target which results in the expression of specific genes that can be translated to specific 
steroid actions (Devlin, 2011). Steroids regulate largely gene expression at a transcriptional 
level. mRNAs are then exported to the cytoplasm, where protein synthesis takes place, 
resulting in alterations in cell growth or physiology that are characteristic of the steroid 
hormone for that target issue. Figure 2-7 shows the mechanism by which sex-steroid exerts 
its intracellular effect. 
Upon release into the circulation, the free steroid hormones exert a negative feedback 
effect on the pituitary and hypothalamus. At a very high dose however, a positive feedback 
effect occur on LH secretion from the pituitary gland, which in turn induces ovulation 
(Devlin, 2011). In the second half of the menstrual cycle, oestrogenis also produced by the 
corpus luteum (Marieb, 2009). Progesterone which is produced by steroidogenic activity in 
the ovary is also a major female sex hormones and is important in the maintenance of 
pregnancy (Devlin, 2011). This hormone acts on the reproductive organs, brain, kidney, 
lungs and joints especially during pregnancy (Santiago et al., 2001). Elevation of the basal 
body temperature following ovulation is due to the thermogenic effect of progesterone in 
the hypothalamus. Testosterone is an anabolic hormone which participates in multiple 
organs functions in male and is also secreted in a small amount in female mainly by the 
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ovaries and adrenal glands (Cox & John-Alder, 2005). In female, testosterone is involved in 
decidualisation while adrenal androgens participate in pubic hair growth and in the post-
menopausal period, is a major precursor for oestrogen (Devlin, 2011).  
 
 
 
Figure 2-7 Sex steroid hormone response 
(www.thepepproject.net) 
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2.5.1 Sex-steroids and Knee Laxity 
Females are exposed to rhythmic rise and fall in the levels of oestrogen and 
progesterone throughout the course of the menstrual cycle. These hormones can influence 
metabolism of the anterior cruciate ligament (Romani et al., 2003; Yu et al., 1999). Sex 
steroids fluctuation during the menstrual cycle has been known to be a risk factor for ACL 
injury in females (Slauterbeck et al., 2002). Beside progesterone, oestrogen has also been 
reported to have influence on knee laxity. This was based on the findings by Dragoo et al, 
(2003) who reported that simultaneous administration of oestrogen and relaxin in guinea 
pigs resulted in increased ligament laxity. Meanwhile, in female, testosterone which levels 
fluctuates during the menstrual cycle (Dawood & Saxena, 1976) promotes increase muscle 
and bone mass and prevent osteoporosis (Cox & John-Alder, 2005; Mooradian et al., 
1987). Testosterone has also been used for postmenopausal hormone therapy in female 
(Bolour & Braunstein, 2005). 
2.6 Relaxin 
Relaxin, a polypeptide hormone which level rises in the second half of the menstrual 
cycle increases with a rising level of progesterone. This hormone (with a classical structure 
of insulin) interacts with G-protein-coupled receptors (GPCRs) which exist in various 
tissues, including the musculoskeletal and non-musculoskeletal systems. Meanwhile, the 
presence of relaxin receptor as evidence from relaxin binding assay and immunostaining 
has been reported higher in female ACL as compared to male (Faryniaz et al, 2006), which 
suggest that female sex-steroids could affect relaxin receptor expression in the ACL. 
Relaxin has been widely implicated in the control of knee joint laxity.  
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 Relaxin, the mammalian 6-kDa heterodimeric polypeptide hormone, is a member of 
the insulin-like superfamily (HISAW, 1926) and consists of seven peptides of high 
structural but low sequence similarity. Relaxin is belongs to a family of peptide family 
hormones, which is believed to have evolved from insulin early in the evolution of 
vertebrates (Bathgate et al., 2006). Relaxin family peptides interact with their receptors, 
which exist in various tissues, including musculoskeletal and non-musculoskeletal systems.  
 The actions of relaxin receptor are mediated by different signalling pathways (Kong 
et al., 2010). Relaxin plays an essential role in the biological processes such as metabolism, 
growth, pregnancy, and parturition in different species including humans and rodents. 
Relaxin circulates in these species during pregnancy emanating from the corpus luteum 
(Conrad & Baker, 2013) and placenta (Goh et al., 2013), however temporal pattern of 
change and serum concentrations of this hormone are different. In rodents, circulating 
relaxin peak concentrations at the end of pregnancy reaches 100 ng/ml, two times greater 
than in human (Sherwood OD, 1994). While relaxin plays important role in collagen 
catabolism of the pubic symphysis during gestation in lower mammals such as mice and 
rats (Samuel et al., 1998), the role of this hormone on pubic symphysis of human is 
however unknown (Hashem et al., 2006).  
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Figure 2-8 Relaxin structure 
 
 
2.6.1 Relaxin roles in different tissues 
Several studies have highlighted the therapeutic potential of relaxin for ectopic 
pregnancy, male infertility, and heart failure, cardiovascular and musculoskeletal diseases. 
Currently, there are seven known relaxin family peptides which are structurally related to 
insulin which include relaxin (RLN)1, RLN2, RLN3, insulin-like peptide (INSL)3, INSL4, 
INSL5 and INSL6 (Bathgate et al., 2013). RLN1 and RLN2 are strong regulators of 
collagen expression and metabolism in fibroblasts, andare differentially expressed in the 
corpus luteum, decidua, and endometrium, as well as prostate tissue while RLN3 is specific 
to the brain (Sherwood, 2005). RLN1 and RLN2 reconcile the hemodynamic changes 
occurring during pregnancy such as cardiac output, renal blood flow, and arterial 
compliance (Kirk, 2011) as well as weakening the pelvic ligaments for parturition in 
species such as guinea pigs and mice (Sherwood OD, 1993). RLN3 is a highly conserved 
neuropeptide in vertebrates, and is involved in a wide range of neuroactivities such as 
response to stress and cognition, as well as in neurological disease (Smith et al., 2011).  
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Relaxin binds to relaxin family peptide receptors (RXFP) and exerts its action 
through a ligand-receptor system in multiple pathways. The relaxin receptor is involved in 
signal transduction between extracellular/intracellular domains. Relaxin1 to 4 hormones are 
ligands for the RXFP1, RXFP2, RXFP3, and RXFP4, respectively (Figure 2.8). This family 
peptides act on four GPCRs (LGR7, LGR8, GPCR135, and GPCR142) (Kong et al., 
2010).RXFP1 and RXFP2 are composed of large extracellular domains which encompass 
of leucine-rich repeats. On the other hand, RXFP3 and RXFP4 proteins are more similar to 
small peptide ligands (Summers et al., 2009). Recently, it has been shown that there is a 
difference in the ligand binding mode between RXFP1 and RXFP2 (Scott et al., 2012). 
RXFP1 and RXFP2 exist in uterus, cervix, vagina, brain, and heart of a number of animal 
species. However, production of these proteins differs among tissues of various species. 
For example RXFP1 is expressed in rats and mice myometrium (Vodstrcil et al., 2010b), 
whereas in human, this receptor is mainly localized to the endometrium (Campitiello et al., 
2011). Moreover, RXFP1 is expressed in the rats and mice heart localized to the atria 
where it mediates positive inotropic and chronotropic responses (Piedras-Renteria et al., 
1997), while there is currently no report of this receptor binding or function in the human 
heart.  
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Evidence also suggests that the functional domains of RXFP1, the cell type in 
which it is expressed, and the ligand used to activate the receptor, all have important roles 
in the musculoskeletal system (Figure 2.9). Relaxin alters cartilage and tendon stiffness by 
activating collagenase. Relaxin is also involved in bone remodelling process and in healing 
of injured ligaments and skeletal muscles (Dragoo et al., 2009; Li et al., 2005). The soft 
tissue-healing cascade is composing of three phases: inflammation, regeneration, and 
fibrosis. Relaxin is a regulator of both inflammation and fibrosis (Mu et al., 2010). Relaxin 
also acts as antifibrotic agent, and favours muscle regeneration and against muscle fibrosis 
to promote regrowth of myofibers in skeletal muscle healing. 
 
 
Figure 2-9 Interaction of RLN1, LN2, and RLN3 proteins 
with their receptors RXFP1, RXFP2, and RXFP3, 
respectively, as well as with insulin growth factor (INSL3) 
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Figure 2-10 A summary of relaxin role in the locomotor system 
(Dehghan et al., 2013b) 
 
2.6.2 Relaxin roles in musculoskeletal tissues 
2.6.2.1 Relaxin effects on joints 
 
RXFP1 and RXFP2 receptors orchestrate several activities in joints laxity through 
combination with sex-steroids hormones. Relaxin in combination with oestrogens may also 
have therapeutic value in the treatment of rheumatoid arthritis (RA) (Ho et al., 2011; 
Santora et al., 2005). RA is a chronic and systemic inflammatory disorder that may affect 
many tissues and organs, but also causes bone destruction through synovial hypertrophy. 
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However, the incidence and severity of this disease during pregnancy is lower than normal. 
During pregnancy, relaxin and oestrogen levels in the serum are elevated leading to 
decrease in inflammation in RA patients (D'Elia et al., 2003; Ho et al., 2011). Relaxin 
exerts its anti-inflammatory effect through down-regulation of neutrophil function (Bani et 
al., 1998) and stimulates leukocyte adhesion and migration in human mononuclear cells 
(Figueiredo et al., 2006). A combined treatment using relaxin and oestrogen appears to 
reduce circulating tumor necrosis factor (TNF)-α level in rat adjuvant-induced arthritis 
model of RA and increased the anti-inflammatory cytokine IL-10 in human 
cells.(Figueiredo et al., 2006; Santora et al., 2005). In view of this, relaxin has a potential 
beneficial effect in the treatment of synovial diseases. 
2.6.2.2 Relaxin effects on bones 
Relaxin along with hormones such as oestrogen and growth factors such as TGF-β 
help orchestrate the bone remodelling process. These factors regulate a cytokine system 
containing three fundamental molecules, the receptor activator of nuclear factor κB ligand 
(RANKL), RANK, and osteoprotegerin (OPG). In the RANKL/RANK/OPG system, 
RANKL on the preosteoblastic/stromal cells binds to its receptor (RANK) on the 
osteoclastic precursor cells and induces expression of a variety of genes to provide the 
crucial signal to drive osteoclast recruitment and development (Facciolli et al., 2009). OPG 
regulates the system through blocking the effects of RANKL and interfering with RANK 
signalling.  
 
Relaxin facilitates differentiation of peripheral blood mononuclear cells (PBMCs) 
into mature osteoclasts during osteoclastogenesis by stimulating osteoblastic/stromal cell 
production, while oestrogen inhibits this process through increasing OPG production 
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(Facciolli et al., 2009). Therefore, relaxin is one of the osteoclast-activating factors that 
increases bone resorption. It is also overexpressed in tumours that promote growth, 
differentiation, and invasiveness, which lead to osteolytic metastases (Clezardin & Teti, 
2007). Together, these data indicate a possible role of relaxin in osteoclastogenesis 
(Facciolli et al., 2009; Ferlin et al., 2010). Relaxin 2 (RLN2) regulates bone metabolism 
and proliferation in human osteoblasts. Stimulation of osteoblasts with RLN2 activates 
adenylate cyclase and increases cAMP production by G- proteins and thereby increases cell 
proliferation (Ferlin et al., 2009). Previous studies have identified an inactivating mutation 
in the RXFP2 gene (T222P), which caused idiopathic osteoporosis in young men through 
functional osteoblast impairment and reduced bone density (Ferlin et al., 2009). A similar 
result was also observed in knockout mouse model (Ferlin et al., 2008). There is also some 
evidence to suggest that higher levels of oestrogen and relaxin in pregnant women 
correlated with an increased prevalence of congenital dysplasia of the hip (CDH) in 
neonates (Saugstad, 1991; Steinetz et al., 2008). In view that relaxin affects both osteoclast 
and osteoblast, therefore this hormone is involved in bone remodelling process, and 
stimulation of osteoblast by relaxin-2 suggest that this hormone is potentially useful in the 
treatment of bone condition such as osteoporosis. 
2.6.2.3 Relaxin effects on ligaments 
Relaxin hormone alters ligament mechanics due to its collagenolytic effect 
mediated by discharge of matrix metalloproteinases (MMPs) (Qin et al., 1997), collagenase 
(Wiqvist et al., 1984), and plasminogen activator (Koay et al., 1983). Relaxin treatment in 
pregnant cattle increased pelvic width and height (Musah et al., 1986; Perezgrovas & 
Anderson, 1982), but not in other joints such as wrist and knee (Marnach et al., 2003; 
Weinberg, 1956). Increase in serum relaxin concentration may also correlate with joint 
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laxity (Dragoo et al., 2011b; Lubahn et al., 2006), but this effect during pregnancy is 
controversial (Forst et al., 1997). Some studies have reported higher relaxin levels in 
pregnant women with pelvic joint instability or hip joint laxity as compared to controls 
(Saugstad, 1991; Steinetz et al., 2008), while other studies did not (Ohtera et al., 2002). 
Two studies on the relationship between serum relaxin levels and joint laxity reported no 
significant association between this hormone level and knee and generalized joint laxity 
(Wolf et al., 2013). Studies have also suggested a relationship between higher relaxin and 
progesterone serum levels in pregnant females with pelvic girdle pain (PPGP) syndrome 
(Kristiansson et al., 1999; MacLennan et al., 1986; Wreje et al., 1995) and pelvic floor 
dysfunction (Harvey et al., 2008), whereas other studies have not found such a relationship 
(Crelin & Brightman, 1957; Petersen et al., 1994; Vollestad et al., 2012). Study design and 
methodological differences may account for some of the conflicting data.  
Relaxin appears to play a role in anterior cruciate ligament (ACL) injury (Dragoo et 
al., 2009). Oestrogen and relaxin receptors have been found in the human female ACL 
(Faryniarz et al., 2006). Studies on the mechanical properties of human ACLs illustrate that 
those treated with relaxin have reduced ligament integrity and may be at higher risk of 
injury (Dragoo et al., 2011b; Toth & Cordasco, 2001). This finding was also replicated in 
an animal model, where rabbits treated with relaxin had significantly weaker ACL’s 
compared with controls (Dragoo et al., 2009). Additionally, there was increased anterior 
tibia displacement on radiographic assessment, indicating ACL laxity, in animals treated 
with relaxin (Dragoo et al., 2009). 
There also may be an association between ACL injuries and stages of menstrual 
cycle. Occurrence of ACL injuries during the ovulatory phase (midcycle) are more frequent 
than the luteal phase (Wojtys et al., 2002). During this period, oestrogen and relaxin levels 
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are high, therefore, activation of the oestrogen and relaxin receptors may be increased (Min 
& Sherwood, 1996). Relaxin activates collagenolytic system, which increases collagenase 
synthesis and finally degrades the extracellular matrix composition (Garibay et al., 2004; 
Guttridge, 2004).  
A prospective study of elite female athletes illustrated that players with increased 
serum relaxin levels had an increased risk of an ACL tear compared with females with 
lower relaxin levels (Dragoo et al., 2011a). Players having a relaxin concentration of 
greater than 6.0 pg/ml had more than a 4 times greater risk of ACL injury. Other studies 
have collaborated these findings (Beynnon et al., 2006a). Relaxin appears to affect other 
ligaments such as volar oblique in perimenopausal women via a receptor-mediated process. 
In this ligament relaxin particularly binds and probably reveals in presence of cellular or 
extracellular matrix receptors (Lubahn et al., 2006).Taken together, these findings indicate 
that while relaxin effects are beneficial to the lower animals especially during pregnancy, 
its proposed effect on the peripheral ligament laxity in humans and animals may predispose 
the joint to a non-traumatic injury. 
2.6.2.4 Relaxin effects on skeletal muscles 
Relaxin helps to regulate normal skeletal muscle through two principle-signalling 
pathways: adenylate cyclase (AC) and nitric oxide (NO). Relaxin activates the AC 
signalling pathway in skeletal muscles through the following signal chain: (Pertseva et al., 
2006; Plesneva et al., 2008; Shpakov et al., 2006; Shpakov et al., 2007; Shpakov et al., 
2004). Relaxin also activates the NO pathway in skeletal muscle via relaxin mediated 
activation of receptor tyrosine kinase (Plesneva et al., 2008). NO regulates various 
biological processes, and is produced by NO synthase (Stamler & Meissner, 2001). There 
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are data which indicate relaxin stimulates NO synthase signalling in the skeletal muscles of 
type 2 diabetic rats, leading to NO dysfunction (Kuznetsova et al., 2010).  
Relaxin may be implicated in the skeletal muscle healing process by regulating 
inflammation, tissue remodelling and, fibrosis (Formigli et al., 2005; Sherwood, 2005). The 
degree of fibrotic response varies with the level of inflammation and injury. Relaxin may 
improve spontaneous regeneration of injured skeletal muscle as illustrated in an injured 
muscle mouse model (Kazumasa et al., 2001; Sato K et al., 2003).During this process, 
skeletal muscle cells regenerate and repair to reduce the size of a damaged or necrotic area 
and replace it with new living tissue. Degeneration/inflammation is retrogressive changes 
in cells and tissues characterized by abnormal structural changes and decreased functions 
(Li et al., 2005; Merchav et al., 2005; Mu et al., 2010; Negishi et al., 2005).  
 
 
 
 
 
 
 
Figure 2-11 Mechanism of regeneration in damaged muscle. MSC (muscle 
satellite cell), MPC (myogenic progenitor cell) 
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In regeneration phase, immature granulation tissue containing active fibroblasts 
produce abundant type III collagen, which fills the defect left by an open wound (Volk et 
al., 2011). Granulation tissue moves, as a wave, from the border of the injury towards the 
centre. As granulation tissue matures, fibroblasts produce less collagen and become more 
spindly in appearance, which then begin to produce a much stronger type I collagen (Syed 
et al., 2011). Some of the fibroblasts mature into myofibroblasts containing similar action 
to the smooth muscle, which enables them to contract and reduce the size of the wound 
(Sarrazy et al., 2011).Fibrosis is the last phase of healing where a non-functional scar tissue 
is formed caused by excessive accumulation of connective tissue following damage. 
Fibrosis often delays and impairs the recovery of damaged tissue (Diegelmann & Evans, 
2004 ). Relaxin has been shown to inhibit fibrosis formation through several mechanisms 
which include neutralization of the effect of TGF1 (transforming growth factor, beta1) 
and activation of the collagenolytic system, which increases collagenase synthesis (Garibay 
et al., 2004; Guttridge, 2004; Mendias et al., 2012; Mendias et al., 2004; Mu et al., 2010; 
Vinall et al., 2011). Through these mechanisms, relaxin reduces the formation of fibrous 
scar tissue. In view of that relaxin plays important role in the healing process, it can 
potentially be used as a therapeutic agent to treat damaged skeletal muscle (Negishi et al., 
2005). 
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2.6.2.5 Relaxin effects on tendons  
Relaxin has been reported to effect tendon metabolism by controlling the length of 
tendon growth (Wood et al., 2003) and reduce tendon stiffness by increasing tendon laxity 
through activation of collagenase. An in-vivo study investigating the growth of rat tails and 
human patellar tendons showed that relaxin levels correlate with tendon length (Wood et 
al., 2003). Rat tail tendons treated with relaxin exhibited alterations in collagen through 
interfering with fibril association and collagen sliding (Wood et al., 2003). Another study 
in women with normal menstrual cycle, who did not take any contraception pills, 
demonstrated a significant link between serum relaxin levels and patellar tendon stiffness. 
Besides, of the reported effects of relaxin on the tendon, potential benefits of relaxin on 
tendon repair and remodelling is largely unknown.  
2.6.2.6 Relaxin effects on Cartilage 
Relaxin appears to decrease knee articular cartilage stiffness (Bonaventure et al., 
1988; Hellio Le Graverand et al., 1998) through induction of collagenase-1, matrix 
Figure 2-12 Mechanism of regeneration in damaged muscle 
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metalloproteinase (MMP-1) and MMP-3, which reduces collagen content and expression in 
fibrocartilaginous cells. Modulation of MMPs to loss of collagen by hormones may 
contribute selectively to degeneration of specific joints fibrocartilaginous explants 
facilitated by proteinases (Hashem et al., 2006; Naqvi et al., 2005). The degradation of 
extracellular matrix in fibrocartilage is synergized by β-oestradiol. Relaxin exerts its effect 
through binding to RXFP1 and RXFP2 receptors.  The ratio of RXFP2 in knee meniscus of 
pregnant rabbits was shown to be more than RXFP1, which may indicate differential role 
of these receptors in the remodelling of fibrocartilage (Wang et al., 2009b). Comparison of 
collagen content in articular cartilage of non-pregnant and pregnant rabbits showed that the 
total RNA levels and chondrocyte metabolism decreased during pregnancy. Depending on 
the level of skeletal maturity, pregnancy can exert both general and specific effects on the 
RNA levels in articular cartilage of the rabbit knee. Thus, relaxin may play a role in 
women’ susceptibility to musculoskeletal disease. Taken together, these findings suggested 
that in female, increased relaxin level may result in undesirable effects on the articular 
cartilage.  
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Table 2-2 Review of previously reported data of relaxin in locomotor system 
Organ Author Year Sample Model Treatment Relaxin Role of relaxin 
Skeleton  
Cartilage Bonaventure 
et al. 
1988 Chondrocytes cell Rb /  vitro Porcine relaxin  NI Modulation of type I, II, 
III collagen expression 
 Naqviet al. 2004 Joint fibrocartilaginous cells Rb / vitro Human relaxin, β-
oestradiol 
NI No increase collagenase1 
& MMP3 expression 
 Hashem et  
al. 
2006 Knee meniscus fibrocartilage 
& articular cartilage 
Rb/ vitro Human relaxin, β-
oestradiol, 
progesterone  
NI No significant change of 
GAGs 
(glycosaminoglycans) & 
collagen 
 Wang et al. 2009 Joint fibrocartilaginous cells  M / vitro NI 1,2 Expression of RXFP2 > 
RXFP1  
Bone Santora et al. 2005 Arthritis paw  R / vivo Porcine relaxin & 17-
β–oestradiol  
NI Combination hormone 
therapy reduced arthritis 
inflammation 
 Kristiansson 
et al. 
2005 Normal osteoblasts cell H / vitro. Relaxin  1,2 Bone resorption by 
mediators 
 Ferlin et al. 2008 Bone densitometry, 
cryptorchidism, osteoblast cell 
H,M/vivo, 
vitro 
Agonists INSL3, 
relaxin, forskolin 
2 Links RXFP2 gene 
mutations with human 
osteoporosis 
 Facciolli et 
 al. 
2009 Osteoclasts cell H/ vitro Relaxin 1 Facilitation the 
differentiation of 
osteoclasts 
 Ferlin et al. 2009 Osteoclasts cell H/ vitro Relaxin 1 Relaxin is a potent 
stimulator of 
osteoclastogenesis 
 Ferlin et al. 2011 Femoral heads osteoblast cell H/ vitro Relaxin 2 2 RXFP2 system is 
involved in bone 
metabolism 
 Ho et al. 2011 Joint tissues, Murine 
osteoblast cells 
R/ vivo & 
vitro 
17-β- oestradiol, 
porcine relaxin 
NI Modulation of RANKL-
OPG system  
Joint Weinberg et 
al. 
1956 4 nonpregnant &11 pregnant H/vivo Relaxinas releasin NI No chang in pelvic 
measurement 
 Cerlin et al. 1957 Pelvic joints R/vivo Relaxin, oestrogen NI No difference in pelvic 
joint flexibility 
 Perezgrovas 
et al. 
1982 Pelvic joint BF/ vivo Porcine relaxin NI Expansion of the pelvic 
area(p) 
 MacLennan 
et al. 
1986 Patients with late pregnancy H/vivo NI NI High relaxin link between 
pelvic pain and joint 
laxity during late 
pregnancy 
 Musahet al. 1986 Pelvic joint BF/vivo Relaxin  NI Induction pelvic 
expansion, highly 
significant interaction(p) 
 Udén et al. 1988 CDH patients  H/vivo NI NI Increased sensitivity of 
the receptors of the 
fibroblasts 
 Saugstadet 
 al. 
1991 153 Pregnant women H/vivo NI NI Congenital hip dysplasia 
rate, consistent 
withoestrogen and relaxin 
levels 
 Petersen et 
 al. 
1994 472 pregnant women H/vivo Ni NI Not associated with 
pregnancy pelvic pain 
 Wreje et al. 1995 19 women H/vivo Oral contraceptive NI Higher relaxin with 
posterior pelvic and 
lumbar pain 
 
 Schauberger 
 et al. 
1996 21 women H/vivo NI 2 No correlation with serum 
relaxin & joint laxity 
 Forst et al. 1997 90 newborn children H/vivo NI NI NI Lower rElaxin in newborns 
with pelvic presentation hip 
instability 
 Vogelet al. 1998 12 girls, three boys newborn H/vivo NI 2 Reduction  of relaxin 
concentration with 
increasing sonographic 
hip 
 Kristiansson 
 et al. 
1999 200 pregnant women H/vivo NI NI Relaxin correlated with 
pelvic pain in early 
pregnancy 
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 Ohtera et al. 2001 Knee joint of nonpregnant 
and pregnant 
R/vivo NI NI Relaxin preventing the 
development of joint 
contracture 
 Arnold et al. 2002 Athlete eumenorrheic 
women and  men  
H/vivo NI NI No effect on knee laxity 
 Marnach et  
al. 
2003 Pregnant women H/vivo NI NI No correlation wrist joint 
laxity and relaxin level 
 Harvey et al. 2008 Pregnant women H/vivo NI NI Higher relaxin and fall 
significantly faster in 
women with PFD 
 Vøllestad et 
 al. 
2012 212 women pelvic joints H/vivo NI NI Contribution with pelvic 
joints laxity but no 
responses to pain & 
disability 
Ligament Albert et al. 1997 455 pregnant women H/vivo NI NI No difference in serum 
relaxin concentration with 
pelvic pain 
 Dragoo et 
al. 
2003 ACL specimens H/vitro Human recombinant 
relaxin 
 Binding of relaxin female 
ACL tissues but not in 
men ACL 
 Galeyet al. 2003 ACL specimens H/vitro Human relaxin NI Competence of the ACL 
to sequester relaxin 
 Faryniarzet 
al. 
2006 ACL injuries cells H/vitro NI NI Increased binding of 
relaxin-labeled in ACL 
fibroblasts cellsmore in 
female 
 Lubahn et 
al. 
2006 Volar oblique 
ligament(VOL) 
H/vitro NI NI Relaxin binds to (VOL)  
perimenopausal women. 
 Dragoo et 
al. 
2009 ACL specimens G/vivo Porcine 
relaxin/oestrogen 
NI Alternation mechanical 
properties of the ACL 
 Dragoo et 
al. 
2011 Female athletes H/vivo NI 2 Higher relaxin in ACL 
tears than without tears 
Muscular        
Muscle Kuznetsova 
et al. 
1999 Type 1,2diabetes skeletal 
muscles 
R/vitro Insulin/  relaxin/IGF-
1 
NI No regulation activity of 
glycogen synthase by 
relaxin 
 Shpakov et 
al. 
2004 Skeletal muscles R/ vitro Inhibitor  NI Inhibitor blocked 
stimulatory effect of 
relaxin on adenylate 
cyclase 
 Li et al. 2005 Tibialis anterior muscles M/ vivo Relaxin  NI Regeneration and 
prevention of fibrosis 
 Merchav et 
al. 
2005 Internal obturator muscles 
withPH 
D/vivo NI 1 Pathogenesis role of 
relaxin on PH 
 Negishi et 
al. 
2005 Skeletal muscles, Myoblasts 
(C2C12 cells) 
R/vivo & 
vitro 
Relaxin  NI Antifibrosis agent and 
improve the healing 
 Shpakov et 
al. 
2006 Skeletal muscles R/vivo Pig relaxin2 1,2 Relaxin2stimulated the 
AC activity 
 Shpakov et 
al. 
2007 Myoblastic cell line R/ vitro Relaxin  1 Stimulation of adenylyl 
cyclase activity 
 Shpakov et 
al. 
2007 Skeletal muscles R/ vivo Porcine relaxin2 2 Regulation of adenylyl 
cyclasesystem under 
hyperglycemia 
 Chistyakova
et al. 
2009 Skeletal muscles F/ vitro Relaxin 2 Relaxin in increasing G-6-
PDH activity 
 Kuznetsova 
et al. 
2010 Type 2 diabetes skeletal 
muscles 
R/vitro Streptozotocin NI Stimulation NO synthase 
in rat skeletal muscles 
 Mu et al. 2010 C2C12 mouse/ myoblasts 
cell , muscle 
H,M/vivo,vi
tro 
Relaxin 1 Regeneration/increased 
angiogenesis/revasculariz
ation  
Tendon Wood et al. 2003 Tail tendon R/vivo Pentapeptide NKISK, 
relaxin 
NI Significantly more creep 
& changes in tendon 
length  
 Pearsonet 
al. 
2011 Patellar& medial 
gastrocnemius tendon, 
H/ vivo NI NI Correlations between 
relaxin & patellar tendons 
stiffness 
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2.7 Summary of literature findings 
Gender related hormonal influence on the knee joint may have important role in higher 
risk for injury in female athletes population. Knee joint is believed to be a critical joint 
which injuries may cause permanent disability to the female athletes. Alterations in 
hormonal patterns during the menstrual cycle might contribute to non-contact injury in 
female at different phases of the menstrual cycle. The mechanisms that contribute to the 
higher incidence of injury rates among the female athletes at different phases of the 
menstrual cycle remains poorly understood. Besides sex-steroids, relaxin is also involved in 
modulating knee laxity. Correlation and interaction between relaxin and sex-steroids in 
females therefore need to be establish in order to gain an insight into the mechanism 
underlying the pathogenesis of non-traumatic knee injury in female. The current study 
hypotheses the relationship between progesterone, oestrogen, testosterone, relaxin, and 
relaxin receptor expression with knee laxity with a particular attention being given to lateral 
and medial knee laxities. 
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3 CHAPTER 3 MATERIALS AND METHODS 
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Figure 3-1 Schematic overview and research methods of the study 
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3.1 Materials 
3.1.1 Animal 
All procedures involving experimental animals were approved by the Faculty of 
Medicine Animal Care and Use Committee (ACUC), University of Malaya (UM) with 
ethics number: FIS/22/11/2011/FD(R). Adult female WKY rats weighing 180-220 grams, 
obtained from the Animal House, Faculty of Medicine, UM were caged in a group of six, in 
a clean and well ventilated standard environment of 12 hours light: dark cycle. The animals 
had free access to soy-free diet (Gold Coin Pellet) and tap water ad libitum.  
 
3.1.2 Chemicals and consumable 
The chemicals and consumables used in this project are shown in Table 3.1. 
 
 
 
43 
 
Table 3-1 Chemicals and consumable used in this project 
No Chemicals Company  
1 Progesterone (100 mg, purity minimum 99 %) Sigma, St. Louis, MO 
2 Testosterone (5 g,purity > 99 %) Sigma, St. Louis, MO 
3 17 Beta-oestradiol  Sigma, St. Louis, MO 
4 Relaxin  Sigma, St. Louis, MO 
5 Peanut oil (P2144, 1L) Sigma, St. Louis, MO 
6 Absolute Ethanol (purity > 99 %) Sigma, St. Louis, MO 
7 Pro-Prep protein extraction solution Intron Biotechnology, Korea 
8 Micro BCA protein assay Kit Thermo Scientific, Rockford, 
USA 
9 7α,17β-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-
1,3,5(10)-triene-3,17-diol (ICI 182/780)  purity ≥ 98 % 
Santa-Cruz Delaware CA, USA 
10 4-[2-phenyo-5,7-bis(trifluoromrthyl)pyrazolo(1,5-a) 
pyrimidin-3-yl] phenol (PHTPP) purity 99.8 % 
Tocris, Bioscience USA 
11 1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-
piperidinylethoxy)phenol]-1N-pyrozole dihydrochloride 
(MPP) purity 99.8 % 
Tocris, Bioscience USA 
12 Mifepristone purity 99.8 % Tocris, Bioscience USA 
13 Flutamide purity≥  98 % Sigma, St. Louis, MO 
14 Finasteride purity ≥  98 % Sigma, St. Louis, MO 
15 Beta Actin antibody Abcam, UK 
16 RXFP1 antibody Abcam, UK 
17 RXFP2 antibody Abcam, UK 
18 4CN optic substrate kit  Bio Rad, Alfred Nobel Drive 
Hercules, CA, USA 
19 Poly Vinylidene fluoride membrane (PVDF) Bio Rad, Alfred Nobel Drive 
Hercules, CA, USA 
20 Bovine Serum Albumin (BSA) Innovative, Peary Court Novi, 
Michigan, USA  
21 Spectra multicolor broad range  Fermentas, USA 
22 Tetramethylenediamine (TEMED) Sigma, St. Louis, MO 
23 RNA later Ambion,Lincoln Center drive, 
USA  
24 RNase Free water Ambion,Lincoln Center drive, 
USA 
25 Micro 96 well plate and cover Applied Biosystems, USA 
26 High capacity RNA to cDNA Applied Biosystems, USA 
27 Fast advanced Master Mix (Taq man) Applied Biosystems, USA 
28 RNA primers assays Applied Biosystems, USA 
29 Rat Enzyme-linked immunosorbent assay (ELISA) kit  CUSABIO, USA 
30 Human Enzyme-linked immunosorbent assay (ELISA) kit  CUSABIO, USA 
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3.1.3 Sterilization 
All experiments matherials (plastic tips, collection tubs, glass disposables) were 
sterilized by autoclaving at 1.05 kg/cm
2
 (15 psi) on liquid cycle for 20 min. Distilled water 
(dH2O) and ultrapure water (Mili-Q or ddH2O) were used for critical parts of the study.  
 
3.2 Methods 
3.2.1 Ovariectomy surgical procedures 
Ovariectomy is used to omit animal’s internal steroid hormones. To remove 
animal’s ovary, rats were anaesthetized with ketamine (80 mg/kg) and xylazine (8 mg/kg). 
Ketamine is a hydrochloric salt and used for general anesthesia in combination with a 
sedative such as xylazine. Xylazine is a drug that used for relaxation, painkilling, and 
general anesthesia in animals. The combination of these two drugs were injected 
intraperitoneally (IP). After injection of ketamine and xylazine rat was placed in left lateral 
position. Before starting, the rat’s operation area was shaved and swabbed with 70 % 
ethanol to remove filth. Small incisions were made in skin and muscle; ovary can be seen 
between fats in the peritoneal cavity. The ovaries were removed and remaining part was 
returned into the peritoneal cavity. Then incision parts of muscle and skin was sutured. 
Ovariectomy operation was completed by dorso-lateral incisions, with same method for 
opposite side (Parhizkar et al., 2008). Two weeks after surgery, rats were prepared to 
continue into further experiment. 
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3.2.2 Animal preparation and administration of sex steroid hormone 
In first part of the study, rats were ovariectomizedtwo weeks prior to steroid 
treatments. Based on the treatment, animals were distributed into different groups (n = 6per 
group). Hormones were injected subcutaneously at the neck cuff with a 24 hours interval 
for 3 days consecutively. Antagonists were also administrated subcutaneously at the neck 
cuff, 30 minutes before the hormone injection. For transcriptome and proteomic studies 
expression level of relaxin receptor isoforms (RXFP1 and RXFP2) mRNA and protein 
were detected in the hamstring muscle, patellar tendon, and collateral ligament tissues. 
Control group, which received peanut oil (vehicle), was also treated for three consecutive 
days. The drugs were dissolved in peanut oil and were subcutaneously administered. 
3.2.3 Identification of oestrous cycle stages 
Vaginal secretions were collected by using a plastic pipette filled with 10 μL of 
normal saline (NaCl 0.9%). The tip of the pipette was inserted into rat vagina, but not 
deeply to avoid cervical stimulation. Unstained material was placed onto a slide and was 
observed under a light microscope. The proportion of different cells was used to determine 
oestrus cycle phases, in which round and nucleated cells are epithelial cells which define 
proestrus; irregular shapes without nuclei are the cornified cells that were observed during 
estrus; little round cells are the leukocytes that characterize diestrus. At metestrus, however, 
three different kinds of cells could be identified 
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Figure 3-2 Identification of the oestrous cycle in rat 
3.2.4 Animal study groups 
3.2.4.1 Oestrogen treated group  
- Control group 
- 4 doses of oestrogen (0.2, 2, 20, 50 g/kg)  
- 7α,17 β-[9 - [(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl] estra - 1, 3, 5(10) - triene-
3,17 - diol (ICI 182/780) (25 mg/kg) 
- Physiological dosage of oestrogen (0.2 g/kg) + ICI 182/780  
- 4 - [2 – phenyo - 5, 7 – bis (trifluoromrthyl) pyrazolo (1, 5 - a) pyrimidin – 3 - 
yl]phenol (PHTPP), an ER - blocker (25 mg/kg), as internal control 
- Physiological dosage of oestrogen + PHTPP (25 mg/kg)  
- 1, 3 – bis (4 - hydroxyphenyl) – 4 – methyl – 5 - [4 - (2 -piperidinylethoxy) phenol] 
- 1N - pyrozole dihydrochloride (MPP), an ER -  blocker (25 mg/kg) as internal 
control 
- Physiological dosage of oestrogen + MPP (25 mg/kg)  
 
3.2.4.2 Progesterone treated group 
- Control group 
- Physiological dosage of progesterone (4 mg/kg) 
- Mifepristone (7.5 mg/kg)as internal control 
- Progesterone (4 mg/kg) + Mifepristone (7.5 mg/kg)  
3.2.4.3 Testosterone treated group  
- Control group 
47 
 
- 2 doses of testosterone (125 and 250 g/kg) 
- 2 doses of testosterone (125 and 250 g/kg)  
- 2 doses of testosterone + Flutamide (10mg/kg) 
- Flutamide (10 mg/kg) as internal control 
- 2 doses of testosterone Finasteride (20 mg/kg) 
- Finasteride (20 mg/kg) as internal control 
 
3.2.4.4 Oestrous cycle   
- Prostrous 
- Estrus 
- Metestrous 
- Diestrous 
 
3.2.5 Investigation of blood serum hormone level 
Blood samples were collected into a separator tube (SST) and allowed to clot for 30 
minutes at room temperature. The samples were centrifuged at 3000×g, for 15 minutes. 
Serum samples were aliquoted and stored at -20° C. Serum samples were analysed in 
duplicate for relaxin by using enzyme-linked immunosorbent assay (ELISA) kit 
(CUSABIO - USA). ELISA was performed according to manufacturer's guidelines. 
Absorbance for relaxin was determined by using a microplate reader (iMark; Bio - Rad, 
Hercules, CA, USA) at a wavelength of 450 nm. A set of standard serial dilutions of known 
concentrations were provided by the manufacturer and were used to construct a standard 
curve to determine the hormone levels. The overall intra-assay percent coefficient of 
variation for rats were 150, 75, 37.5, 18.75, 9.4, 4.7, 2.4, 0 ng/ml.Standard curves were 
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created by serial dilution and hormones concentration in the samples were determined from 
the standard curve. 
 
3.2.6 Knee range of motion (ROM) 
Rat’s knee ROM was measured using digital miniature goniometer. A day after the 
last day of drug treatment, the rats were anesthetized using ketamine and xylazine (80 + 8 
mg/kg).  The depth of unconsciousness was confirmed from the lack of response to painful 
stimuli, which was usually applied at the plantar surface of the foot (Flecknell, 2009). It is 
important to maintain the animal in deep anaesthesia in order to prevent active muscle 
contraction in response to pain which will increased resistance towards passive traction 
(Bazin et al., 2004). The hip and knee joints were fixed and rest on the sensor. Meanwhile, 
the lower leg (knee up to the ankle) was tied in-situ to the device arm. Rat knee ROM was 
measured by pulling the device arm in a clockwise direction at a minimum constant force 
(12 ± 1 N) using a mini digital Newton meter (American Weight, USA; model: AMW – SR 
- 1KG). Once the force exceed 13 N, the traction applied was immediately terminated and 
the angle obtained was recorded which represents passive extension. Assessment of the 
angle was made in different groups of treatment. This device and its function are shown in 
Figure 3.3.  
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Figure 3-3 Measurement of rat’s ROM by digital miniature goniometer 
(Patent IC/No: PI 2013701411). The image of digital goniometer is shown. The device consisted of 
an arm that is attached to a sensor, which can detect changes in the angle once the arm is rotated. 
The sensor is connected to software which analysed the angle using Torque principle. ”Torque, is 
the tendency of a force to rotate an object around a fixed axis and is defined by “ = r F sin  ” 
formula. r: rat leg length (r), F: force (A), θ: angle between the applied force and rat’s ROM (A and 
B distance). 
 
 
Figure 3-4 Digital Newton meter 
(American Weight, USA; model: AMW-SR-1KG) 
 
Arm 
NewtonMeter  
Center ofrotation+ sensor 
Animal support 
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3.2.7 Real Time PCR (qPCR) 
3.2.7.1 Real Time PCR, principle  
The Polymerase Chain Reaction (PCR) is a process for the amplification of specific 
fragments of DNA / RNA. Real time PCR is a specialized technique that allows a PCR 
reaction to be visualized “in real time” as the reaction progresses and known as a sensitive 
technique to calculate gene expression in the data that were collected during the PCR 
amplification process. Quantitative PCR (qPCR) is used in variation of molecular biology 
studies such as Gene expression analysis: Cancer and Drug research, Disease diagnosis 
(Viral quantification), Food testing, animal and plant breeding (Gene copy number), and for 
determining of DNA / RNA interfering (Palmer et al., 2003). Although in normal PCR, the 
product can only measure at the end of process, in qPCR it can be measured while it occurs. 
The development of fluorogenic labelled probes also made it possible to eliminate post-PCR 
processing for the analysis of probe degradation. This method able to detect small difference 
between samples compare to other methods, however it needs high cost reagents and equipment 
(Wong & Medrano, 2005). 
 
Reverse transcription-quantitative of mRNA or Real-time can be achieved as a one-
step or two-step procedure. The most common method for gene expression investigation is 
two-step RT-qPCR. With one-step method, the reverse transcription and PCR amplification 
steps are performed in a single buffer system while two-step procedure is performed in two 
separate reactions that allow storage of cDNA for long time (Wong & Medrano, 2005). 
Two-step RT-qPCR was performed in this study. There are two different types of methods 
for detection of PCR:  TaqMan and SYBR Green. Each method has its limitations and 
benefits. TaqMan chemistry (known as fluorogenic 5´ nuclease) enables you to perform 
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multiplex PCR, SYBR Green method (highly specific, double standard DNA binding) has 
only Quantification probe. TaqMan assay was used in this study. Real time PCR 
amplification is shown in Figure 3.5. 
 
3.2.7.2 Real-time PCR demonstration 
 
 
 
 
 
 
 
3.2.7.3 Sample collection and Tissue processing for RNA isolation  
Patellar tendon and collateral ligament tissues were exposed after 3 days treatment 
and from the rat knee washed with PBS buffer and soaked in five volume of RNA Later. 
RNA later solution was used to stabilize and protect tissues cellular RNA (Ambion, L/N: 
1206029). Samples can be preserved in RNA Later solution at – 20 ° C or below for up to 
2 years. Total RNA was extracted from 30 mg tissues (wet weight) that were floating into 
the RNA later solution using the RNeasy Fibrous tissue Mini kit (QIAGEN, Germany). 
 
Figure 3-5 Real time PCR amplification view 
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3.2.7.4 RNA extraction 
RNeasy® Fibrous Tissue kit (QIAGEN, Germany) specific kit for fibre-rich tissues 
was used to isolate RNA from hamstring muscle, patellar tendon, and lateral collateral 
ligament. The kit contains are: Buffer RLT, Buffer RW1, Buffer RPE, RNase-Free Water, 
Proteinase K, RNeasy Mini Spin Columns, Collection Tubes (1.5 ml), RNase-Free DNase I 
(lyophilized), Buffer RDD. The tissues were retrieved from RNA later solution with 
sterile forceps and drip-dried immediately with an absorbent paper towel, then soak into the 
lysis RLT Buffer added with β-mercaptoethanol. A 30 mg (wet tissue) was homogenized 
using a rotor–stator TissueRuptor (230V, 50-60 Hz_ QIAGEN, Germany). Homogenate 
was incubated at 55°C for 20 minutes with added 590 μl RNase-free water and 10 μl 
proteinase K solution to the lysate. The supernatant transferred after Centrifuging (20 – 
25°C for 3 minutes) to the new tube and then 0.5 volumes (usually 450 μl) of pure ethanol 
added to cleared lysate. It was mixed well by pipetting and Transferred 700 μl of the 
sample, to the RNeasy Mini spin column placed in a 2 ml collection tube (2 times), by 
discarding the flow through. After washing with RW1 buffer, mixed of 10 μl DNase I stock 
solution and 70 μl buffer RDD was added directly to the RNeasy spin column membrane to 
remove DNA. DNase I is sensitive to physical denaturation. Mixing should carry out by 
gently inverting the tube. This mixture was incubated for 20 minutes at room temperature 
(20 – 30°C). The membrane then was washed twice with 500 μl of RPE washing buffer. 
RNA was collected by Placing of RNeasy spin column in a new 1.5 ml collection tube and 
adding 30 – 50 μl RNase - free water. 
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3.2.7.5 RNA quality control 
The pure isolated RNA may be contaminated by DNA, protein or phenol that could 
inhibited the RNA downstream solicitation. Therefore, evaluating of RNA integrity and 
quality is necessary. The purity and concentration of RNA was evaluated by A260/280, 
A260/230 UV absorption ratios (Gene Quant 1300, UK). Agarose gel is the most common 
way to evaluate RNA integrity. Each RNA sample was assessed by integrity of Ethidium-
Bromide agarose gel 1 % and evaluated by electrophoresis in TBE buffer. After run the 
agarose gel for 45 minutes in 90 V, gel was observed in the specific gel documentation 
system (Vilber Lourmat, Fisher Scientific). RNA sharp and clear bands can be seen in 18S 
and 28S rRNA. To catch the RNA bands location 1Kb DNA ladder was used.  
 
 
Figure 3-6 RNA gel electrophoresis 
 
3.2.8 RNA to cDNA converssion 
To perform the two-step Real time PCR method, RNA samples need to be converted 
to cDNA. Reverse transcription into cDNA was performed by using Two-Step qRT-PCR 
kit, High capacity RNA to cDNAby Applied Biosystems_US. This kit contains reagents for 
reverse transcription (RT) buffer and enzyme to convert total RNA to single-stranded 
54 
 
cDNA. According to the manufacturer’s guidelines total RNA converted to cDNA by 
adding of up to 9 μl RNA (1000 ng), 10 μl of RT buffer, and 1 μl of RT enzyme. To 
perform reverse transcription of converting, optimized program the thermal cycler 
conditions was used. The program was included 37°C for 60 minutes, 95°C for 5 minutes 
and hold in 4°C (Kwok & Higuchi, 1989). The total tube of cDNA can be stored in –80 ° C 
for long term storage.  
3.2.9 Real time PCR running 
After converted total RNA to cDNA and their quantification, two-step Real time 
PCR was run to evaluate the mRNA gene expression by following the manufacturer 
procedures. The amplified region of cDNA was tagged with fluorescence-labeled probe. 
The specificity of the primer and the probe ensures that the expression of the target DNA 
was specifically evaluated. Real time PCR does not require a time consuming post 
amplification gel electrophoresis due to its high sensitivity. TaqMan probe has a sensitivity 
of 100 % and a specificity of 96.67 % (Tsai et al., 2012) and is capable of detecting as few 
as 50 copies of RNA/ml and as low as 5 - 10 molecules (Hofmann-Lehmann et al., 2002).  
 
All reagents including probes and primers were obtained from Applied Biosystems, 
USA. Primers were designed by the same company for specific targets: RXFP1: 
Rn01495351; Lot no: 926762, and RXFP2: Rn01412901; Lot no: 651878, amplifies 116 bp 
segment of RXFP1 from the whole mRNA length of 2277 bp, and 138 bp segment of 
RXFP2 from the whole mRNA length of 2214 bp. Hprt1 and GAPDH were used as 
reference genes. Expression levels of Gapdh andHprt1 in each sample were determined for 
normalisation as housekeeping genes. The catalogue number for the housekeeping genes 
are: GAPDH, Rn99999916_S1, Lot no: 10377343, which amplifies 87 bp segment of 
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GAPDH from the mRNA length of 1307 bp and Hprt1, Rn01527840, Lot No: 1118680, 
which amplifies 67 bp, segment from the mRNA length of 1260 bp. The target assay was 
validated in-silico using whole rat genome sequences and in - vitro using whole rat cDNA 
sequences to ensure target sequences were detected (Applied Biosystems, USA). Nuclease-
free water was used throughout Real-time PCR and qPCR experiments. 
 
To carry out the reaction combination 50 ng of cDNA in 1 µl, 5 µl of master mix 
buffer, 1 µl of each target primer, and 3.5 RNase free water was loaded in 96 well plates. 
The total volume of PCR mixture was 10 µl in each well. All experiments samples were 
loaded in three biological replicates. After prepared the reaction plate, plate was loaded into 
the Applied Biosystem Step One Plus thermal cycler. Real time-PCR program was set 
according to manufacture protocol included 2 minutes at 50ºC reverse transcriptase, 20 
seconds at 95ºC activation of polymerase, denaturation at 95ºC for 1 second and annealing 
at 60ºC for 20 seconds. Denaturing and annealing step was performed for 40 cycles.  
3.2.10 Data Analysis for Quantification of Gene Expression 
Data was analysed according to Comparative fold changes in expression were 
method (Wong & Medrano, 2005):  
Δ Ct = Ct of target gene – Ct of housekeeping genes average 
ΔΔ Ct = ΔCt of treated samples – Δ Ct of non-treated samples 
Fold changes = Ct (2
-ΔΔCt
) 
Amplifications of the target and reference genes were measured in the samples and 
reference. Measurements were standardized using the GenEx software. The relative 
quantity of target in each sample was determined by comparing normalized target quantity 
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in each sample to normalized target quantity average in the references. Data Assist v3 
software from Applied Biosystems was used to calculate RNA folds changes. 
3.2.11 Protein expression by Western blotting 
3.2.11.1 Western blotting- principle 
Western blotting or protein immunoblot is an analytical technique that is commonly 
accepted to detect specific proteins in the total extracted protein from tissue or cell lines. 
This method separates the protein by running the gel electrophoresis and identifies with 
specific antibodies according to their size. The bands blot is on a membrane (nitrocellulose 
or PVDF). The first step in western blotting is running the gel electrophoresis to separate 
the total protein, then antigen was transferred to the blotting membrane electrophoretically. 
In this study PVDF (polyvinylidene difluoride) membrane was used. In the next step, 
protein was transferred to PVDF membrane; the remaining protein site was blocked to 
reduce nonspecific bands. After blocking, membrane was soaked into the primary and 
secondary antibodies to bind and specify the target protein. Finally, the target protein was 
visualized with incubation of membrane into the substrate detection reagent (Walker, 
1996).  
3.2.11.2 Sample collection and Tissue processing for protein extraction 
Hamstring muscle, patellar tendon, and collateral ligament tissues were exposed and 
immediately frozen in liquid nitrogen (- 196°C) and then stored at – 80°C prior to protein 
extraction.  
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3.2.11.3 Protein extraction 
Total protein was extracted with using PRO-PREP (Intron, UK) solution kit. This 
kit is able to isolate protein from whole cell of tissue. This solution included is of highly 
denature ionic detergent such as sodium dodecyl sulphate (SDS), lithium dodecyl sulphate 
and sodium deoxycholate that can isolate protein as a monomeric for any protein molecular 
weight analysis and western blot. It also contain zwitterioninc detergent CHAPS (3 - [(3 -
Choamidopropyl) dimethylammonio] - 1 - propanesulfonate) which is more effective in 
disrupting protein interaction. Total protein was isolated by following the protocol:  
1 - 30 mg of hamstring muscle (wet tissue) was separated and soaked into the 400 µl of 
extraction solution. Whole part of patellar tendon and collateral ligament were cut and 
placed into the 250 µl into the solution. The maximum weight of patellar tendon and 
collateral ligament were 15 mg. 
2- The tissues were homogenised with using an ultrasonic cell disruptor (Branson) by 
putting on ice to disrupt tissues.  
3- After 10 minutes homogenising; samples were incubated at – 20oC for 30 minutes to 
persuade cell lysis. This step was performed two times to increase protein concentration. 
4- The samples were centrifuged 15 minutes, at 4°C, 13000 rpm to separate supernatant. 
The supernatant then transferred into the new 1.5 tube and stored in – 20°C. 
3.2.11.4 Protein quantification  
Protein quantification was performed to determine samples concentration by using 
Micro BCA Protein Assay kit (Thermo Scientific™ - US). This kit contains Micro BCA 
Reagent A (MA), Micro BCA Reagent B (MB), Micro BCA Reagent C, andBovine Serum 
Albumin (BSA) as Standard Ampules at 2.0 mg/mL in a solution of 0.9 % saline and 0.05 
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% sodium azide. The Kit is a detergent-compatible bicinchoninic acid formulation for the 
colorimetric detection and quantitation of total protein.A purple-colored reaction product is 
formed by the chelation of two molecules of BCA with one cuprous ion (Cu 
+ 1
). This 
water-soluble complex exhibits a strong absorbance at 570 nm wavelength that is linear 
with increasing protein concentrations. The samples concentration were calculated from a 
linear plot of BCA standard concentration (Axis X) of the intensity by changing of colour 
in absorbance. This absorbance obtained from the reaction between BSA and BCA 
reagents. Standard concentrations of BSA were prepared at 10, 8, 6, 4, 2, 1, 0.5, and 0 
µg/ml. The samples then were diluted 1 in 50 with PBS buffer. 50µl of total protein 
samples or standard as a serial dilution were added to 50 µl of BCA reagents in a Greiner 
UV Transparent 96 Well Plate (Thermo Scientific™ - US) in triplicate. The plate was 
incubated for 2 hours at 37 ° C, then the intensity of changed colours were qualified by 
using a plate reader at wavelength of 570 nm. Standard curve was generated by serial 
dilution and samples protein concentration calculated from the standard curve.  
 
 
 
Figure 3-7 Standard curve for protein determination 
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3.2.12 Western blot running 
SDS-PAGE running: Electrophoresis gel or SDS-PAGE gel (sodium dodecyl sulfate 
polyacrylamide gel electrophoresis) can be one-dimensional or two-dimensional technique 
to detect and characterize of specific protein. One-dimensional electrophoresis is used for 
most protein and nucleic acid separations. Relocation of protein in electrophoresis is based 
on charges, mass, size and strength of electrical field (Bolt & Mahoney, 1997).  
 
The matrix is polyacrylamide gel that is polymer of acrylamide and bis- acrylamide 
(Sigma-US), the presence of N, N, Nʹ, Nʹ - tetramethyleethylenediamine (TEMED), and 
ammonium per sulphate (APS), catalyses the gel polymerization (Walker, 2007). 
According to the protein size, samples separate within the gel and determine by their 
molecular weight. High percentage of gel for low molecular weight and low percentage for 
high molecular weight is recommended. Ionic detergent SDS is used in polyacrylamide gel, 
which denatures the protein and makes them negatively charged. The charge is equally 
distributed to protein molecule based on their length and lead to migration according to the 
size.  
Polyacrylamide gel contain of two different parts (resolving and stacking) with 
separate formulation. Resolving part used at the bottom of gel caster with a pH of 8.8 and 
stacking part is placed above the resolving with a pH of 6.8. In this study, resolving gel 
with 12 % for (RXFP1, RXFP2, and Beta Actin) was used. Stacking gel is used to pack 
protein together after loading and mostly prepare in 4 %. The gel was prepared in gel cast 
and kept overnight at 4°C. The compositions of each gel are shown in Table 3.2. 
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Table 3-2 Composition of 12 % resolving and 4 % stacking gel 
Stock solution Resolving gel 12 % Stacking gel 4 % 
Acrylamide  8.3 ml 0.665 ml 
4X resolving  4 ml _ 
4X Stacking _ 1.25 ml 
10 % SDS 0.2 ml 50 µl 
10 % APS 0.1 ml 25 µl 
TEMED 7 µl 5 µl  
Double distilled H2O 6.4 ml 3 ml 
 
 
The following day equal volume of samples (20 µg) were mixed with loading dye, 
then boiled for 5 minutes and loaded in the gel. Gel cast then placed inside the 
electrophoresis tank and bathed in migration buffer with the recommended time as 
instructed by the manufacturer. Pre-stained protein marker was loaded into the one of the 
empty wells to assess protein size bands. Rabbit polyclonal Beta Actin (Abcam, UK) was 
used as loading control, to check whether all samples have been loaded equally, and 
compare the expression of different samples. Electrophoresis was disconnected when the 
front dye reached at the bottom of the gel.  
 
Transfer to membrane: The separated samples by electrophoresis, the protein transferred 
to PVDF (BIORAD, UK) membrane for immunoblotting. A hydrophobic membrane needs 
to prewet into pure methanol (2 minutes) and then into the twobin buffer (5 minutes) which 
contain 20 % methanol. The presence of methanol in twobin buffer (transfer buffer) is to 
promote dissociation of SDS from the protein and improve adsorption of protein onto the 
membrane (Pettegrew et al., 2009). The PVDF membrane was placed next to the gel. The 
two were sandwiched between absorbent materials, and clamped between solid supports to 
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maintain tight contact between the gel and membrane without air bubbles. Samples 
transformation can perform in wet or semi-dry conditions. In this study, wet condition tank 
is used. The gel membrane sandwich was placed in wet transfer tank for electro blotting at 
constant voltage of 100 V for 90 minutes. After transferred membrane was exposed and 
washed with PBST (phosphate buffer saline-tween 20) for 3 times, 5 minutes.  
 
Blocking step: To block the membrane, two blocking solutions were traditionally used: 
non-fat milk or BSA (5 %). Milk is cheaper but is not recommended for studies of 
phospho-proteins, it cause high background because the phospho-specific antibody detects 
the casein present in the milk. BSA was used to block the membrane 90 minutes at 4°C 
under agitation. Washing with PBST 3 times, 5 minutes is necessary on this step before 
incubation with primary antibody. 
 
Incubation with antibodies: primary antibody was diluted 1:1000 in PBST buffer and 
incubated with membrane 60 minutes at 4°C under agitation. After washing with PBST 
buffer, secondary antibody (attached to horseradish peroxidase-HRP) was diluted 1:2000 
and incubated for 60 minutes under agitation. 
 
Visualizing:tovisualize the target protein band Opti - 4CN 
TM
Substrate kit was used. This 
kit is colorimetric (HRP) substrate and detected band can be seen by necked eyes. Primary 
and secondary antibodies that used in this study are shown in Table 3.3. 
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Table 3-3 primary and secondary antibodies that have been used in western blot. 
Target protein Primary antibody Secondary anti body 
RXFP - 1/LGR7 Rabbit polyclonal Mouse anti-rabbit HRP 
RXFP - 2/ LGR8 Mouse polyclonal Rabbit anti-mouse HRP 
Beta Actin Rabbit polyclonal Goat anti-rabbit HRP 
 
 
3.2.13 Western blot data Analysis 
The visualized blots of target protein, membrane were captured by a gel 
documentation system (Vilber Lourmat, from Fisher Scientific, USA). The density of each 
band was determined using Image J software (National Institutes of Health, USA). The 
ratio of each target band over Beta actin was calculated and considered as the expression 
level of the target proteins.  
3.3 Human study 
Fortyhealthy females (20 athletes; 20.3 ± 1.28 years, 163 ± 2.75 cm height and 20 
non-athletes; 21.7 ± 2.27 years, 158.5 ± 5.28 cm heights) who were not on hormonal 
contraceptives and were confirmed to have regular menstrual cycles after 3 cycles were 
monitored for 3 consecutive months volunteered to participate in this study. The inclusion 
criteria include no history of knee surgery or injury or history of injury or chronic pain in 
both lower extremities for the past 1 year. Subjects were not on specific medications. 
Eumenorrhic, Amenorrheic, Polymenorrhoeic subjects were excluded. The participants 
were informed the detail of the study from the information sheet, and written informed 
consent was provided. This study was approved by the Institutional of Medical Centre 
Board, University Malaya with Medical Ethics No: 1010.90. 
63 
 
3.3.1 Blood sample collection and serum hormones’ analyses 
Blood samples were collected 3 times per month: on day first of menstruation, day 
12 which was in the follicular phase, and day 20 which was in the mid luteal phase 
(Widmaier et al., 2006). The phases were determined using fertility chart and blood 
samples were withdrawn via venepuncture. After collection into a separator tube (SST), 
blood was allowed to clot for 30 minutes at room temperature. The blood was then 
centrifuge at 3000 g, for 15 minutes. Serum samples were then aliquoted and were stored at 
– 20°C. Enzyme-linked immunosorbent assay (ELISA) was performed using Elisa kit 
(CUSABIO - USA) to measure the levels of relaxin. Meanwhile, Radioimmunoassay was 
used to measure the level of oestrogen, progesterone and testosterone. 
3.3.2 Basal Body Temperature 
The basal body temperature (BBT) is used to determine whether the cycle is an 
ovulatory cycle. An ovulatory cycle was featured by a slight increase ~0.5
o
C of BBT which 
usually occur in the mid of the cycle. BBT was measured when the body is at rest. In 
determining BBT, rectal temperature was obtained. The temperature was taken at 7 o’clock 
in the morning for 1 month duration. The sample of BBT recorded is shown in Figure 3.8. 
 
Figure 3-8 Basal body temperatures chart 
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3.3.3 Knee rotational movement 
In this part of study we were examined the knee rotational movement by performing 
a varus-valgus examination using a manual orthopaedic goniometer ruler (model: 
MR0104PVC material 180°). These tests were used to measure the varus/valgus angles and 
the internal/external rotational laxity of the knee joint.Data were collected by measuring 
subjects both knees. In order to establish the reliability of the data, varus-valgus test were 
accomplished by fixing the knee at 30° and 0°. All procedures were identical to those 
described in the clinical examination textbook (Bendjaballah et al., 1997). Varus-Valgus 
test were performed by placing unusual stresses forces on the articular surfaces, joint 
capsule and ligaments.  
 
Varus test is a stress force applied from the lateral side of the femur by adducting 
the ankle. Testing LCL (lateral collateral ligament) is performed by flexing the knee at 30 ° 
and 0 °, with subjects lying flat.  One hand of the examiner was placed over the lateral joint 
line while another hand holds the lower leg firmly at the ankle. Meanwhile, valgus force is 
a stress force applied on the lateral side by abducting the ankle. Stretching of MCL (medial 
collateral ligament) was performed in medial side of the knee by flexing the knee at 30  and 
0 °, with patient lying flat with one examiner  hand was placed over the medial joint line 
and another hand holds the lower leg firmly. In order to ior to check for the relaibility of the 
data, these tests were performed by 3 different examiners and the data was gathered prior to 
analyses. 
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Figure 3-9 Knee rotational movement investigation by Varus-Valgus test at 30° 
 
 
 
 
Figure 3-10 Knee rotational movement investigation by Varus-Valgus test at 0° 
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3.3.4 Data analysis of knee laxity in human 
All the data were presented as mean ± standard deviation, analysed by descriptive 
analysis to determine hormone levels and rotational angles of each subject throughout the 
menstrual cycle.One-way ANOVA was usedto ascertain the correlation by using SPSS 
18.0. p< 0.05 was considered as statistically significant.As for each variables, 3 
measurements was used to evaluate the differences between 3 observations, one way 
repeated measure Anova was applied and the results revealed that there were no significant 
differences among these three observations.Therefore, the mean of these observations was 
computed and used for data analysis. Two-way ANOVA was usedto compare athletes and 
non-athletes groups. For variables with a normal distribution, Pearson correlation 
coefficient and for non-normal distributed variable, Spearman correlation coefficient was 
applied. 
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4 CHAPTER 4 
Sex-Steroid Regulation of Relaxin Receptor Isoforms 
(RXFP1 & RXFP2) Expression in the Patella Tendon 
and Lateral Collateral Ligament of Female WKY Rats 
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4.1 Introduction 
Relaxin which consist of relaxin-1, -2 and -3 and insulin-like peptides (INSL3, 4, 5 
and 6) (Park et al., 2005) is a polypeptide hormone that possesses structural similarity to 
insulin and is primarily synthesized by the corpus luteum and placenta (Conrad & Baker, 
2013). Relaxin binds to and activates G-protein-coupled receptors (GPCRs): 
RXFP1(LGR7) and RXFP2(LGR8) (Scott et al., 2012). Human relaxins H1 and H2 
activate both RXFP1 and RXFP2 (Nair, 2012), while rat relaxin1 binds weakly to RXFP2 
(Scott et al., 2005). Relaxin H3 binds selectively to RXFP1 as well as RXFP3 (GPCR135) 
and RXFP4 (GPCR142) (Rosengren et al., 2006 ). RXFP1 and RXFP2 are the two main 
relaxin receptor isoforms (Schwabe & Büllesbach, 2007).  
 
Relaxin activity has been reported in both pregnant and non-pregnant female primates 
and non-primate vertebrates (Cernaro et al., 2013; Hayes, 2004). In primates, ovarian 
relaxin is not required for successful term pregnancy (Hayes, 2004) however is required to 
maintain pregnancy in rats and pigs  (Sherwood OD, 1993). During pregnancy in mice, 
relaxin is involved in transformation of pubic joint cartilage into a more flexible and elastic 
interpubic ligament in order to accommodate the enlarging uterus (Lippert et al., 1987). In 
non-pregnant rats, relaxin administration alone or in combination with oestrogen reduces 
pubic symphysis collagen content, with progesterone antagonizing this effect (Samuel et 
al., 1996). Meanwhile, during pregnancy in rats, relaxin was reported to regulate collagen 
catabolism in the pubic symphysis (Samuel et al., 1998). In lower species such as rodents, 
relaxin action may be more reflective than in humans where serum relaxin level was found 
to have no link to the generalized joint laxity (Wolf et al., 2013).  
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Relaxin affects tissues’ extracellular matrix components including collagen, H2O and 
hyaluronan. Relaxin increases cervical hyaluronan content by up-regulating the expression 
of hyaluronic acid synthase (Soh, 2012). This effect will result in loosening of tissues’ 
dense collagen fiber network. Relaxin has been shown to possess anti-fibrotic action by 
down-regulating fibroblast activity, increasing collagenases synthesis and inhibit 
transforming growth factor (TGF-)-stimulated collagen-l lattice contraction in rat kidney 
(Masterson et al., 2004). Relaxin up-regulates matrix metalloproteinases (MMP), a family 
of extracellular proteases that interfere with matrix remodeling by their ability to degrade 
extracellular matrix components including collagen (Chow et al., 2012). Relaxin has been 
reported to stimulate the expression of collagenase-1, MMP-1, MMP-3 (Hashem et al., 
2006), MMP-9, and MMP-13 in fibrocartilaginous cells (Ahmad, 2012) and MMP-2 in 
periodontal ligament cells (Ho, 2009; Miao, 2011).  
 
Sex-steroids have been reported to affect relaxin receptor expression. In the human 
endometrium, relaxin receptor isoforms expression vary across the menstrual cycle with 
low level expressed during the proliferative phase and rises sharply at the time of ovulation 
(Bond et al., 2004). In neonatal porcine uterus, oestrogen increases RXFP1mRNA 
expression, while in cervix, oestrogen increases and relaxin decreases the expression of this 
receptor (Yan et al., 2008).During late pregnancy in mice, relaxin has no influence on 
RXFP1 expression (Siebel et al., 2003 ). Progesterone has been reported to increase the 
expression of RXFP1 in the pregnant rat uteri (Vodstrcilet al., 2010a ) while oestrogen was 
found to regulate RXFP1 mRNA expression in human cervix at term (Maseelall, 2009). 
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Knee is another potential target for relaxin action. Currently, little is known with 
regards to the expression of RXFP1 and RXFP2 in the knee. Wang et al. (Wang et al., 
2009a) reported that relaxin receptors were expressed in mouse knee fibrocartilage. In 
humans, relaxin receptors have been identified in the anterior cruciate ligament (ACL) in 
male and female knee (Faryniarz et al., 2006), with higher expression in female (Dragoo et 
al., 2003). This gender specific difference suggests the influence by female sex hormones. 
Apart from ACL, the expression of relaxin receptors in other knee structures including 
patellar tendon and lateral collateral ligament is currently unknown. Together with ACL, 
they participate in the control of knee stability during movement.  
 
We hypothesized that female sex hormones affect RXFP1 and RXFP2 expression in 
the patella tendon and lateral collateral ligament, thus affecting knee laxity. This could 
explain differences in the incidence of non- contact knee injury between male and female 
(Sutton & Bullock, 2013), and in female at different phases of the menstrual cycle (Hansen 
et al., 2013). In view of this, we investigated these isoforms expression in the patella 
tendon and lateral collateral ligament in rat model in order to provide the mechanism 
underlying changes in knee laxity under different sex-steroid influence. 
4.2 Results 
4.2.1 Plasma Sex-Steroid Levels following Subcutaneous Hormone Injection 
In Table 4-1, the average hormones level in the blood in different groups of 
treatment is shown. Our findings indicate that serum levels of oestrogen and testosterone 
correlate with the doses administered. Subcutaneous injection of 0.2g/ml 
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oestrogenresulted in plasma level of approximately two times higher than the control while 
injection of 4 mg progesterone resulted in five times higher level than the control. 
 
Table 4-1 Plasma sex steroid level following subcutaneous hormone injection. 
Values were given as mean ± standard error of mean. E – Oestrogen, P – progesterone and 
T – testosterone. The level of hormones in the blood correlates with the amount injected via 
the subcutaneous route. 
 
 
4.2.2 RXFP1 and RXFP2 Proteins Expression in the Patellar Tendon and Lateral 
Collateral Ligament 
In Figure4-1, the expression of RXFP1 protein is the highest in the lateral collateral 
ligament of progesterone treated rats with 1.75 fold increase as compared to control. 
Treatment with oestrogen at 0.2 µg/ml resulted in a slight but significant increase in the 
expression of RXFP1 protein as compared to control (p<0.05). Treatment with higher 
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oestrogen doses (>2µg/ml) resulted in a dose-dependent increase in RXFP1 protein 
expression with 43 and 100 percent increase following treatment with 20 and 50µg/ml 
oestrogen respectively. Testosterone treatment resulted in a significant decrease in the 
expression of RXFP1 (0.54 and 0.45 fold increase following subcutaneous administration 
of 125 and 250µg/ml testosterone respectively).  
 
 
Figure 4-1 The expression of RXFP1 protein in the total homogenate of collateral ligament 
from ovariectomised rats treated with different sex-steroids: C- control; 0.2E – 0.2µg/ml 
oestrogen; 2E - 2µg/ml oestrogen, 20E - 20µg/ml oestrogen; 50E –50µg/ml oestrogen; P – 
4mg progesterone; 125T – 125µg testosterone; 250T – 250µg testosterone, LCL-lateral 
collateral ligament. Data were expressed as mean ± SEM, n=6 per treatment group. * 
p<0.05 as compared to control, Shapiro-Wilk test, p= 0.319732. A dose-dependent increase 
in RXFP1 protein expression was observed following oestrogen treatment.  Progesterone 
caused the highest increase while testosterone caused a decrease in this isoform expression. 
The image was cut in order to arrange the bands in sequence with the label on the x-axis of 
the bar chart 
 
In Figure 4-2, the expression of RXFP1 protein in the patellar tendon following 
treatment with 4mg progesterone is 2.71 folds higher than the control. Oestrogen treatment 
resulted in a dose-dependent increase in this protein expression (1.25 to 2.67 fold increase 
following treatment with oestrogen at doses between 0.2 to 50µg/ml). Testosterone 
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treatment resulted in a dose-dependent decrease in RXFP1 protein expression (0.65 and 
0.51 fold decrease) following treatment with 125 and 250µg testosterone respectively. The 
expression of RXFP1 protein in the patella tendon was higher than the lateral collateral 
ligament.  
 
 
 
Figure 4-2 The expression of RXFP1 protein in the total homogenate of the patellar tendon 
from ovariectomised rats treated with different sex-steroids: C- control; 0.2E – 0.2g/ml 
oestrogen; 2E - 2g/ml oestrogen, 20E - 20g/ml oestrogen; 50E –50g/ml oestrogen; P – 
4mg progesterone; 125T – 125g testosterone; 250T – 250g testosterone PT- patella 
tendon. Data were expressed as mean ± SEM, n=6 per treatment group. * p<0.05 as 
compared to control, Shapiro-Wilk test, p= 0.282109. A marked increase in the expression 
of RXFP1 protein occurs following treatment with high doses of oestrogen (20 & 50g/ml). 
Meanwhile, progesterone treatment caused the highest increase while testosterone caused a 
decrease in RXFP1 protein expression in the tendon. The image was cut in order to arrange 
the bands in sequence with the label on the x-axis of the bar chart. 
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In Figure 4-3, the expression of RXFP2 protein in the lateral collateral ligament was 
the highest following treatment with progesterone (0.93 fold increase as compared to 
control) (p<0.05). A dose-dependent increase in the expression of RXFP2 protein was 
observed following treatment with increasing doses of oestrogen (0.93 to 1.09 fold increase 
with oestrogen doses between 0.2 to 50µg/ml). Treatment with 0.2µg/ml oestrogen did not 
result in a significant increase in RXFP2 protein expression as compared to control. 
Treatment with 125 and 250µg/ml testosterone resulted in a significant decrease in the 
expression of RXFP2 protein, with 13 and 14 percent reduction as compared to control.  
 
In Figure 4-3, the expression of RXFP2 protein in the patellar tendon was the 
highest following progesterone treatment (1.28 fold increase as compared to control). 
Treatment with increasing doses of oestrogen resulted in a dose-dependent increase in 
RXFP2 protein expression; although the increase observed following 0.2µg/ml oestrogen 
treatment was not significantly differ from the control. A significant reduction in RXFP2 
protein expression was noted following treatment with 250g testosterone, which was 21.9 
percent lower than the control. In the patella tendon, the expression of RXFP1 exceeds 
RXFP2 by more than two times in particular following treatment with high oestrogen doses 
(20 and 50µg/ml) and progesterone.  
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Figure 4-3 The expression of RXFP2 protein in the total homogenate of collateral ligament 
from ovariectomised rats treated with different sex-steroids: C- control; 0.2E – 0.2g/ml 
oestrogen; 2E - 2g/ml oestrogen, 20E - 20g/ml oestrogen; 50E –50g/ml oestrogen; P – 
4mg progesterone; 125T – 125g testosterone; 250T – 250g testosterone, LCL-lateral 
collateral ligament. Data were expressed as mean ± SEM, n=6 per treatment group. * 
p<0.05 as compared to control, Shapiro-Wilk test, p= 0.776415. The expression of RXFP2 
protein was increased following treatment with oestrogen at doses exceeding 2g/ml.  
Meanwhile, progesterone caused the highest increase while testosterone caused a decrease 
in RXFP2 protein expression. The image was cut in order to arrange the bands in sequence 
with the label on the x-axis of the bar chart.  
 
 
4.2.3 RXFP1and RXFP2 mRNAs Expression in the Patellar Tendon and Lateral 
Collateral Ligament 
In Figure 4-4, following progesterone treatment, the expression of RXFP1 mRNA in 
the lateral collateral ligament was 2.71 folds higher as compared to control. The lowest 
expression was noted following treatment with 250µg testosterone, which was 27 percent 
lesser than the control. Treatment with oestrogen resulted in a dose-dependent increase in 
RXFP1 mRNA expression (1.21 to 2.13 fold increase following treatment with 0.2 to 
50µg/ml oestrogen).  
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Figure 4-4 The expression of RXFP1 mRNA in the lateral collateral ligament 
fromovariectomised rats treated with different sex-steroids: C- control; 0.2E – 0.2g/ml 
oestrogen; 2E - 2g/ml oestrogen, 20E - 20g/ml oestrogen; 50E –50g/ml oestrogen; P – 
4mg progesterone; 125T – 125g testosterone; 250T – 250g testosterone, LCL-lateral 
collateral ligament. Data were expressed as mean ± SEM, n=6 per treatment group. * 
p<0.05 as compared to control, Shapiro-Wilk test, p= 0.313319. A dose-dependent increase 
in RXFP1 mRNA expression was noted with increasing doses of oestrogen. Progesterone 
treatment caused the highest increase while testosterone caused a dose-dependent decrease 
in RXFP1 mRNA expression 
 
In figure 4-5, the expression of RXFP1 mRNA in the patellar tendon was the 
highest following treatment with progesterone (2.86 fold increase as compared to control). 
Treatment with testosterone at 125 and 250g/ml resulted in a significant reduction in 
RXFP1 mRNA expression as compared to control (p<0.05), with 16 and 26 percent 
decrease respectively. Oestrogen administration resulted in a dose-dependent increase in 
the expression of RXFP1 mRNA (1.63 to 2.23 fold increase following treatment with 0.2 to 
50µg/ml oestrogen), which were significantly higher than the control (p<0.05). The level of 
expression of RXFP1 in the patellar tendon was higher than its expression in the lateral 
collateral ligament.  
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Figure 4-5 The expression of RXFP1 mRNA in the patellar tendon 
from ovariectomised rats treated with different sex-steroids: C- control; 0.2E – 0.2g/ml 
oestrogen; 2E - 2g/ml oestrogen, 20E - 20g/ml oestrogen; 50E –50g/ml oestrogen; P – 
4mg progesterone; 125T – 125g testosterone; 250T – 250g testosterone, PT-patella 
tendon. Data were expressed as mean ± SEM, n=6 per treatment group. * p<0.05 as 
compared to control, Shapiro-Wilk test, p= 0.207574. A dose-dependent increase in RXFP1 
mRNA was noted following increasing dose of oestrogen. Meanwhile progesterone 
treatment resulted in the highest increase while testosterone reduced the mRNA expression. 
 
In figure 4-6, the expression of RXFP2 mRNA in the lateral collateral ligament was 
increased following progesterone treatment which was 1.58 fold higher than the control. 
Oestrogen treatment resulted in a dose-dependent increase in RXFP2 mRNA expression 
(1.13 to1.43 fold increase following treatment with 0.2 to 50µg/ml oestrogen). Treatment 
with low dose oestrogen (0.2µg/ml) however did not result in any significant change in the 
mRNA expression, while treatment with higher oestrogen doses (>2µg/ml) resulted in a 
significant increase in the mRNA level as compared to control. Testosterone treatment at 
125 and 250µg/ml resulted in a significant decrease in RXFP2 mRNA expression as 
compared to 0.2µg/ml oestrogen and the control (p<0.05).  
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Figure 4-6 The expression of RXFP2 mRNA in the lateral collateral ligament 
from ovariectomised rats treated with different sex-steroids: C- control; 0.2E – 0.2g/ml 
oestrogen; 2E - 2g/ml oestrogen, 20E - 20g/ml oestrogen; 50E –50µg/ml oestrogen; P – 
4mg progesterone; 125T – 125g testosterone; 250T – 250µg testosterone, LCL-lateral 
collateral ligament.Data were expressed as mean ± SEM, n=6per treatment group. * p<0.05 
as compared to control, Shapiro-Wilk test, p= 0.668854. Treatment with oestrogen at doses 
exceeding 2g/ml resulted in a dose-dependent increase in RXFP2 mRNA expression. 
Meanwhile, progesterone caused the highest increase while testosterone treatment resulted 
in a decrease in this isoform mRNA expression.  
 
In figure 4-7, the expression of RXFP2 mRNA in the patella tendon was the highest 
following treatment with progesterone (2.28 fold increase as compared to control). 
Oestrogen treatment resulted in a dose-dependent increase in RXFP2 expression (1.13 to 
2.01 fold increase following treatment with 0.2 to 50µg/ml oestrogen). Treatment with 125 
and 250µg/ml testosterone resulted in a significant reduction in RXFP2 mRNA expression 
(0.79 and 0.5 fold- respectively) as compared to control. RXFP2 mRNA expression in the 
patella tendon exceeds its expression in the lateral collateral ligament only following 
treatment with 50µg/ml oestrogen and progesterone.  
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Figure 4-7 The expression of RXFP2 mRNA in the patellar tendon from ovariectomised 
rats treated with different sex-steroids: C- control; 0.2E – 0.2g/ml oestrogen; 2E - 2g/ml 
oestrogen, 20E - 20g/ml oestrogen; 50E –50g/ml oestrogen; P – 4mg progesterone; 125T 
– 125g testosterone; 250T – 250g testosterone, PT-patellar tendon. Data were expressed 
as mean ± SEM, n=6 per treatment group.  * p<0.05 as compared to control, Shapiro-Wilk 
test,p= 0.842243. An increase in the RXFP1 mRNA was noted following treatment with 
oestrogen at doses exceeding 2g/ml. Progesterone treatment resulted in the highest 
increase while testosterone caused a dose-dependent decrease in RXFP2 mRNA 
expression. 
 
4.3 Discussion 
Our findings have revealed the followings: (i) The expression of RXFP1 protein and 
mRNA in knee lateral collateral ligament and patellar tendon were up-regulated by 
oestrogen and progesterone, and were down-regulated by testosterone (ii) RXFP2 protein 
and mRNA expression were up-regulated by oestrogen at doses exceeding 2µg/ml and 
progesterone. Treatment with 0.2µg/ml oestrogen however had no significant effect on the 
expression of this receptor isoform, (iii) The expression of RXFP1 protein and mRNA in 
the patellar tendon under the influence of oestrogen and progesterone was higher than its 
expression in the lateral collateral ligament, (iv) No significant changes in RXFP2 
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expression was noted between patella tendon and lateral collateral ligament except 
following treatment with 50µg/ml oestrogen and progesterone, where higher expression 
was noted in the former than the latter and (iv) RXFP1 is the main isoform expressed in the 
patella tendon and lateral collateral ligament of the rat knee joint. 
 
The effect of relaxin on ligament laxity has long been reported(Becker GJ, 2001). 
The first evidence was documented by Hisaw in 1926 where relaxin infusion in mice was 
found to cause relaxation of the pelvic ligament (MacLennan, 1981). Research related to 
relaxin effect on knee joint laxity has become increasingly important in the recent years due 
to the reported increase in the incidence of non-contact knee injury among the female 
athletes. Recent evidence suggested that plasma relaxin level correlates with the increase in 
incidence of ACL tear in elite female athletes (Dragoo et al., 2011b). In addition to knee, 
the laxity of trapezial-metacarpal joint in humans (Wolf et al., 2013) and pubic ligaments in 
mice (Lippert et al., 1987)has also been reported to change with changes in plasma relaxin 
level.  
 
The influence of female sex-hormones on relaxin action in the knee ligaments has 
been proposed. In-vitro binding assay has revealed that relaxin binding to the female ACL 
was higher than male ACL. This finding was supported by the increase in the number of 
relaxin receptors expressed in the female ACL as compared to male (Dragoo et al., 2003). 
Quantitation of relaxin receptors by radioligand binding assay in the human ACL fibroblast 
cells has revealed that relaxin binding was present in four out of five female ACL fibroblast 
as compared to one out of five male ACL fibroblast (Faryniarz et al., 2006). The direct 
influence of oestrogen on ACL laxity has been documented by Dragoo et al (Dragoo et al., 
2009) where three weeks combined infusion of oestrogen and relaxin to the guinea pigs has 
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resulted in increased anterior tibial dislocation, indicating an increase in ACL laxity. 
Meanwhile, in rabbit temporomandibular joint and pubic symphysis, concomitant 
administration of relaxin with oestrogen was found to cause loss of glycosaminoglycans 
and collagen from these tissues, which will lead to an increase in the ligament laxity. 
Progesterone administration meanwhile prevented this effect (Hashem et al., 2006). 
 
Although this study has not provided direct evidence of an increase in the expression 
of relaxin receptors in the ACL under sex-steroid effect, we have for the first time shown 
that oestrogen and progesterone upregulate the expression of relaxin receptor isoforms 
(RXFP1 and RXFP2) in the patella tendon and lateral collateral ligament. In other tissues 
including uterus (Vodstrcil et al., 2010a) and cervix (Maseelall et al., 2009), oestrogen was 
also reported to upregulate the expression of the relaxin receptors. In this study, modulation 
of RXFP1 and RXFP2 expression by sex-steroids could provide the basis underlying the 
effect of these hormones on knee joint laxity. Recently, relaxin was also found to have 
significant effect on the patellar tendon stiffness in healthy, young and normally 
menstruating women (Pearson et al., 2011). Although the actual mechanism is unknown, 
this effect could possibly be mediated through upregulation of RXFP1 and RXFP2 by sex-
steroids, which levels fluctuate throughout the menstrual cycle. The mechanisms that lead 
to the changes in knee ligament laxity following the binding of relaxin  to its receptors have 
been earlier discussed (introduction section). 
 
Our findings have important implication as it could help to explain differences in the 
incidence of non-contact knee injury between male and female. Female was reported to 
have two to ten times higher risk of injury than male and is related to phases of the 
menstrual cycle (Hansen et al., 2013) which pointed towards the involvement of sex-
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steroids. The effect of oestrogen on  RXFP1 and RXFP2 expression in the patellar tendon 
and lateral collateral ligament  of rats’ knee confirmed the involvement of this hormone in 
modulating knee laxity. At low dose (0.2µg/ml), which correlate with the plasma oestrogen 
level of 69.7 ± 0.12pg/ml (table 1), the expression of RXFP1 was higher than the control 
although no significant changes in RXFP2 expression were noted. The mean reported 
plasma oestrogen level in the early follicular phase of the menstrual cycle was 31 pg/ml 
(0.31 X 10
-4
µg/ml) (Fenichel et al., 1989). In rat at proestrous, oestrogen level was found to 
be higher at 40.5 pg/ml (0.45 X 10
-4
µg/ml) (Walf et al., 2009 ). In view that 0.2µg/ml 
oestrogen administration resulted in the plasma oestrogen level of 69.7 pg/ml, which was 
slightly higher than the level observed in humans and rats at the follicular phase and 
proestrus stage respectively, there is a possibility that this level could affect knee ligament 
laxity via upregulating the expression of relaxin receptor isoforms rendering the tissue to be 
more sensitive towards relaxin action. 
 
Meanwhile, administration of 2, 20 and 50 µg/ml oestrogen resulted in the circulating 
plasma level of 195.2 ± 0.31, 267.7 ± 0.76 and 329.4 ± 2.33 pg/ml respectively (table 1). 
Treatment with oestrogen at doses exceeding 2g/ml resulted in higher expression of 
RXFP1 and RXFP2 as compared to the control and 0.2g/ml oestrogen.High oestrogen 
level in the blood could be achieved at the time of ovulation, with the reported level of 
400pg/ml (0.4 X 10
-3
µg/ml) (Fenichel et al., 1989). Shultz et al (Shultz et al., 2010) 
reported that high incidence of non-contact knee injury occur in the pre-ovulatory phase, 
which suggested that increased oestrogen level may have significant impact on the knee 
ligament laxity. Several other findings have also reported that increased incidence of non-
contact knee injury during the ovulatory phases of the cycle (Park et al., 2009b; Romani et 
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al., 2003; Wojtys et al., 2002) was related to the effect of high oestrogen doses on knee 
ligament laxity. Oestrogen- induced upregulation of relaxin receptors will augment relaxin 
effect on the knee. 
 
High plasma oestrogen can be achieved following consumption of oral contraceptive 
pills (OCP) that contains 15 to 50 µg oestrogen (Dhont, 2010). In the female athletes, OCP 
is consumed for birth control purpose and to prevent menstruation in order to improve their 
physical performance (Frankovich & Lebrun, 2000). Few studies have reported that OCP 
intake could influence knee laxity; however their findings seem to be conflicting. Hicks-
Little et al, (Hicks-Little et al., 2007) and Cammarata et al (Cammarata & Dhaher, 2008) 
reported that female on OCP tend to have higher knee laxity, while others reported the 
opposite (Martineau et al., 2004). Meanwhile, few other studies found no relationship 
between OCP consumption and knee ligament laxity (Agel et al., 2006; Dhont, 2010). 
Differences in sex-steroid content between different OCP formulations could be the reason 
for this variability. 
 
While oestrogen has been shown to affect ACL laxity in the animal model (Dragoo et 
al., 2009), little is known with regards to the effect of progesterone and testosterone on 
knee ligament laxity. Dragoo et al, measured serum relaxin concentration (SRC) in elite 
collegiate female athletes and had observed a positive correlation between SRC and serum 
progesterone concentration in athletes who are oligomenorrheic, eumenorrheic, not on oral 
contraceptive and have ovulatory cycle (Dragoo et al., 2011a). In this study, serum 
progesterone level was measured to confirmed luteal phase measurement of relaxin as 
relaxin levels are known to be higher in this phase. Other studies involving female athletes 
has also indicated that knee laxity was increased during ovulation and in the luteal phase of 
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the menstrual cycle (Hicks-Little et al., 2007). Meanwhile, a positive correlation between 
changes in knee laxity and knee joint load has been reported from follicular phase to 
ovulation, and from ovulation to the luteal phase (Park et al., 2009b), where the latter phase 
is associated with high serum progesterone level. Our findings which revealed an up-
regulation of RXFP1 and RXFP2 isoforms in the patella tendon and lateral collateral 
ligament by progesterone further support these observations. The increase in these isoforms 
expression in the collateral ligaments predisposes the knee towards non-contact injury 
especially during excessive varus or valgus movement.  
 
Progesterone upregulation of RXFP1 and RXFP2 expression in the knee was 
supported by findings in other tissues including the pregnant rat uteri, where this hormone 
was found to cause an increase in RXFP1 expression in the myometrium (Vodstrcil et al., 
2010a ). In the mammary glands, progesterone was reported to stimulate relaxin receptor 
expression which resulted in reduced breast laxity. This effect is due to a decrease in the 
collagen content of the mammary gland’s extracellular matrix in the presence of relaxin 
(Winn et al., 1994). In this study, the plasma level achieved following subcutaneous 
progesterone injection was 23.67 ± 0.13 ng/ml, which was slightly higher than the 
maximum plasma level reported during the luteal phase of the cycle in premenopausal 
female, at 17.02 ng/ml (Shultz et al., 2006). This indicate that the level of progesterone in 
the luteal phase can cause an increase in knee laxity, rendering the knee to be more 
susceptible towards a non-contact injury.  
 
Finally, we have also observed that RXFP1 and RXFP2 expression in both patellar 
tendon and lateral collateral ligament was down-regulated by testosterone and this effect 
was dose-dependent. In the female, the presence of androgen receptor was reported in the 
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ACL (Lovering & Romani, 2005), suggesting that testosterone could influence knee laxity. 
Testosterone level was found to fluctuate throughout the menstrual cycle, with the highest 
level noted in the luteal phase (Shultz et al., 2004).Down-regulation of RXFP1 and RXFP2 
expression by testosterone in the patella tendon and lateral collateral ligament indicated that 
knee laxity could be reduced under the influence of this hormone. A recent finding by 
O’Leary et al, (O'Leary et al., 2013) indicated that prolonged aerobic exercise in women 
with normal menstrual cycle can induce a short-term elevation in plasma testosterone level. 
We hypothesized that a continuous short-burst in plasma testosterone may result in down-
regulation of relaxin receptors in these knee structures, thus could help to reduce knee 
laxity in exercising women. In addition to this, testosterone has also been reported to 
increase the strength of the muscles  that control knee joint movement (Bhasin et al., 1996). 
Taken together, these findings may explain increased knee joint stiffness in female 
following testosterone administration. 
 
In conclusion, our study has provided novel evidences that sex-steroid affect RXFP1 
and RXFP2 expression in the patellar tendon and lateral colateral  ligament of the rat knee 
joint.These findings are important as it may help to provide the basis underlying increased 
in incidence of non-contact knee injury in female as compared to male and in female at 
different phases of the menstrual cycle. Precaution however should be taken when 
projecting these findings to humans as recent evidence suggested that there was apparently 
no relationship between serum relaxin and joint laxity (Wolf et al., 2013). 
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5 CHAPTER 5 
Testosterone Reduces Knee Passive Range of 
Motion and Expression of Relaxin Receptor 
Isoforms via 5α-Dihydrotestosterone and 
Androgen Receptor Binding 
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5.1 Introduction 
Range of motion (ROM), defined as the movement potential of a joint from full flexion 
to full extension is controlled by the connective tissue, muscles, tendons, and 
ligaments(Schmitz et al., 2013). Knee joints connect femur to tibia and fibula through the 
collateral and anterior cruciate ligaments (Marieb & Hoehn, 2013). Medial and lateral 
collateral ligaments (MCL and LCL) prevent excessive varus-valgus-forces while anterior 
cruciate ligament (ACL) prevents knee hyperextension (Marieb & Hoehn, 2013).The 
patellar tendon, which connects patella to tibia tuberosity stabilizes the patella and also 
prevents knee hyperextension(Janousek, 1999). Evidence suggests that gender could 
influence knee laxity. Females have been reported to have greater knee laxity than males(Hsu 
et al., 2006; Wojtys et al., 2003). Additionally, females have also been reported to have 
greater ankle laxity (Beynnon et al., 2005). These gender specific differences suggest that 
male and female sex hormones participate in controlling the generalized joint laxity. So far, 
studies investigating the relationship between sex hormones and joint laxity mainly focused 
on the knee and the findings remain inconclusive.  
 
Relaxin, a member of the insulin-like superfamily, has been implicated in the 
modulation of joint laxity (Dragoo et al., 2009). In primates, relaxin-1 (Rln1), 2 (Rln2), and 
3 (Rln3) are the main isoforms (Chen et al., 2012) while in rats, mice and pigs, Rln1 and 
Rln3 are the main subtypes(Sherwood, 2004). Relaxin increases the joint laxity via up 
regulating expression and stimulating activity of matrix metalloproteinases (MMPs), 
collagenases which stimulates collagen degradation and inhibit collagen synthesis by 
fibroblasts (Lee et al., 2012). Relaxin effect is mediated via binding to the relaxin receptor, 
which consists of the two main isoforms, RXFP1 and RXFP2 (Scott et al., 2012). Relaxins 
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binding to RXFP1 and RXFP2 are species specific. In humans, Rln1 and Rln2 have similar 
binding affinity to RXFP1 and RXFP2, while in rats Rln1 binds weakly to RXFP2 (Scott et 
al., 2005). Meanwhile, Rln3 has been reported to bind to RXFP1, RXFP3, and RXFP4 
(Bathgate et al., 2005) while insulin-like factor 3 (Insl3), whichis structurally related to 
relaxin, selectively binds to RXFP2 (Kumagai et al., 2002). Serum relaxin level fluctuates 
throughout the reproductive cycle and is markedly increased during pregnancy (Forst et al., 
1997). Studies have shown a higher plasma relaxin level in pregnant women with pelvic 
joint instability and increased hip joint laxity(Saugstad, 1991; Steinetz et al., 2008). While 
reports have indicated a positive correlation between the serum relaxin concentration and 
joint laxity (Dragoo et al., 2011b), relaxin effect on the joint is more reflective in rodents 
than in humans (Sherwood, 2004). 
 
Testosterone, an anabolic steroid produced by the testes, ovaries and adrenal glands has 
serum concentration seven to eight times greater in male than in female (He et al., 2007 
).Testosterone promotes the development of secondary male sexual characteristics such as 
increased in muscle and bone mass and induced male sexual behavior while its active 
metabolite, 5α-DHT promotes male pattern hair distribution. Additionally, testosterone also 
stimulates erythropoiesis and increase muscle strength (Barrett et al., 2009). Despite being 
produced in low amounts, testosterone is essential for several key reproductive processes in 
female such as decidualization (Ishikawa et al., 2007). The classical effect of testosterone is 
mediated via a genomic pathway involving the androgen receptor (AR)while a non-genomic 
pathway mediates its rapid effect(Kouloumenta et al., 2006). An understanding of the 
testosterone effect on joint laxity is currently not fully understood. Few studies have 
suggested that testosterone could influence knee laxity however, its exact role remain 
elusive. Shultz et al.(Shultz et al., 2004) reported that testosterone has a positive rather than 
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a negative relationship with changes in knee laxity in the presence of oestrogen and 
progesterone. On the other hand,Rozzi et al.(Rozzi et al., 1999) reported that male athletes 
have greater knee joint laxity that female athletes, suggesting a negative influence of 
testosterone on laxity. 
 
The notion that testosterone decreases joint laxity is further supported by the reported 
increase in the collagen content of the prostate, breast and capsular tissue and an increase in 
knee ligament repair strength by testosterone (Lovering & Romani, 2005). In view of the 
fact that relaxin increases while testosterone may decrease joint laxity(Shultz et al., 2004), 
we hypothesized that testosterone down regulates the expression of the relaxin receptor in 
the joint, rendering this tissue to be insensitive towards relaxin action. This study therefore 
aimed to investigatethe effect of testosterone on knee joint laxity and changes in relaxin 
receptor expression under testosterone influence. Additionally, the involvement of the 
androgen receptor and testosterone active metabolite, 5α-DHT, in mediating testosterone 
effect was also investigated. 
 
5.2 Results 
5.2.1 Passive Knee ROM in Testosterone-Treated Ovariectomised Rats 
The degree of knee joint angle (differences between passive flexion and extension) 
is shown in Figure 5-1. There was a significant difference in the angle between 
testosterone-treated and control groups where testosterone caused a decrease in the passive 
ROM. Testosterone effect was antagonized by flutamide (FLU) and finasteride (FIN). 
Following treatment with 125 and 250 μg/kg testosterone, the ROM was 6.22° and 6.45° 
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lower respectively than the non-treated group (p <0.05). The degree of knee joint angle in 
the groups receiving 125 and 250μg/kg testosterone was greater in the presence of FLU, 
which were 13.49° and 15.87°higher respectively (p <0.05) as compared to without FLU 
treatment. The angles in the groups receiving 125 and 250μg/kg testosterone were also 
noted to be greater in the presence of FIN, which was 12.84° and 14.82°higher respectively 
(p <0.05)as compared to without FIN treatment. Knee joint angle was significantly higher 
in the presence of relaxinin all groups except in the group receiving both doses of 
testosterone where no difference in the angles was noted. The angle was the highest in the 
control group, reduced in the presence of testosterone and significantly increased in the 
presence of FLU and FIN. 
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Figure 5-1 Passive ROM of the rat knee 
Treatment with peanut oil (control), testosterone, testosterone plus FLU or FIN with and 
without relaxin. Our findings indicated that treatment with 125 and 250 μg/kg testosterone 
significantly reduced the knee ROM as compared to control. In the presence of relaxin, 
knee ROM in the control group was significantly higher than in the testosterone-treated 
group. Relaxin administration to the group treated with testosterone did not result in a 
significant increase in the passive knee ROM as compared to without relaxin. The presence 
of FLU and FIN significantly increase the knee ROM which was further increased 
following relaxin administration (p <0.05). * p <0.05 as compared to in the absence of 
relaxin;
†
p <0.05 as compared to control; 
#
p <0.05 as compared to in the absence of FLU or 
FIN.C: control, R: relaxin, T125: 125 µg/kg/day testosterone, T250: 250 µ/kg/day 
testosteroneFLU: flutamide, FIN: finasteride. 
 
5.2.2 RXFP1 and RXFP2 mRNA Expression in Patellar Tendon 
In Figure 5-2, RXFP1 mRNA expression in the patellar tendon following 125 and 250 
μg/kg testosterone treatment was lower than the control (p <0.05). Administration of FLU to 
125 and 250μg/kg testosterone treated groups resulted in an increase in RXFP1mRNA 
expression by approximately 0.69 and 0.86 fold respectively (p <0.05). Finastride 
administration to these groups also resulted in 0.20 and 0.22 fold increase in RXFP1 
mRNA expression respectively. The expression of RXFP2 mRNA in the patellar tendon in 
125 and 250μg/kg testosterone-treated groups following FLU administration was 0.30 and 
0.71 fold higher respectively (p <0.05). The expression of RXFP2 mRNA in the group 
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receiving 125 and 250μg/ kg testosterone treatment plus FIN administration was also 
increased by 0.38 and 0.39-fold respectively (p <0.05).  
 
 
 
Figure 5-2 Changes in RXFP1 and RXFP2 mRNA expression in the presence of FLU and 
FIN in the patellar tendon of steroid-replaced ovariectomised rats. Treatment with 125 and 
250μg/kg/day testosterone caused a significant decrease in RXFP1 and RXFP2 mRNA 
levels as compared to control. Administration of flutamide and finasteride significantly 
antagonized the inhibitory effect of testosterone on RXFP1 and RXFP2 expression with 
FLU effect relatively higher than FIN for RXFP1, however no significant differences were 
noted for RXFP2 mRNA.
†
p <0.05 as compared to control *p <0.05 as compared to 
testosterone only treatment for the respective group. T125: 125 µg/kg/day testosterone, 
T250:  250 µg/kg/day testosterone, FLU: flutamide, FIN: finasteride. 
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5.2.3 RXFP1 and RXFP2 Protein Expression in Patellar Tendon 
In Figure 5-3, the expression of RXFP1 protein in the patellar tendon was higher in the 
group receiving FLU with testosterone (0.79 and 0.83 fold increase respectively as 
compared to 125 and 250μg/kg testosterone only treatment (p <0.05). The expression of 
RXFP1 protein in the groups receiving FIN with testosterone was also significantly 
increased as compared to without FIN(0.59 and 0.52-fold increase respectively as 
compared to 125 and 250μg/kg testosterone only treatment)(p <0.05). The expression of 
RXFP2 protein in the patellar tendon was increased following treatment with FLU plus the 
two doses of testosterone, (0.29 and 0.36-fold increase respectively as compared to 125 and 
250μg/kg testosterone treatment alone) (p <0.05). The expression of RXFP2 protein was 
significantly increased following treatment with FIN plus testosterone as compared to 
testosterone only treatment (0.2 and 0.24-fold increase respectively as compared to 125 and 
250μg/kg testosterone) (p <0.05). 
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Figure 5-3 The expression of RXFP1 and RXFP2protein in the patellar tissue homogenate 
from ovariectomised rats treated with testosterone with and without FLU and FIN. A 
decreasein RXFP1 protein expression was noted following testosterone treatment which 
was antagonized by FLU and FIN. The expression of RXFP2 protein was reduced 
following testosterone treatment which was also antagonized by FLU and FIN. The 
antagonizing effect of FIN indicated that DHT and not testosterone mediates the inhibition 
of RXFP1 and RXFP2 protein expression(Data were expressed as mean ± SEM, n = 6 per 
treatment group; 125T: 125μg testosterone; 250T: 250μg testosterone; FLU: 10 mg/kg 
flutamide; FIN: 20 mg/kg finasteride). †p <0.05 as compared to control *p <0.05 as 
compared to testosterone only treatment for the respective group. 
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5.2.4 RXFP1 and RXFP2 mRNA Expression in Lateral Collateral Ligament 
In Figure 5-4, the expression of RXFP1 mRNA in the lateral collateral ligament was 
reduced following treatment with testosterone at 125 and 250μg/kg/day. Administration of 
FLU and FIN resulted in a significant increase in mRNA expression where effect of the 
latter suggested DHT-mediated testosterone effect. Meanwhile, decreased RXFP2 mRNA 
expression was also noted following testosterone treatment alone (0.31 and 0.33 fold decrease 
respectively following exposure to 125 and 250μg/kg testosterone) which was also 
antagonized by FLU and FIN (p <0.05). 
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Figure 5-4 Changes in RXFP1 and RXFP2 mRNA expressionin the lateral collateral 
ligament of steroid-replaced ovariectomised rats in the presence of FLU and FIN. 
Treatment with 125 and 250μg/kg/day testosterone caused a decrease inRXFP1 and RXFP2 
mRNA expression as compared to control (testosterone only treatment) (p <0.05). 
Administration of flutamide and finasteride caused a significant increase in the expression 
of RXFP1 and RXFP2 with FLU inhibition was relatively greater than FIN for RXFP1, 
however FIN inhibition was relatively higher than FLU for RXFP2mRNA expression.
†
p <0.05 
as compared to control.*p <0.05 as compared to testosterone only treatment for the 
respective group. 
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5.2.5 RXFP1 and RXFP2 Protein Expression in Lateral Collateral Ligament 
In Figure 5-5, the expression of RXFP1 protein in the lateral collateral ligament was 
reduced following testosterone only treatment, which was antagonized by FLU and FIN. 
FLU administration resulted in 0.28 and 0.48-fold increase in RXFP1 expression as 
compared to 125 and 250μg/kg testosterone only treatment respectively(p <0.05). The 
reduced RXFP1 expression following 125 and 250 μg/kg testosterone administration was 
antagonized by FIN (p >0.05). A decrease in the expression of RXFP2 protein in the lateral 
collateral ligament following administration of both doses of testosterone was also 
antagonized by FLU and FIN.  
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Figure 5-5 The expression of RXFP1 and RXFP2 protein 
RXFP1 and RXFP2 protein from the homogenate of lateral collateral ligaments of 
ovariectomised rats treated with 125 and 250 μg/kg testosterone with and without FLU and 
FIN administration. A dose-dependent decrease in RXFP1 protein expression was noted 
following treatment with both doses of testosterone which was antagonized by FLU and 
FIN. Similarly, a decrease in RXFP2 protein expression was observed following treatment 
with both doses of testosterone which was antagonized by FLU and FIN. Data were 
expressed as mean ± SEM, n = 6 per treatment group; 125T: 125μg testosterone;250T: 
250μgtestosterone; FLU: 10 mg/Kg FLU; FIN: 20 mg/kg FIN.†p <0.05 as compared to 
control;*p <0.05 as compared to testosterone only treatment for the respective group. 
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5.3 Discussion 
To the best of our knowledge, this study is the first to demonstrate the effect of 
testosterone on knee laxity in an ovariectomised rat model. Ovariectomy was performed to 
investigate sex-steroid effect on the ligament laxity, as removal of endogenous hormone 
and replacement with exogenous steroid would ensure that the effect observed was due to 
the action of individual steroid rather than the combined effect of multiple steroids 
produced by the ovaries. In the female of reproductive age, 25% of the circulating 
testosterone originates from the ovaries while the remaining is derived from conversion of 
androsteinedione into testosterone in the adrenal gland(Speroff et al., 1989). In humans, the 
level of endogenous testosterone has been reported to fluctuate throughout the menstrual 
cycle which was the highest at around the time of ovulation (Rao & Kotagi, 1982). A recent 
finding by O’Leary et al.(O'Leary et al., 2013) reported that a prolong edaerobic training in 
the eumenorrheic women induces a short-term elevation in the plasma testosterone levels, 
which appears to be unrelated to the level of oestrogen and the phases of menstrual 
cycle.There is currently no report on changes in the testosterone level throughout the 
oestrous cycle.  
 
Testosterone has been proposed to influence knee laxity in female. A positive 
correlation between plasma testosterone, free androgen index (FAI) and anterior cruciate 
ligament stiffness has been reported in young females near ovulation (Lovering & Romani, 
2005). The mechanisms underlying testosterone effect on ligament laxity is unknown, 
however a limited finding in the prostate gland indicated that testosterone as opposed to 
oestrogen affects collagen metabolism (Srinivasan et al., 1986) via down regulating the 
expression of oestrogen receptor (ER)-α(Asano et al., 2003). So far, no study has reported 
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testosterone effect on relaxin receptor expression in the joints, although relaxin has been 
shown to affect ligament laxity and its receptor was expressed in female knee joint of both 
humans(Dragoo et al., 2003) and rodents (Dragoo et al., 2009). Our findings which 
revealed down regulation of relaxin receptor expression in the knee ligaments and tendons by 
testosterone has provided explanation for the observed decrease in knee passive ROM under 
testosterone influence. A decrease in knee passive ROM could be due to decreases in the 
relaxin effect on ligament, rendering the tissue to have decreased laxity.  
 
Our study has provided the first direct evidence on testosterone effect on the passive 
ROM in rats’ knee. We have shown that testosterone reduces the ROM, which was 
inhibited by FLU and FIN. In the group receiving 125 and 250μg/kg/day testosterone 
treatment, the presence of relaxin did not significantly increase knee passive ROM. This 
finding suggested that knee was not responsive to relaxin in the presence of testosterone 
due to relaxin receptor down regulation. The knee ROM was however increased following 
FLU or FIN administration, suggesting that inhibition of androgen binding to its receptor 
and conversion of testosterone to DHTcaused the increase in knee laxity. FLU inhibition 
confirmed the release of DHT-mediated inhibition on relaxin receptor expression through 
androgen receptor binding. Relaxin administration resulted in further increase in knee laxity 
in the groups receiving both testosterone doses with FLU or FIN, which again suggested the 
release of DHT-mediated inhibition on relaxin receptor expression. Meanwhile, increased 
knee laxity in the groups receiving testosterone with FLU or FIN without relaxin suggested 
that endogenously produced relaxin from sources such as breast(Speroff et al., 1989)might 
influence knee laxity.  
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The presence of AR has been reported in human female knee joint (Fytili et al., 
2005; Lovering & Romani, 2005). In this study, inhibition of testosterone-mediated down-
regulation of RXFP1 and RXFP2 protein and mRNA expression in the patellar tendon and 
lateral collateral ligament by FLU confirmed AR involvement in mediating testosterone 
effect. Our findings have also confirmed DHT involvement in mediating testosterone action 
as evidenced from the antagonizing effect of FIN on testosterone-mediated decrease in knee 
passive ROM as well as testosterone-mediated down-regulation ofRXFP1 and RXFP2 
protein and mRNA expression in these knee structures. FIN is a competitive, selective, and 
reversible inhibitor of 5α-reductase, an enzyme that converts testosterone to DHT (Frye et 
al., 1998). In females, DHT exerts multiple physiological effects mainly in the uterus and 
ovaries (Cárdenas & Pope, 2005). DHT has also been reported to cause an increase in the 
twitch and titanic contraction of fast-twitch skeletal muscle in mice (Hamdi & Mutungi, 
2010). Although we have shown evidence that DHT is most likely involved in causing a 
decrease in knee laxity, further studies are needed to support DHT participation such as 
identifying the expression and measuring the activity of 5α- reductase enzyme in the knee. 
In our study, a direct effect of DHT on knee laxity and relaxin receptor isoforms expression 
was unable to be investigated since this prohibited compound was not commercially 
available.  
 
Our findings have important implications in the field of exercise physiology. 
Testosterone could affect female knee laxity as its level was reported to be the highest in 
the ovulatory phase of the menstrual cycle (Lovering & Romani, 2005). Although we have 
found that testosterone decreases knee laxity, the findings by Shultz et al.(Shultz et al., 
2005) who reported a positive correlation between plasma oestrogen and testosterone level 
with knee laxity throughout the menstrual cycle suggested dominant effects of oestrogen over 
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testosterone. In female athletes, anabolic steroids are widely used to boost their physical 
performances. Despite reported adverse effects, this drug could help to strengthen the knee 
via its effect on ligament and tendon laxity, which could improve athletes’ short-term 
performance as well as reduce the risk of non-contact knee injury. Additionally, the 
strength of the muscles controlling knee joint movement was also increased(Bhasin et al., 
1996). This study has shown for the first time the direct effect of testosterone on knee passive 
ROM and RXFP1 and RXFP2 protein and mRNA expression in a rat model, which was 
mediated via DHT and involved androgen receptor binding. These therefore could explain 
the protective role of testosterone against non-contact knee injury in female. Precaution 
however is needed when extrapolating these data to humans since relaxin action on human 
joints might not be as pronounced as those observed in rodents (Wolf et al., 2013). 
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6 CHAPTER 6 
Oestrogen Receptor (ER)-α, β and Progesterone 
Receptor (PR) Mediates Changes in Relaxin 
Receptor (RXFP1 and RXFP2) Expression and 
Passive Range of Motion of Rats' Knee  
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6.1 Introduction 
Sex-steroids have been reported to regulate changes in knee laxity (Dehghan et al., 
2014 ). E2 cause increased (Dragoo et al., 2009) while testosterone cause decreased 
(Dehghan et al., 2014) knee laxity in rodents. In humans, knee laxity was reported to 
increase at around the time of ovulation, indicating of E2 influence (Zazulak et al., 2006). 
Knee laxity was also reported to be the highest in the luteal phase of the menstrual cycle, 
suggesting of P4 influence (Heitz et al., 1999). Meanwhile, high E2 level was reported to 
cause increased anterior tibial dislocation in rats during pregnancy (Charlton et al., 2001). 
The mechanisms underlying E2 and P4 effects on knee laxity are not well understood, 
however evidences suggested that these effects could be mediated via changes in collagen 
turnover (Song et al., 2014), modulation of enzymes activity involved in collagen 
metabolism (Shan et al., 2013) as well as response of tissues towards relaxin via changes in 
the amount of receptor expressed (Dehghan et al., 2014 ). 
 
The effect of sex-steroids is preceded by the binding to intracellular receptor, 
located either in the cytosol or nuclear compartments (Bayard et al., 1978). Binding of 
ligands to this receptor  will initiate translocation of ligand-receptor complex to the nucleus 
where it acts as a transcription factor which binds to hormone responsive elements (HRE) 
on DNA, initiating gene transcription (Wierman, 2007). Two forms of ER have been 
identified i.e. ERα and ERβ, which varies in the tissue distribution. Meanwhile, PR  also 
varies in tissues distribution (Edwards, 2005). ER and PR have been identified in human 
anterior cruciate ligament (ACL) (Liu et al., 1996) which could explain changes in knee 
laxity under different sex-steroid influence. Sex-steroids modulate joint laxity either 
directly or indirectly. E2 was reported to cause a significant loss of glycosaminoglycans 
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(GAGs) and collagen content from the pubic symphysis, temporomandibular joint disc and 
articular cartilage of the knee in rabbits (Hashem et al., 2006).E2 also affects the expression 
of several isoforms of metalloproteinase (MMPs-1, 3 and 13) as well as tissue inhibitor of 
metalloproteinases (TIMP 1) (Lee et al., 2003) which were involved in collagen turnover. 
Meanwhile, E2 and P4were also reported to induce protein and mRNA expression of relaxin 
receptors (RXFP1 and RXFP2) which result in increase tissue response towards relaxin 
(Dehghan et al., 2014 ).  
 
Relaxin, a 6-kDa polypeptide is structurally related to insulin and is produced by the 
corpus luteum and placenta . Relaxin exerts various effects on the musculoskeletal system 
via binding to several isoforms of relaxin receptor (RXFP1, RXFP2, RXFP3 and RXFP4) 
(Dehghan et al., 2013a) and participates in extracellular matrix remodeling (Sherwood, 
1994). Relaxin receptor expression has been identified in human female ACL (Dragoo et 
al., 2003). Relaxin regulates synthesis and/or degradation of matrix macromolecules via 
modulating the activity of several members of MMP enzymes (Naqvi et al., 2005). Serum 
relaxin levels have been  reported to correlate with the levels of MMP-1 in anterior oblique 
ligament of thumb (Wolf et al., 2013) while relaxin effect on MMP-9 was found to be 
mediated via binding to RXFP1 (Ahmad et al., 2012).  
 
We hypothesized that E2 and P4 effects on knee laxity and the expression of RXFP1 
and RXFP2 receptors were mediated via ER isoforms (ERα and ERβ) and progesterone 
receptor (PR) respectively. The aim of this study is therefore to investigate the involvement 
of sex-steroid receptors in mediating E2 and P4 effects on knee passive ROM and relaxin 
receptor isoforms expression in the patellar tendon, collateral ligaments and hamstring 
muscles which are involved in controlling knee joint movement.  
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6.2 Results 
6.2.1 Effect of steroid receptor antagonists on RXFP1 and RXFP2 mRNA and proteins 
expression in the patellar tendon 
 
 
 
 
 
C 
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Figure 6-1 RXFP1& RXFP2 mRNA and protein expression 
(A) The expression of RXFP1 mRNA in the patellar tendon of ovariectomized rats treated 
with E2, P4 and their antagonists. Control; 0.2E – 0.2µg/kg E2; ICI+0.2E- ICI 182/780 (25 
mg/kg) + 0.2 µg/kg E2; MPP+0.2E – MPP (25mg/kg) + 0.2µg/kg E2; PHTPP+0.2E –
PHTPP (25 mg/kg) + 0.2 µg/kg E2; P- 4mg/kg P4; Mife+P- 7.5 mg/kg mifepristone +4 
mg/kg P4. Data were expressed as mean ± SEM, n = 6 per treatment group and * p < 0.05 
as compared to control, #p<0.05 as compared to the respective agonist only treatment. (B) 
The expression of RXFP2 mRNA in the patellar tendon of ovariectomized rats treated with 
E2, P4 and their antagonists: Control; 0.2E – 0.2 µg/kg E2; ICI+0.2E- ICI 182/780 (25 
mg/kg) + 0.2 µg/kg E2; MPP + 0.2E – MPP (25 mg/kg) + 0.2 µg/kg E2; PHTPP+0.2E –
PHTPP (25 mg/kg) + 0.2 µg/kg E2; P- 4 mg/kg P4; Mife + P- 7.5 mg/kg mifepristone +4 
mg/kg P4. Data were expressed as mean ± SEM, n = 6 per treatment group and * p<0.05 as 
compared to control, #p<0.05 as compared to the respective agonist only treatment. (C) 
Ratio ofRXFP1& RXFP2/ β-actin protein expression levels in patellar tendon of 
ovariectomized rats treated with E2, P4 and their antagonists. Control; 0.2 E – 0.2 µg/kg 
E2; ICI+0.2 E- ICI 182/780 25 mg/kg + 0.2 µg/kg E2; MPP+0.2 E – MPP 25 mg/kg + 0.2 
µg/kg E2; PHTPP+0.2 E – PHTPP 25 mg/kg + 0.2 µg/kg E2; P- 4 mg/kg progesterone; 
Mife + P- 7.5 mg/kg mifepristone + 4 mg/kg  P4. Data were expressed as mean ± SEM, 
n=6 per treatment group and * p < 0.05 as compared to control, #p<0.05 as compared to the 
respective agonist only treatment. 
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In figure 6-1, the expression level of RXFP1 mRNA in the patellar tendon of 
ovariectomized rats received E2 was reduced by approximately 0.81, 1.4 and 1.62 fold in 
the presence of ICI 182/780, MPP, and PHTPP respectively as compared to 0.2 µg E2 
treatment alone. The expression of RXFP1 mRNA was the highest in the P4 treated group 
which was antagonized by approximately 2.31 fold in the presence of PR blocker, 
mifepristone.  
 
The expression level of RXFP2 mRNA in patellar tendon following E2 treatment 
was significantly reduced by approximately 0.35, 0.97 and 1.12 fold in the presence of ICI 
182/780, MPP, and PHTPP respectively as compared to 0.2 µg E2 treatment alone. The 
expression of RXFP2 mRNA in the patellar tendon which was the highest following 
treatment with P4 was significantly reduced by approximately 1.45 fold following PR 
antagonist, mifepristone administration. 
 
Meanwhile, RXFP1 and RXFP2 protein expressions in the patellar tendon were the 
highest following P4 treatment. Mifepristone caused a significant decrease in both isoforms 
expression. The expressions of RXFP1 and RXFP2 under E2, which were significantly 
higher than control, were inhibited by ICI 182780, MPP and PHTPP. PHTPP caused the 
highest inhibition on RXFP1 and RXFP2 protein expression.  
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6.3 Effect of steroid receptor antagonists on RXFP1 and RXFP2 mRNA and proteins 
expression in the collateral ligaments 
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Figure 6-2 RXFP1& RXFP2 mRNA and protein levels in collateral ligament 
(A) The expression of RXFP1 mRNA in collateral ligament of ovariectomized rats treated 
with E2, P4 and their respective antagonists. Control; 0.2E – 0.2 µg/kg oestrogen; ICI + 
0.2E - ICI 182/780 (25 mg/kg) + 0.2 µg/kg E2; MPP + 0.2 E – MPP (25 mg/kg) + 0.2 
µg/kg E2; PHTPP + 0.2 E – PHTPP (25 mg/kg) + 0.2 µg/kg E2; P - 4mg/kg P4; Mife + P - 
7.5 mg/kg mifepristone +4 mg/kg P4. Data were expressed as mean ± SEM, n=6 per 
treatment group and * p < 0.05 as compared to control, #p<0.05 as compared to the respective 
agonist only treatment.(B) The expression of RXFP2 mRNA in collateral ligament of 
ovariectomized rats treated with E2, P4 and their antagonists: Control; 0.2 E – 0.2 µg/kg 
E2; ICI+0.2 E- ICI 182/780 (25 mg/kg) + 0.2 µg/kg E2; MPP+0.2 E – MPP (25 mg/kg) + 
0.2 µg/kg E2; PHTPP+0.2 E –PHTPP (25 mg/kg) + 0.2 µg/kg E2; P-4 mg/kg P4; Mife + P-  
7.5 mg/kg mifepristone + 4 mg/kg P4. Data were expressed as mean ±  SEM, n=6 per 
treatment group and * p < 0.05 as compared to control, #p<0.05 as compared to the respective 
agonist only treatment.. (C) Ratio ofRXFP1& RXFP2/ β-actin protein levels in collateral 
ligament in presence of oestrogen& progesterone antagonists. Control; 0.2 E – 0.2 µg/kg 
E2; ICI + 0.2 E- ICI 182/780 (25 mg/kg) + 0.2 µg/kg E2; MPP+0.2 E – MPP (25 mg/kg) + 
0.2 µg/kg E2; PHTPP+0.2 E – PHTPP 25 mg/kg + 0.2 µg/kg E2; P-4 mg/kg P4; Mife + P- 
7.5 mg/kg mifepristone + 4 mg/kg P4. Data were expressed as mean ± SEM, n=6 per 
treatment group and * p < 0.05 as compared to control, #p<0.05 as compared to the respective 
agonist only treatment. 
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In Figure 6-2, the expression levels of RXFP1 mRNA in ovariectomised rats 
collateral ligaments of the knee were decreased in the presence of steroid receptor 
antagonists. The expression of RXFP1 mRNA was increased following oestrogen treatment 
and was reduced in the presence of different antagonists, by approximately 0.96, 0.81 and 
1.07 fold decrease following administration of ICI 182/780, MPP and PHTPP respectively. 
The expression of RXFP1 mRNA in the collateral ligaments which was the highest 
following administration of P4 was reduced in the presence of PR antagonist, mifepristone 
by approximately 2.28 fold.  
 
The expression level of RXFP2 mRNA in ovariectomized rats received E2 treatment 
was decreased in the presence of ERα and ERβ antagonists. The expression of RXFP2 
mRNA in the collateral ligament was approximately 0.93, 0.73 and 1.09 fold lower 
following administration of ICI 182/780, MPP and PHTPP respectively as compared to in 
the absence of these receptor blockers. The expression of RXFP2 mRNA in collateral 
ligament was the highest following P4 treatment which was reduced by approximately 1.09 
fold following PR antagonist, mifepristone administration.  
 
Meanwhile, RXFP1 and RXFP2 protein expression in the collateral ligament was 
significantly increased under P4 influence and was antagonized by mifepristone. Under E2 
influence, these isoforms expression were slight but significantly higher than the control 
group. Administration of ICI 182780, MPP and PHTPP resulted in a marked inhibition of 
RXFP1 and RXFP2 proteins expression under E2 with PHTPP administration caused the 
greatest inhibition.  
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6.4 Effect of steroid receptor antagonists on RXFP1 and RXFP2 mRNA and proteins 
expression in the hamstring muscles 
 
 
 
 
 
 
113 
 
 
 
Figure 6-3 RXFP1& RXFP2 mRNA and proteins levels in the hamstringmuscle 
(A) The expression of RXFP1 mRNA in the hamstring muscle of ovariectomized rats 
treated with E2, P4 and their antagonists. Control; 0.2 E – 0.2 µg/kg E2; ICI+0.2 E- ICI 
182/780 25 mg/kg + 0.2 µg/kg E2; MPP+0.2 E – MPP (25 mg/kg) + 0.2 µg/kg E2; 
PHTPP+0.2 E –PHTPP (25 mg/kg) + 0.2 µg/kg E2; P-4 mg/kg P4; Mife + P- 7.5 mg/kg 
mifepristone +4 mg/kg P4. Data were expressed as mean ± SEM, n=6 per treatment group 
and * p < 0.05 as compared to control. (B) The expression of RXFP2 mRNA in the 
hamstring muscle of ovariectomized rats treated with E2, P4 and their antagonists: Control; 
0.2 E – 0.2 µg/kg E2; ICI+0.2 E- ICI 182/780 (25 mg/kg) + 0.2 µg/kg E2; MPP+0.2 E – 
MPP (25 mg/kg) + 0.2 µg/kg E2; PHTPP+0.2 E –PHTPP (25 mg/kg) + 0.2 µg/kg E2; P-4 
mg/kg P4; Mife + P-  7.5 mg/kg mifepristone + 4 mg/kg P4. Data were expressed as mean 
± SEM, n=6 per treatment group and * p < 0.05 as compared to control. (C) Ratio 
ofRXFP1& RXFP2/ β-actin protein expression levels in hamstring muscle of 
ovariectomized rats treated with E2, P4 and their antagonists. Control; 0.2 E – 0.2 µg/kg 
E2; ICI+0.2 E- ICI 182/780 (25 mg/kg) + 0.2 µg/kg E2; MPP + 0.2E – MPP (25 mg/kg) + 
0.2 µg/kg E2; PHTPP+0.2E –PHTPP (25 mg/kg) + 0.2 µg/kg E2; P- 4mg/kg P4; Mife + P- 
7.5 mg/kg mifepristone + 4 mg/kg P4. Data were expressed as mean ± SEM, n = 6 per 
treatment group and * p < 0.05 as compared to control, #p<0.05 as compared to the respective 
agonist only treatment. 
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In figure 6-3, the expression level of RXFP1 mRNA in ovariectomized rats' 
hamstring muscle under the effect of E2was reduced in the presence of ER antagonists, ICI 
182/780, MPP, and PHTPP by approximately 0.92, 0.71 and 1.07 fold respectively as 
compared to 0.2 µg E2 treatment alone. Expression of RXFP1 mRNA in the hamstring 
muscle was the highest following treatment with P4 and was markedly reduced in the 
presence of PR antagonists, mifepristone by approximately 2.31 fold as compared to P4 
treatment alone.  
 
The expression level of RXFP2 mRNA in ovariectomized rats hamstring muscle 
was reduced by  approximately 0.91, 0.83 and 1.09 fold following treatment with ICI 
182/780, MPP, and PHTPP respectively as compared to treatment with 0.2 µg E2 alone. 
The expression of RXFP2 mRNA was the highest following P4 treatment which was 
reduced by approximately 1.09 fold in the presence of PR antagonist, mifepristone. 
Meanwhile, in the hamstring muscle, RXFP1and RXFP2 proteins were expressed the 
highest in P4 treated group which were antagonized by mifepristone. E2 treatment resulted 
in slightly higher RXFP1 and RXFP2 protein expression which were markedly inhibited 
following administration of PHTPP, MPP and ICI 182 780.  
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6.5 Knee passive ROM in the presence of steroid receptor antagonist 
 
Figure 6-4 Knee passive ROM of ovariectomised rats 
Rats received different doses of E2, P4 and the receptor antagonists with and without 
relaxin. Control; E – 0.2 g/kg E2; E+RLN- E2 plus Relaxin, E+ICI- E2 plus 25 mg/kg ICI 
182/780; E+ICI+RLN- E2 plus 25 mg/kg ICI 182/780 plus Relaxin, E+M- E2 plus 25 
mg/kg MPP, E+M+RLN- E2 plus 25 mg/kg MPP+Relaxin, E+PH- E2 plus  25 mg/kg 
PHTPP, E+PH+RLN- E2 plus  25 mg/kg PHTPP plus Relaxin, P-4 mg/kg P4; P+RLN- 
ICI-P4 plus Relaxin, P+MF- P4 plus Mifepristone (7.5 mg/kg) and P+MF+RLN-  P4 plus 
Mifepristone (7.5 mg/kg)  plus Relaxin. Data were expressed as mean ± SD, n=6 per 
treatment group and * p < 0.05 as compared to control, #p<0.05 as compared to the without 
receptor blocker, †p<0.05 as compared to withour relaxin. Knee passive ROM was 
following E2 and P4 treatments. 
 
 
In Figure 6-4, the increase in knee passive ROM in E2 treated group (p<0.05 as 
compared to control) was antagonized by MPP and PHTPP however not by ICI 182780. 
Knee passive ROM was the highest following P4 treatment (mean = 92.4 
o 
±4.13) which 
was antagonized by mifepristone (p<0.01). Relaxin administration caused an even higher 
increase in knee passive ROM in the control, E2 and P4-treated groups, however no 
significant changes in knee ROM were observed in the groups received E2 plus MPP, E2 
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plus PHTPP treatments as compared to similar groups without relaxin. Meanwhile, relaxin 
administration in the group received P4plus mifepristone treatment also did not cause any 
significant changes in knee passive ROM.  
 
6.6 Discussion 
This study reveals the presence of ERα, ERβ and PR in patellar tendon, collateral 
ligaments and hamstring muscle of rats. In this study, the administration of PHTPP, an ERβ 
antagonist markedly reduce the expression of RXFP1 and RXFP2 mRNA in the patellar 
tendon, collateral ligaments and hamstring muscles. PHTPP is a specific ERβ antagonist 
with a 36-fold selectivity over ERα, therefore its inhibition on oestrogen effect would 
confirm the involvement of  ERβ subtypes in mediating the biological effects of oestrogen 
(Compton et al., 2004). Previous study has also reported the presence of ER (general) in the 
synoviocytes, fibroblasts and ligament's blood vessel of the knee joint (Liu et al., 1996) 
which could support our functional observations. 
 
Meanwhile, the effect of ICI 182780 (fulvestrant), a potent anti-oestrogen which 
was known to disrupt receptor translocation into the nucleus as well as increase receptor 
degradation (Osborne et al., 2004; Wakeling, 2000) on E2-mediated expression of relaxin 
receptors was also documented in this study. ICI 182 780 binds to ER with affinity 
approximately 100 times greater than tamoxifen, a partial anti-oestrogen however with no 
agonist activity on oestrogen sensitive tissue such as uterus (Robertson, 2001). Our findings 
which indicate that ICI 182780 administration did not result in a significant decrease in 
RXFP1 and RXFP2 mRNA expression in the patellar tendon of rats received E2 treatment, 
suggested that ligand-receptor complex translocation into the nucleus may not be required 
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for mediating E2 effect in this tissue, most probably due to the presence of abundance 
nuclear ER. In mouse, ICI 182780 has been reported to disrupt nuclear-cytoplasmic 
shuttling where the receptor could be retained in the cytoplasm, therefore blocking E2 effect 
(Dauvois et al., 1993). We speculated that in the tendon, cytoplasmic shuttling may not 
occur, therefore E2 effects could be minimally affected by ICI 182780. There is also a 
possibility ICI 182780 may not reached the target site in the tendon due its poor 
vascularization as compared to synovium (Rempel & Abrahamsson, 2001). In contrast, ICI 
182780 exerts a strong inhibition on RXFP1 and RXFP2 mRNA expressions in the 
collateral ligaments and hamstring muscles indicating that these tissues were responsive 
towards ICI 182780 inhibition. Administration of a specific ERα antagonist, MPP also 
resulted in a significant inhibition of RXFP1 and RXFP2 mRNA in the patellar tendon, 
collateral ligament and hamstring muscles, however the degree of inhibition were 
significantly lesser than following PHTPP treatment. This finding indicates that despite of 
its presence, ERα is not the main isoform expressed in these tissues.  
 
Our findings further revealed that RXFP1 and RXFP2 protein expressions follow an 
almost identical pattern to that of mRNA. Administration of ICI 182780, MPP and PHTPP 
significantly inhibit these proteins expression in the muscle, tendon and ligaments 
surrounding the knee joint. PHTPP exerts the strongest inhibition therefore confirmed that 
ERβ is the main ER isoform expressed. Milder inhibition by MPP suggested that ERα was 
also involved in mediating RXFP1 and RXFP2 expression while variable degree of 
inhibition by ICI 182780 indicates that E2 in general is required for the expression of 
relaxin receptor isoforms proteins.  
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Meanwhile, the involvement of PR in mediating the up-regulation of RXFP1 and 
RXFP2 mRNA in the patellar tendon, collateral ligaments and hamstring muscles was 
confirmed from the inhibition by mifepristone. In addition to these knee-related structures, 
PR was also reported to be expressed in the synovium and ACL of human knees (Liu et al., 
1996), which could explain P4 effect on knee laxity.   
 
Our functional study revealed the lack of relaxin effect in rats received ERα, ERβ 
and PR antagonists which indicate that these receptors were required to mediate relaxin 
effects on the knee. Relaxin administration caused increased in knee passive ROM in the 
groups treated with E2 and P4  however not in the control group, suggesting that these 
hormones were required to mediate relaxin effects in causing increase in knee passive 
ROM. Relaxin could act directly via inducing the activity of MMP, an enzyme responsible 
for collagen breakdown (Naqvi et al., 2005). E2 and P4have been shown to up-regulate the 
expression of relaxin receptors in ovariectomised rats' knee (Dehghan et al., 2014 ), 
therefore relaxin effects were augmented in the presence of these hormones.  Our findings 
confirmed that both E2 and P4 up-regulate RXFP1 and RXFP2 in the patellar tendons, 
hamstring muscles and collateral ligaments via ERβ>>ERα and PR which cause the 
increase in knee laxity under these hormones influences.  
 
In conclusion, this study has provided evidences to support the involvement of ERα, 
ERβ and PR in mediating E2 and P4-induced increase in knee passive ROM and RXFP1 and 
RXFP2 expression in the structures controlling knee joint movements. We have shown that 
E2 effects were mediated mainly via binding to ERβ. Modulation of relaxin receptor 
expression by selective antagonists to ERβ  and PR could be useful to prevent the increase 
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in knee laxity under different sex-steroid influence thus could help to lower the incidence of 
non-contact knee injury which is related to different phases of the reproductive cycle. 
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7 CHAPTER 7 
Changes in Laxity and Expression of Relaxin 
Receptor Isoforms (RXFP1 and RXFP2) of Rats' 
Knee at Different Phases of Oestrus Cycle   
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7.1 Introduction 
Joint laxity has been reported to be modulated by hormones. In lower species such 
as rodents, relaxin, a polypeptide produced by the corpus luteum in non-pregnant females 
(Dehghan et al., 2014)was found to reduce laxity of the pelvic joint ligament during 
pregnancy in species such as guinea pigs, mice and bats (Sherwood et al., 1992). In rats, 
relaxin administration has been reported to reduce the organization and mechanical strength 
of periodontal ligaments (Madan et al., 2007).  In human females, serum relaxin levels was 
found to positively correlate with the incidence of anterior cruciate ligament tear, 
suggesting of relaxin influence on knee laxity (Dragoo et al., 2011a). Additionally, relaxin 
receptor has also been reported to be expressed in the anterior cruciate ligament (Dragoo et 
al., 2003). Meanwhile, in rats, both relaxin receptor isoforms, RXFP1 and RXFP2 were 
found to be expressed in knee collateral ligaments and patellar tendon (Dehghan et al., 
2014 ).  
There were evidences, which suggest the involvement of female hormones in 
modulating joint laxity. Following pregnancy in rats, knee joint contracture which was 
created by prolonged immobilization was reduced as compared to the non-pregnant rats, 
suggesting the influence of progesterone in the decrease in joint laxity (Ohtera et al., 2002). 
A pregnancy-associated increase in laxity of medial collateral ligament was also observed 
in rabbits (Hart et al., 2000). Increased in the incidence of back pain in humans during 
pregnancy is also related to increase in pelvic ligament laxity, influence by progesterone 
with little influence by relaxin (Aldabe et al., 2012). In ovariectomised sheep, 
administration of physiologic dose of oestrogen and oestrogen receptor antagonist was 
found to have no significant effect on anterior cruciate and medial colateral ligaments of the 
knee (Strickland et al., 2003).  Several studies in humans have indicated the influence of 
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female sex hormones i.e. oestrogen and progesterone on knee laxity. Zazulak et al, 
(Zazulak et al., 2006) and Park et al, (Park et al., 2009a) reported that laxity was the highest 
at ovulation indicating of oestrogen influence. Knee laxity was also high in the luteal phase 
of the cycle, indicating of progesterone influence (Shultz et al., 2005). 
Despite of its use as experimental model, changes in knee laxity in rodent 
throughout phases of the oestrus cycle is widely unknown. Additionally, mechanisms 
underlying these changes have not been fully elucidated. Based on the reported modulation 
of relaxin receptor expression by sex-steroids (Dehghan et al., 2014 ), we hypothesized that 
expression of relaxin receptor isoforms in the knee and muscles controlling knee joint 
movement changes at different phases of the oestrus cycle. The aims of this study were 
therefore to investigate changes in knee passive range of motion (ROM) and expression of 
relaxin receptor isoforms, RXFP1 and RXFP2 in the patellar tendon, collateral ligaments 
and hamstring muscles which could contribute to the observed changes in knee laxity at 
different phases of the cycle. 
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7.2 Results 
7.2.1 Knee Passive ROM at different phases of the oestrus cycle 
 
Figure 7-1 Knee passive ROM at different phases of the oestrus cycle 
Ps-proestrus; Es-estrus; Ms; metestrus; Ds; diestrus. Data were expressed as mean ± SEM 
and n = 6 per treatment group. Knee ROM was the highest at proestrus and diestrus phases 
and the lowest at estrus and metestrus phases. 
 
 
Figure 7-1 shows knee passive ROM in intact female rats at different phases of the 
oestrus cycle. The ROM was the highest at proestrus and diestrus. Meanwhile, knee ROM 
was the lowest at estrus and metestus which were significantly lower than proestrus and 
diestrus.  
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7.2.2 RXFP1 & RXFP2 expressions in hamstring muscle at different phases of the oestrus 
cycle 
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Figure 7-2 RXFP1& RXFP2 mRNA and protein expression in the hamstring muscle 
at different phases of the oestrus cycle. The expression of (A) RXFP1 mRNA (B) RXFP2 
mRNA and (C) RXFP1& RXFP2 proteins in the hamstring muscle. The highest mRNA 
and protein expression levels were noted at proestrus phase. Ps-proestrus; Es-estrus; Ms; 
metestrus; Ds; diestrus. Data were expressed as mean ± SEM and n = 6 per treatment 
group.  
 
Figure 7- 2 shows (A) RXFP1 mRNA, (B) RXFP2 mRNA and (C) RXFP1 and 
RXFP2 over β-actin protein expressions in the hamstring muscles of intact rats at different 
phases of the oestrus cycle. Our findings indicate that RXFP1 and RXFP2 mRNA levels 
were the highest at proestrus and diestrus (proestrus >> diestrus) followed by metestrus and 
estrus.  The expression was the lowest at oestrus.  In the hamstring muscle, RXFP1 mRNA 
level was higher than RXFP2. Meanwhile, RXFP1 and RXFP2 proteins were expressed the 
highest during proestrus followed by diestrus. The expression was the lowest at metestrus. 
The levels of RXFP1 protein expressed in the muscles were higher than RXFP2.  
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7.2.3 RXFP1 & RXFP2 expression in patellar tendon at different phases of the oestrus 
cycle 
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Figure 7-3 RXFP1& RXFP2 mRNA and protein expression levels in patellar tendon 
at different phases of the oestrus cycle. The expression of (A) RXFP1 mRNA (B) RXFP2 
mRNA and (C) RXFP1& RXFP2 protein in patellar tendon. mRNA and protein expression 
levels were highest at proestrus and diestrus phases. Ps-prosterous; Es-estrus; Ms; 
metestrus; Ds; diestrus. Data were expressed as mean ± SEM and n =6 per treatment group. 
 
Figure 7-3 shows (A) RXFP1 mRNA, (B) RXFP2 mRNA and (C) RXFP1 and 
RXFP2 over β-actin protein expressions in the patellar tendon of intact rats at different 
phases of the oestrus cycle. Our findings indicate that expression of RXFP1 mRNA was the 
highest during proestrus followed by diestrus phases of the cycle. The expression was the 
lowest at estrus phase. RXFP2 mRNA expression was also the highest at proestrus 
followed by diestrus and the lowest at estrus. Meanwhile, RXFP1 and RXFP2 proteins 
were expressed the highest at proestrus followed by diestrus and the lowest at estrus and 
metestrus phases. No differences in expression levels of RXFP1 were noted between 
proestrus and diestrus phases of the cycle.  
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7.2.4 RXFP1 & RXFP2 expression in collateral ligament at different phases of the oestrus 
cycle 
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Figure 7-4 RXFP1& RXFP2 mRNA and protein expression levels in collateral ligament 
at different phases of the oestrus cycle. The expression of (A) RXFP1 mRNA (B) RXFP2 
mRNA and (C) RXFP1& RXFP2 protein expression in collateral ligament. mRNA and 
protein expressions were the highest at proestrus phase followed by diestrus phase. Ps-
proestrus; Es- estrus; Ms; metestrus; Ds; diestrus. Data were expressed as mean ± SEM and 
n = 6 per treatment group.  
 
 
 
Figure 7-4 shows (A) RXFP1 mRNA, (B) RXFP2 mRNA and (C) RXFP1 and 
RXFP2 over β-actin protein expressions in the collateral ligaments of intact rats at different 
phases of the oestrus cycle. Our findings indicate that RXFP1 mRNA expression was the 
highest at proestrus and slightly lower at diestrus. However, no significant different were 
noted in RXFP1 expression between these cycle phases. RXFP1 mRNA expression was the 
lowest at estrus and metestrus. Meanwhile, RXFP2 expression was the highest at proestrus 
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which was approximately 1.5 fold higher than diestrus. The expression was the lowest at 
estrus. RXFP1 and RXFP2 proteins expressions were also the highest at proestrus followed 
by diestrus and the lowest at estrus and metestrus.  It was noted that the levels of expression 
of RXFP2 mRNA and protein in the ligament exceed RXFP1 which was in contrast to the 
patellar tendon and hamstring muscles where RXFP1 isoform was the most dominant.  
 
Table 7-1 Serum hormone level in non ovariectomized rat at different phases of the oestrus 
cycle 
Oestrus cycle Hormone level 
(Mean ± SD) 
Oestrogen:  
- Proestrus  
- Estrus    
- Metestrus   
- Diestrus  
 
39.376± 4.56  pg/ml 
12.64± 2.98   pg/ml 
8.035± 1.09   pg/ml 
16.487± 2.32  pg/ml 
Progesterone  
- Proestrus  
- Estrus    
- Metestrus   
- Diestrus 
 
              22.87± 2.65  ng/ml 
14.92± 2.054  ng/ml 
              16.96± 2.73   ng/ml 
24.03± 3.085  ng/ml 
Relaxin  
- Proestrus  
- Estrus    
- Metestrus   
- Diestrus 
 
12.34 ± 3.96  pg/ml 
8.04 ± 1.17   pg/ml 
9.48 ± 1.75   pg/ml 
              18.03 ± 2.85 pg/ml 
  
 
Table 7 shows the levels of oestrogen, progesterone and relaxin at different phases 
of the cycle in intact rats. The level of oestrogen was the highest at proestrus which was 2.3 
fold higher than at diestrus. The level at estrus was lower than diestrus. Oestrogen level was 
the lowest at metestrus. Progesterone level was the highest at diestrus which was 1.7 times 
higher than at estrus. The level at proestrus was slightly lower than at diestrus. Progesterone 
level was the lowest at estrus. Meanwhile relaxin level was the highest at diestrus followed 
by proestrus. Relaxin level was the lowest at estrus which was nearly 2.5 times lower than 
at diestrus.  
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7.2.5 Correlation between serum relaxin and progesterone 
 
Figure 7-5 Correlation between serum relaxin and progesterone levels. 
 
 
A strong positive correlation (r = 0. 901) was observed between serum progesterone 
and relatin levels throughout the oestrus cycle.  
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7.3 Discussion 
This study reported for the first time changes in knee passive ROM in rats at 
different phases of the oestrus cycle. Our findings indicate that the ROM was the highest at 
proestrus which correlates with the highest serum oestrogen and progesterone levels and at 
diestrus which correlate with the highest serum progesterone levels. The serum hormone 
levels observed in this study were consistent with the reports in rats where progesterone and 
oestrogen levels peak at proestrus with another progesterone peak was observed at diestrus 
(Staley & Scharfman, 2005). The influence of female sex-hormone on knee laxity has been 
demonstrated by Woodhouse et al, (Woodhouse et al., 2007) where intact female rats 
received daily injection of synthetic oestrogen (ethinylestradiol) and progesterone 
(levonogestrel) have a significantly reduced ACL stiffness as compared to the non-treated 
rats during femur-ACL-tibia loaded-to-failure test. Dragoo et al, (Dragoo et al., 2009) 
demonstrated that combined administration of relaxin and oestrogen to guinea-pigs resulted 
in increased anterior tibial translation and a significantly weaker ACL on load-to-failure 
testing. Oestrogen at increasing doses were also reported to cause decreased human and 
rabbit ACLsfibroblast proliferation and collagen synthesis in culture (Thornton et al., 
2007). In humans, reports have indicated that high oestrogen levels in the ovulatory phases  
of the menstrual cycle were associated with high incidence of ACL injury (Beynnon et al., 
2006a) most probably due to decreased ACL laxity under the influence of this hormone 
(Shultz et al., 2005).  
Progesterone has also been reported to affect ligament laxity. In humans, correlation 
between serum progesterone levels and ACL stiffness has been suggested from the 
observed decreased in ACL laxity in the post-ovulatory (luteal) phase of the menstrual 
cycle (Park et al., 2009b; Romani et al., 2003). Human female athletes on oral 
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contraceptive pills containing high doses oestrogen and progesterone have greater ACL 
laxity than athletes not on OCPs (Lee et al., 2014). The mechanisms underlying oestrogen 
and progesterone effect on knee laxity is not fully understood, however there were 
evidences which indicate that oestrogen stimulates collagenase, an enzyme responsible for 
collagen breakdown (Rajabi, 1991). Oestrogen and progesterone have recently been shown 
to up-regulate the expression of the receptors for relaxin, RXFP1 and RXFP2 in knee 
structures of rats (Dehghan et al., 2014 ). Oestrogen and progesterone have also been 
shown to inhibit collagen synthesis in the tendon and skeletal muscles (Hansen et al., 
2009), which could contribute to the decreased in knee laxity. 
 Our findings also indicate that serum relaxin level was the highest at diestrus phase 
of the cycle. This was consistent with the reported increase in relaxin synthesis by the 
corpus luteum which was formed following ovulation and was maintained throughout 
diestrus phase of the cycle (Fields & Fields, 1985). In lower species such as rodents, relaxin 
affects laxity of the joints (Sherwood et al., 1992) although no correlation between 
peripheral joint laxity and serum relaxin levels were noted in human females during 
pregnancy (Schauberger et al., 1996). Despite of the lack of correlation, relaxin receptor 
expression has been identified in humans' ACL ligaments (Dragoo et al., 2003)and 
ligament fibroblast (Faryniarz et al., 2006) apart from the reported expression in the rats' 
patellar tendon and collateral ligaments (Dehghan et al., 2014). Relaxin has been reported 
to induce activity of matrix metalloproteinases (MMPs) which are involved in the collagen 
breakdown (Hashem et al., 2006; Naqvi et al., 2005). The high levels of relaxin at diestrus 
and proestrus as observed in this study could contribute to the increase in knee passive 
ROM. A strong correlation between serum relaxin and progesterone levels suggested that 
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both hormones might be involved in the increase in knee laxity especially during diestrus 
phases of the cycle. 
Our findings further indicated the changes in expression of two main receptors for 
relaxin,  RXFP1 and RXFP2 in the hamstring muscles, patellar tendon and collateral 
ligaments, which participate in maintaining knee stability. We have shown that RXFP1 and 
RXFP2 expressions were the highest during proestrus and diestrus phases of the cycle, with 
the expression levels during the former were slightly greater than the latter. In muscles and 
tendon, RXFP1 was the main isoform while in the ligament, RXFP2 levels was the highest. 
Increased expression of these receptor isoforms could explain the augmented response of 
the hamstring muscle, patellar tendon and collateral ligament to relaxin in causing a 
reduction of knee laxity as reflected from the increase in passive ROM.  
In conclusion, our study has shown that knee passive ROM in rats changes at 
different phases of the oestrus cycle, which most likely correlates with the changing levels 
of sex-steroid hormones. Additionally, fluctuation in relaxin level might also contribute to 
these observed effects. Differential regulation of RXFP1 and RXFP2 in the knee and its 
related structures by the changing levels of sex-steroids could complement changes in the 
relaxin levels to produce maximum effect on knee laxity. 
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8 CHAPTER 8 
Changes in Serum Sex-Steroid and Relaxin 
Levels throughout the Menstrual Cycle and its 
Relationship with Lateral and Medial Knee 
Laxities in Athlete and Non-Athlete Females 
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8.1 Introduction 
Knee joint, being the largest in the body, has its stability maintained by the shape of 
condyles and menisci and the surrounding structures. The four knee ligaments i.e. anterior 
cruciate ligament (ACL), posterior cruciate ligament (PCL), medial collateral ligament 
(MCL) and lateral collateral ligament (LCL), capsules (posteromedial and posterolateral) 
and iliotibial tract significantly contribute to maintaining knee stability (Fuss, 1989). In full 
extension, posterior oblique ligament and posteromedial capsule resist valgus stress while 
at 30 degrees flexion, MCL is the primary restraint (Messner & Gao, 1998). MCL together 
with posterior oblique ligament also resists abnormal internal tibial rotation (Kakarlapudi & 
Bickerstaff, 2000). Lateral collateral together with  popliteofibular and cruciate ligaments 
act as a primary stabilizer to the lateral opening of the joint (Ullrich et al., 2002). The laxity 
and integrity of MCL and LCL could be assessed by varus and vulgus stress tests (Romero 
et al., 2002).  
Menstrual cycle is associated with fluctuations in the levels of sex-steroids i.e. 
oestrogen and progesterone (Bäckström et al., 1982). In addition, testosterone (Liening et 
al., 2010) and relaxin (Johnson et al., 1993) levels were also reported to fluctuate. For a 28 
days menstrual cycle, days 1–9 marked the follicular phase with oestrogen predominates, 
days 10–14 marked the ovulatory phase, where oestrogen continues to prevail and reaches 
its peak while days 15–28 is the luteal phase where progesterone levels surpass that of 
oestrogen (Heitz et al., 1999). Relaxin, which is secreted by the ovaries and reaches its 
peak during the luteal phase, exerts multiple systemic effects especially during pregnancy 
(Parry & Vodstrcil, 2007). Meanwhile, a very low level of testosterone fluctuates 
throughout the cycle and is involved in oestrogen formation and preparation of the 
endometrium for decidualization (Belanger et al., 2004).  
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Female has two to ten times greater risk of non-traumatic knee injury than male 
(Hansen et al., 2013). The reason for this is unclear, however evidences suggested that 
female sex-hormones could influence knee laxity (Park et al., 2009a).  There were 
conflicting reports with regards to the effect of sex-hormones on knee laxity. While some 
reported that female anterior knee laxity was the highest in the follicular (pre-ovulatory) 
phase (Beynnon et al., 2006b; Hewett et al., 2007), others reported that laxity was the 
greatest in the ovulatory (Adachi et al., 2008; Park et al., 2009a; Wojtys et al., 1998) and 
luteal phases (Dragoo et al., 2011a; Hicks-Little CA, 2007 ) of the cycle. There were also 
reports which indicate that no differences in laxity was observed across phases of the 
menstrual cycle  (Karageanes et al., 2000 ). In addition to sex-steroids, relaxin was also 
reported to  influence knee ligament laxity where high relaxin levels correlate with the 
increase in  laxity (Dragoo et al., 2011a). 
 
While most studies reported the influence of sex-steroids on ACL laxity, changes in 
LCL and MCL laxities remains largely unknown. Additionally, relationship between sex-
steroids and relaxin with medial and lateral knee laxities have never been reported. We 
hypothesized that medial and lateral knee laxities changes at different phases of the 
menstrual cycle, therefore contributes towards difference in the incidence of non-contact 
knee injury with cycle phases. This study therefore aimed to investigate changes in medial 
and lateral knee laxities in female athletes and non-athletes at different menstrual cycle 
phases and their relationship with the levels of sex-steroids and relaxin in the circulation.  
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8.2 Results 
8.2.1 Body Composition Analyses 
 
Table 8-1 Characteristics and demographics at different phases of the menstrual cycle. 
*p<0.05 as compared to the athletes/non-athletes group 
Variables Athletes 
Mean ± SD 
Non-Athletes 
Mean ± SD 
Age (years) 20.3 ± 1.28 21.7 ± 2.27 
Height (cm) 163 ± 2.75 158.5 ± 5.28 
Weight (kg) 
- Menstruation  
- Follicular phase 
- Luteal phase 
 
58 ± 7.93 
57.5 ± 7.75 
58 ± 7.93 
 
56.5 ± 9.96 
55.7 ± 9.99 
56.1 ± 10 
Total Body Water (kg) 
- Menstruation  
- Follicular phase 
- Luteal phase 
 
30.8 ± 2.42* 
30.4 ± 2.33* 
30.6 ± 2.45* 
 
27 ± 3.19 
27 ± 3.1 
27.1 ± 3.2 
Total Protein (kg) 
- Menstruation  
- Follicular phase 
- Luteal phase 
 
7.18 ± 0.75 
7.21 ± 0.81 
7.21 ± 0.85 
 
8.24 ± 0.66* 
8.24 ± 0.66* 
8.22 ± 0.65* 
Total Mineral (kg) 
- Menstruation  
- Follicular phase 
- Luteal phase 
 
3.08 ± 0.25* 
3.03 ± 0.26* 
3.05 ± 0.27* 
 
2.73 ± 0.32 
2.69 ± 0.3 
2.71 ± 0.33 
Skeletal Muscle Mass (kg) 
- Menstruation  
- Follicular phase 
- Luteal phase 
 
23 ± 2.05* 
22.7 ± 2.02* 
22.8 ± 1.91* 
 
19.7 ± 2.55 
19.7 ± 2.47 
19.8 ± 2.58 
Body Fat Mass (kg) 
- Menstruation  
- Follicular phase 
- Luteal phase 
 
15.7 ± 5.34 (26.7%) 
15.9 ± 5.44 (26.7%) 
16.1 ± 5.5 (27.3%) 
 
19.1 ± 7.02(33.4%)* 
19 ± 7.34 (33 %)* 
19 ± 7.06 (33 %)* 
Body Mass Index (kg/m
2
) 
- Menstruation  
- Follicular phase 
- Luteal phase 
 
21.9 ± 2.55 
21.8 ± 2.59 
22 ± 2.67 
 
22.2 ± 3.37 
22.2 ± 3.51 
22.2 ± 3.39 
Waist Hip Ratio 0.82 ± 0.04 0.84 ± 0.06* 
Fitness Score (points) 75.1 ± 2.93* 69.3 ± 5.51 
Basal Metabolic Rate (kcal) 
- Menstruation  
- Follicular phase 
- Luteal phase 
 
1284 ± 75.8* 
1272 ± 75* 
1275 ± 77.2* 
 
1160 ± 96.6 
1167 ± 90.9 
1170 ± 94.7 
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Differences between body compartment in athletes and non-athletes at different 
phases of the menstrual cycle are shown in Table 3. Body composition measured by 
bioelectrical impedance analysis (BIA) method. The average total body water, total protein, 
total mineral, skeletal muscle mass, body fat mass, body mass index, waist hip ratio, fitness 
score and basal metabolic rate in athletes and non-athletes population were presented. Data 
showed the mean and standard deviation for the impedance measurements. Measurement 
was performed twice and the average values entered was the final measurement. The 
Levene’s equality of variable assumption stated that there were no significant difference 
between the variables (Cohen, 1988). 
 
Our findings indicate that athletes mean weight were generally higher than non-
athletes although the differences were not statistically significant.  The weight was higher 
in the luteal phase and menstruation as compared to the follicular phase. Athletes were in 
general have higher total body water than non-athletes. There were no significant difference 
in total body water between phases of the menstrual cycle. Meanwhile, total protein content 
was significantly higher in non-athletes as compared to athletes (p<0.05) and no significant 
difference was noted between phases of the menstrual cycle. Total mineral content in 
athletes was significantly higher than non-athletes and in both groups, total mineral content 
was the highest in the menstruation phase of the cycle.  
 
Skeletal muscle mass was found to be higher in athletes as compared to non-athletes 
(p<0.05) and was not significantly differ between phases of the menstrual cycle. Body fat 
mass was higher in non-athletes than athletes (p<0.05) which also not significantly differ at 
different cycle phases. Body mass index was slightly lower in athletes than non-athletes 
although no significant difference was noted between the two groups. Waist hip ratio was 
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significantly lower in athletes than non-athletes, while fitness score index was much higher 
in athletes than non-athletes (p<0.05). Finally, athletes have higher basal metabolic rate 
(BMR) than non-athletes with no significant difference was noted between phases of the 
menstrual cycle.  
 
Table 8-2 Knee joint varus/valgus angles on 0 and 30° 
 Athletes 
Mean(SD) 
Non-Athletes 
Mean (SD) 
T value P value Effect size 
Varus 0° 
- Menstruation  
- Follicular phase 
- Luteal phase 
 
3.75 (1.13) 
1.80 (0.43) 
5.45 (1.01) 
 
5.33(1.02) 
3.44(0.95) 
7.19(1.01) 
 
4.63 
7.00 
5.46 
 
<0.05 
<0.05 
<0.05 
 
1.47 
2.38 
1.72 
Valgus 0° 
- Menstruation  
- Follicular phase 
- Luteal phase 
 
3.09 (1.21) 
1.39 (0.51) 
4.76 (1.32) 
 
4.76(.89) 
3.44(.56) 
5.56(.72) 
 
4.99 
12.09 
2.37 
 
<0.05 
<0.05 
<0.05 
 
1.60 
3.83 
0.78 
Varus 30° 
- Menstruation  
- Follicular phase 
- Luteal phase 
 
11.48(1.21) 
9.35(0.75) 
14.25(1.18) 
 
12.80(1.03) 
10.95(0.72) 
15.11(1.05) 
 
3.74 
6.89 
2.44 
 
<0.05 
<0.05 
<0.05 
 
1.18 
2.18 
0.77 
Valgus 30° 
- Menstruation  
- Follicular phase 
- Luteal phase 
 
9.58(1.56) 
7.63(1.00) 
11.64(1.29) 
 
11.71(1.51) 
10.11(0.88) 
12.98(1.79) 
 
4.40 
8.36 
2.73 
 
<0.05 
<0.05 
<0.05 
 
1.39 
2.64 
0.87 
 
 
Table 8-2 shows the degree of knee angles at 0
o
 and 30
o
flexion  in varus and valgus stress 
tests in athletes and non-athletes. In varus 0
o
 test, non-athletes have higher knee angle as 
compared to athletes at all phases of the cycle. In both groups, knee angle was the highest 
in the luteal phase, followed by menstruation phase and the lowest in the follicular phase. 
In varus 30
o
 test, non-athletes have higher knee angle than athletes at all phases of the cycle 
(p<0.05). Similarly, in both groups, the highest knee angle was noted in the luteal phase, 
followed by menstruation and the lowest in the follicular phase.  
In valgus 0
o
 test, non-athletes appear to have greater knee angle in all phases of the 
cycle as compared to athletes (p<0.05). The highest angle was noted in the luteal phase, 
followed by menstruation and follicular phases. In valgus 30
o
 test, non-athletes was still 
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found to have greater knee angle as compared to athletes at all phases of the cycle with the 
highest noted in the luteal phase.  
 
8.2.2 Changes in Serum Sex-Steroids and Relaxin Levels at Different Phases of the 
Menstrual Cycle 
Table 10 shows the values of serum sex-steroids and relaxin levels in athletes and 
non-athletes females at different phases of the menstrual cycle. Our findings indicate that 
the highest oestrogen level was observed in the follicular phase in both groups. There were 
no significant differences in oestrogen levels between athletes and non-athletes. 
Meanwhile, progesterone levels were the highest in luteal phase with athletes have a 
significantly lower progesterone level than non-athletes. Similarly, progesterone level was 
also higher in non-athletes as compared to athletes at menstruation, although this level was 
approximately 12 times lower than in the luteal phase of the cycle. No significant 
difference in the level was observed in the follicular phase between the two groups.  
 
Meanwhile, testosterone level, which was far lower than oestrogen and 
progesterone, was found to be higher in non-athletes than athletes. In the non-athletes, 
testosterone level was the highest in the follicular phase followed by luteal phase. The 
lowest level was noted in athletes at menstruation. Serum level of relaxin was the highest in 
athletes as compared to the non-athletes, particularly during the follicular and luteal phases 
of the cycle. No significant difference in relaxin level was noted between the two groups 
during the menstruation phase.  
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Table 8-3 Sex-steroids and relaxin levels at different phases 
 Athletes 
Mean(SD) 
Non-Athletes 
Mean(SD) 
T value P value Effect size 
Oestrogen (pg/ml) 
- Menstruation  
- Follicular phase 
- Luteal phase 
 
170.20(39.86) 
507.35(161.52) 
439.50(150.54) 
 
197.65(71.97) 
492.30(276.96) 
409.45(163.89) 
 
1.49 
0.21 
0.60 
 
>0.05 
>0.05 
>0.05 
 
0.50 
0.07 
0.19 
 
Progesterone (ng/ml) 
- Menstruation  
- Follicular phase 
- Luteal phase 
 
2.28(1.00) 
1.80(1.24) 
24.74(11.34) 
 
4.19(2.53) 
1.74(0.60) 
31.33(8.09) 
 
3.14 
0.20 
2.12 
 
<0.05
**
 
>0.05 
<0.05
**
 
 
1.08 
0.07 
0.68 
 
Testosterone (ng/ml) 
- Menstruation  
- Follicular phase 
- Luteal phase 
 
0.82(0.38) 
1.21(0.54) 
1.22(0.61) 
 
1.24(0.47) 
1.39(0.48) 
1.37(0.63) 
 
3.08 
1.12 
0.76 
 
<0.05
**
 
>0.05 
>0.05 
 
0.99 
0.36 
0.24 
 
Relaxin (pg/ml) 
- Menstruation  
- Follicular phase 
- Luteal phase 
 
2.10(0.56) 
1.38(0.87) 
15.58(5.36) 
 
1.69(1.27) 
0.34(0.45) 
10.35(2.96) 
 
1.33 
4.73 
3.82 
 
>0.05 
<0.05
**
 
<0.05
**
 
 
0.45 
1.58 
1.26 
 
 
8.2.3 Correlations between Sex-Steroids and Relaxin Levels with Knee Joint Angles 
 
Table 8-4 Correlation of sex steroid and knee angles in total polulation 
 0 
o
 30 
o
 
 varus valgus varus valgus 
Oestrogen 
- Pearson 
 
-0.15 
 
-0.17 
 
-0.09 
 
-0.14 
Progesterone 
- Spearman 
 
0.70** 
 
0.62** 
 
0.76** 
 
0.62** 
Testosterone 
- Pearson 
 
0.07 
 
0.12 
 
0.12 
 
0.07 
Relaxin 
- Spearman 
 
0.58** 
 
0.50** 
 
0.65** 
 
0.47** 
 
 
Table 8-5 Correlation of sex steroid and Knee angles in athletes 
 0 
o
 30 
o
 
 varus valgus varus valgus 
Oestrogen 
- Pearson 
 
-0.13 
 
-0.15 
 
-0.04 
 
-0.14 
Progesterone 
- Spearman 
 
0.66** 
 
0.58** 
 
0.70** 
 
0.59** 
Testosterone 
- Pearson 
 
0.05 
 
0.03 
 
0.06 
 
-0.06 
Relaxin 
- Spearman 
 
0.69** 
 
0.65** 
 
0.74** 
 
0.64** 
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Table 8-6 Correlation of sex steroid and Knee angle in non-athletes 
 0 
o
 30 
o
 
 varus valgus varus valgus 
Oestrogen 
- Pearson 
 
-0.17 
 
-0.26* 
 
-0.13 
 
-0.17 
Progesterone 
Spearman 
 
0.72** 
 
0.65** 
 
0.80** 
 
0.60** 
Testosterone 
- Pearson 
 
-0.10 
 
0.01 
 
0.01 
 
0.00 
Relaxin 
- Spearman 
 
0.81** 
 
0.73** 
 
0.80** 
 
0.62** 
* Correlation is significant at the 0.05 level 
** Correlation is significant at the 0.01 level 
 
Table 11, 12 and 13 show correlation between sex-steroid and knee joint angle in all 
subjects, in athletes and non-athletes respectively. In general, there were strong correlations 
between serum progesterone and relaxin levels with knee joint angles as determined by 
varus and valgus tests (both at 0
o
 and 30
o
). In athletes, a significant correlation between 
progesterone and relaxin levels with knee joint angles in both tests were also observed. 
Similar observation was noted in non-athlete subjects. The highest correlation was 
observedbetween serum progesterone and relaxin levels with knee angle at 30
0
 in varus test 
in athletes and non-athletes.  
 
8.3 Discussion 
Our findings revealed the followings: (i) athletes have higher total body water, total 
mineral content, skeletal muscle mass, fitness score and BMR however lower total protein 
content, body fat mass and waist to hip ratio as compared to non-athletes, (ii) athletes have 
lower medial and lateral knee angles than non-athletes, (iii) both athletes and non-athletes 
have the highest medial and lateral knee angles in the luteal phase of the cycle, (iv) in both 
athletes and non-athletes, the levels of progesterone and relaxin were the highest in the 
luteal phase while oestrogen was the highest in the follicular phase, (v) progesterone levels 
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in athletes was lower than non-athletes in the luteal and menstruation phases of the cycle 
and (vi) there was a strong correlation between serum progesterone and relaxin levels and 
knee joint angles (both in varus and valgus tests) in athletes and non-athletes. 
 
Our findings which indicate that medial and lateral knee laxities were the highest in 
the luteal phase of the cycle correlate with higher serum progesterone and relaxin levels and 
were supported by several previous observations. Higher incidence of anterior cruciate 
ligament tear and non-contact knee injury in the post-ovulatory  (Zazulak et al., 2006) and 
luteal (Hicks-Little CA, 2007 ; Park et al., 2009a) phases have been reported. This increase 
could be attributed to higher plasma progesterone and relaxin levels in the luteal phase as 
both hormones have been implicated in the increase in knee laxity. Recent evidence 
suggested that anterior laxity and valgus movement of the knee correlate with blood 
progesterone level (Bell DR, 2014 ). Progesterone, which levels is high during pregnancy 
has been implicated in the increase in medial collateral ligamentlaxity in rabbits (Hart et al., 
2000). Meanwhile, serum biomarkers of collagen degradation (ICTP) was reported to be 
high in early luteal phase in eumenorrhoeic women which correlates with increased anterior 
knee laxity (Shultz et al., 2012), pointing towards progesterone influence. Heitz et al (Heitz 
et al., 1999)reported that a significant increase in ACL laxitywas observed with peak levels 
of progesterone in physically active females.  
 
Relaxin levels also correlated with the increase in knee laxity. Our findings indicate 
that the level of relaxin was the highest in the luteal phase and correlate with the increase in 
serum progesterone level. This finding is consistent with the report that serum relaxin levels 
positively correlates with progesterone (Dragoo et al., 2011b). Futhermore, Dragoo et al, 
(Dragoo et al., 2011a) reported a strong correlation between serum relaxin levels and 
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incidence of ACL tear in elite collegiate female athletes .Relaxin administration to guinea 
pigs also resulted in weaker ACL laxity (Dragoo et al., 2009). It has been proposed that 
relaxin acts via several mechanisms to cause increase in the laxity of the ligaments. Relaxin 
has been reported to up-regulate matrix metalloproteases (MMPs) (Naqvi et al., 2005) 
which cause increase collagen breakdown, therefore increase ligament laxity (Pearson et 
al., 2011). Progesterone may enhance relaxin action which could result in a further decrease 
in the laxity of the ligaments. Progesterone has been reported to up-regulates the expression 
of relaxin receptor isoforms RXFP1 and RXFP2 in rat's knee joint (Dehghan et al., 2014 ). 
Besides the rats' knee, relaxin receptors have also been found in human's knee (Dragoo et 
al., 2003)and carpometacarpal (Wolf et al., 2013) joints. 
 
We have shown that medial and lateral knee laxities in non-athletes as measured by 
varus and valgus tests at 0
o
 and 30
o
 were higher than athlete females with the highest 
laxities in the luteal phase of the cycle. Progesterone levels were higher in non-athletes than 
athletes, which could be one of the reason for the increase in laxity as previously discussed. 
There were no significant differences in oestrogen and testosterone levels between athletes 
and non-athletes in the luteal and follicular phases of the cycle although testosterone level 
is slightly lower in athlete during menstruation phase. Although oestrogen level was high in 
the follicular phase, laxity appears to be the lowest. Our finding is in contrast with several 
studies which reported increased incidence of non-contact knee injury during ovulatory 
phases of the cycle (Park et al., 2009b; Romani et al., 2003; Wojtys et al., 2002), correlates 
with high levels of oestrogen. We concluded that oestrogen could confer protection against 
non-contact knee injury in female. In addition, our findings also revealed that serum 
progesterone and relaxin levels were the lowest in the follicular phase, which suggest that 
these hormones may have little influence on knee laxity during this phase. Our finding was 
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supported by the observation by Wojtys et al, (Wojtys et al., 1998) who reported 
significantly fewer injuries in the follicular phase as compared to post-ovulatory phase. 
Meanwhile, in this study, the influence of testosterone on medial and lateral knee laxities 
were rather vague. No significant difference in testosterone levels were noted between 
athletes and non-athletes females during the follicular and luteal phases of the cycle. A 
recent finding by O’Leary et al, (O'Leary et al., 2013) indicated that prolonged aerobic 
exercise in women with normal menstrual cycle can induce a short-term elevation in 
plasma testosterone level, however this effect was not seen in our study.  Shultz et al, 
(Shultz et al., 2004; Shultz et al., 2005) reported that testosterone effect on knee laxity 
could be masked by the effect of other predominant hormones namely oestrogen and 
progesterone.  
Our finding revealed that serum relaxin level in athletes is approximately 4 and 1.5 
times higher during the follicular phase and luteal phase respectively than non-athletes. In 
athletes, relaxin level is the highest in the luteal phase (15.58±5.36pg/ml) which suggest 
that relaxin may not have a role in determining knee  laxity in humans. The increase in 
medial and lateral knee laxity in the luteal phase could be due to higher serum 
progesterone. The lower knee laxity in athletes could also be contributed by a greater 
muscular control in view that athletes have greater skeletal muscle mass and greater fitness 
ratio which could help to exert greater tone that resist an increase in knee joint movement. 
In this study, varus and valgus tests were performed by three (3) experience examiners and 
were found to have high intra-rater reliability and adequate inter-rater reliability. Wiertsema 
et al, (Wiertsema et al., 2008) reported that clinical examination such as theLachman test is 
a reliable measure to determine anterior–posterior laxity of the ACL while  arthrometer was 
used mainly to determine anterior tibiofemoral movement with limited application in 
determining medial and lateral laxities of the knee.  
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In conclusion, our study has demonstrated for the first time changes in medial and 
lateral knee laxities in athletes and non-athletes females at different phases of the menstrual 
cycle. We have shown that serum sex-hormones in particular progesterone has a strong 
association with the increase in medial and lateral laxities of the knee. Although relaxin 
levels is increased in parallel to the increase in progesterone level, this hormone however 
may have little influence on laxity. In contrast to the popular belief, oestrogen may not have 
role in the increase in laxity particularly in the follicular phase of the cycle.  
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9 CHAPTER 9: CONCLUSION 
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In this study, we investigated the effect of sex-steroids (oestrogen, progesterone, 
testosterone and relaxin) and oestrous cycle stages/menstrual cycle phases on knee joint 
laxity. The key findings of this thesis are as follows:  
 
1. RXFP1 is the main isoform expressed in the hamstring muscle, patellar tendon and 
collateral ligaments of the knee joint. 
2. RXFP1 is up regulated by oestrogen and progesterone, but down-regulated by 
testosterone. 
3. RXFP2 expression is up regulated by oestrogen at doses exceeding 2 µg/ml and 
progesterone in the hamstring muscle, patellar tendon and collateral ligament, but 
there is no significant effect of 0.2 µg/ml oestrogen on this receptor expression.   
4. RXFP1 and RXFP2 are up regulated in the hamstring muscle as compared with 
patellar tendon and collateral ligaments. 
5. RXFP1 is up regulated in the hamstring muscle treated by oestrogen, but no 
significant changes in RXFP2 expression. 
6. RXFP1 and RXFP2 up regulated by progesterone, but down regulated by 
testosterone. 
7. Higher expression of RXFP1 in the patellar tendon under oestrogen or progesterone 
treatments than in the ligament, but no significant changes in RXFP2 expression in 
tendon and ligament, except following 50 µg/ml oestrogen and progesterone 
treatment.  
8. Knee range of motion is increased under the effect of 20 and 50 µg/ml oestrogen 
and progesterone and decreased with presence of testosterone. 
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9. Oestrogen antagonists (ICI 182/780, MPP, PHTPP) administration blocked 
oestrogen influence on RXFP1 and RXFP2 expressions in hamstring muscle, 
patellar tendon, and collateral ligament. 
10.  Knee range of motion is reduced following treatment with 0.2 µg/ml dose 
oestrogen + ICI 182/780/ MPP/ PHTPP 
11.  Decreased knee range of motion and RXFP1 and RXFP2 expressions in presence 
of mifepristone + progesterone in all hamstring muscle, patellar tendon and 
collateral ligaments tissues.   
12.  RXFP1andRXFP2expressionsare increased in presence of flutamide and finastride 
in hamstring muscle, patellar tendon and collateral ligament. 
13.  Knee range of motion in increased in the presence of flutamide and finastride.  
14. The correlations of RXFP1andRXFP2 expressions with knee range of motion are 
observed at proestrus and diestrus stages of the oestrous cycle. 
15. The mean of varus-valgus angle is higher in the non-athletes group compared to 
athletes group throughout the menstrual cycle phases. 
16.  Greater varus-valgus angle is observed in luteal phase than follicular phase in 
athletes and non-athletes population 
17. There is a significant correlation between progesterone/relaxin and knee laxity 
among athletes and non-athletes groups in different phases of the menstrual cycle 
18. There is no significant correlation between oestrogen/testosterone between both 
athletes and non-athletes groups in different phases of the menstrual cycle. 
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In conclusion, investigation of complex relationship between several hormones and 
expression of relaxin receptor isoforms on rat knee tissues indicated that RXFP1 is the 
main isoform in these tissues and expressed higher in the hamstring muscle more than 
patellar tendon and collateral ligaments. Progesterone and oestrogen up regulated and 
testosterone down regulated the RXFP1 and RXFP2 expressions in the rat knee tissues.This 
effect could be due to a decrease of collagen content in these tissues and extracellular 
matrix in the presence of relaxin hormone. Hence, the effects of reproductive hormones on 
knee surrounding tissues suggested that these hormones influence knee laxity. We 
postulated that increase in plasma testosterone may result in down-regulation of relaxin 
receptors in these knee structures, thus could help to reduce knee laxity in exercising 
women. The highest level of progesterone in the luteal phase can cause an increase in knee 
laxity, rendering the knee to be more susceptible towards a non-contact injury. In addition 
to this, testosterone has also been reported to increase the strength of the muscles that 
control knee joint movement.  
 
Moreover, rat knee range of motion increased under treatment of oestrogen and 
progesterone and decreased under testosterone. Progesterone treatment resulted in the 
highest increase in the knee range of motion correlated to both relaxin receptor isoforms’ 
expressions in patellar tendon and lateral collateral ligaments. Increased expression of 
RXFP1, as compared with RXFP2, mediates increased knee joint laxity in response to high 
doses of oestrogen and physiological dose of progesterone. Our findings thus could explain 
higher vulnerability of female than male towards non-traumatic knee with oestrogen and 
progesterone fluctuation at various phases of reproductive cycle.  
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Our results also illustrated that testosterone by interceding relaxin receptors decreased 
knee laxity and thereby range of motion. However, flutamide and finasteride antagonists 
showed suppressor effect on testosterone and consequently altered RXFP1 and RXFP2 
expressions in hamstring muscle, patellar tendon, and lateral collateral ligaments, 
inequitably.Taken together, these findings may explain increased knee joint stiffness in 
female following testosterone administration. These findings provide better understanding 
of the underlying mechanism of sex-steroid modulation of relaxin receptors expression and 
its influence on the knee laxity. Further studies should investigate the direct and indirect 
mechanisms underlying these associations. 
 
In this study, we also examined the expression of relaxin receptor during oestrous cycle. 
Higher expressions of RXFP1and RXFP2 observed in proestrous and diestrous stages 
correlated to higher knee range of motion. Progesterone and relaxin levels were at their 
highest in the same stage as greater knee range of motion was observed. Relaxin hormone 
can stimulates degradation of collagen content and prevents fibrogenesis (Samuel, 2005). 
Ligamentous and tendonous laxity can partially be influenced by relaxin hormone during 
proestrous and diestrous stages.  
 
We evaluated serum oestrogen, progesterone, testosterone, relaxin hormones, and 
varus-valgus assessments in female athletes and non-athletes. In line with our previous 
findings, we found there was positive correlation between progesterone/relaxin and knee 
rotational movement during different phases of a menstrual cycle. The knee rotational 
movement for athletes and non-athletes did not show any relationship with 
oestrogen/testosterone. The highest level of progesterone/relaxin and the greatest angle of 
knee were observed in luteal phase in both groups and lowest level observed in follicular 
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phase. Since progesterone and relaxin are involved in collagen metabolism, these hormones 
may influence knee joint laxity via this mechanism.  
 
This study provided insight into the effect of sex-steroids on RXFP1 and RXFP2 
expressions on the hamstring muscle, patellar tendon, and collateral ligament, and 
relationship between oestrogen, progesterone, testosterone, and relaxin with knee rotational 
movement during reproductive cycles.  Increased expression of RXFP1, as compared with 
RXFP2, mediates increased knee joint laxity in response to high doses oestrogen and 
progesterone and at proestrous and diestrous stages of the oestrous cycle. Our findings thus 
could explain higher vulnerability of female than male towards non-traumatic knee with 
oestrogen and progesterone fluctuation at various phases of menstrual cycle. Finally, these 
findings provide better understanding of the underlying mechanism of sex steroid 
modulation and relaxin hormone interaction and its influence on the knee laxity.Future 
studies on fluctuation of sex steroid hormones interaction in both gender are warranted to 
elucidate the physiological cause of this selectivity in the impact of relaxin and endocrine 
system on the phenotype of various tissue. 
 
The human body joints’ appears to react to menstruation hormones levels (oestrogen, 
progesterone, testosterone, and relaxin) by causing a change at the cellular level of the knee 
tissue thus resulting in changing of knee laxity. Endogenous and exogenous female sex 
steroids have effect on many metabolic parameters but these agents do not restrict the 
female athletes to compete in sports, recreationally or professionally. It is important to 
recognize all components of the knee injury mechanism in order to address the potential for 
prevention and screening programs that considers for risk factors and multifaceted interplay 
of these factors. More studies is needed to investigate the influence of hormones on joint 
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laxity as well as the influence of other factors that are associated with the female menstrual 
cycle, such as weight, age, altered reaction times, the circulation of hormones, shoe-surface, 
athletes level, fatigue, environmental conditions, water retention, to find an explanation for 
the disproportional distribution of knee injuries. 
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AppendicesAppendix A: reagent preparation 
SDS-page 
1. Acrylamide (Acrylamide, MW: 71.08 kd and bisacrylamide, MW 154.17 kda) 
 
Stock concentration of acrylamide: 30% 
Stock concentration of bisacrylamide: 0.8%  
Acrylamide (30g) and bisacrylamide (0.8g) was dissolved in double distilled water. 
The solutions were topped up to 100ml with double distilled water and stored in dark 
at 4 ºC. 
 
2. 4 x resolving buffer (ph 8.8) (Tris, MW: 121.1 kda) 
 
Stock solution (1.5M):  18.17g of tris was dissolved in double distilled water and 
volume topped up to 100ml. The solution was stored at 4ºC. 
 
3. 4 x stacking buffer (ph 6.8) (Tris, MW: 121.1 kdh) 
 
Stock solution (0.5M): 3.03g of tris was dissolved in double distilled water and volume 
topped up to 50ml. The solution was stored at 4ºC. 
 
4. Sodium dodoceyl sulphate (SDS) (MW: 288.38 kdh) 
 
Stock solution (10%):  5g of sodium dodoceyl sulphate was dissolved in double 
distilled water and volume topped up to 50ml. The solution was stored at 4 ºC. 
 
5. Ammonium persulphate (APS) (MW : 228.2 kda) 
 
Stock solution (10%):  0.1g of ammonium persulphate was dissolved in double 
distilled water and volume topped up to 1ml. The solution was stored at 4 ºC. 
 
6. 2 x treatment buffer 
 
Stock concentration of tris: 0.125M (ph 6.8) 
Stock concentration of SDS: 4% 
Stock concentration of glycerol: 20% 
Stock concentration of dithiothreitol: 0.2M 
Stock concentration of bromophenol blue: 0.02% 
Glycerol (2ml), dithiothreitol (0.31g), bromophenol blue (0.002g), SDS (4ml of 10% 
SDS) and tris (2.5ml of 0.5M tris) was dissolved in double distilled water. The solution 
were topped up to 10ml with double distilled water and stored at 20ºC. 
 
178 
 
7. Tank buffer (Tris,MW: 121.1 kd and glycine, MW 75.07 kda) 
 
Stock concentration of tris: 0.025M (ph 8.3) 
Stock concentration of glycine: 0.192M 
Stock concentration of SDS: 0.1% 
Tris (3.03g), glycine (14.41 g) and SDS (1g) was dissolved in double distilled water. 
The solution were topped up to 1000L with double distilled water and stored at RTºC. 
 
8. Recipe of 2 mini resolving SDS-page gel (gel percentage: 12%) 
 
 
Composition volume 
Acrylamide  8.3ml 
4 x resolving buffer 4.0ml 
Sodium dodoceyl sulphate 0.2ml 
Ammonium persulphate 100µl 
Double distilled water  6.4ml 
TEMED  6.75µl 
 
9. Recipe of 2 mini stacking SDS-page gel 
 
Composition volume 
Acrylamide 0.665ml 
4 x stacking buffer 1.25ml 
Sodium dodoceyl sulphate 50µl 
Ammonium persulphate 25µl 
Double distilled water 3ml 
TEMED 2.5µ 
 
Reagent used for Coomassie blue staining 
1. Coomassie blue solution 
 
Stock concentration of coomassie: 0.025% 
Stock concentration of methanol: 40% 
Stock concentration of acetic acid: 7% 
Coomassie (0.05g), methanol (80ml) and acetic acid (14ml) was topped up to 200ml 
with double distilled water and stored at RTºC. 
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2. Destain solution ǀ 
 
Stock concentration of methanol: 40% 
Stock concentration of acetic acid: 7% 
Methanol (80ml) and acetic acid (14ml) was topped up to 200ml with double 
distilled water and stored at RTºC. 
 
3. Destain solution ǁ 
 
Stock concentration of methanol: 40% 
Stock concentration of acetic acid: 7% 
Methanol (10ml) and acetic acid (14ml) was topped up to 200ml with double 
distilled water and stored at RTºC. 
 
 
Western-blot 
1. Towbin buffer 
 
Stock concentration of tris: 25mM 
Stock concentration of glycine: 192mM 
Stock concentration of glycine: 192mM 
Tris (3.03g) and glycine (14.4g) was dissolved in double distilled water. The 
solution were topped up to 1L with double distilled water and stored at RT. 
 
2. Phosphate buffer saline-tween (TBST) 
 
Stock concentration of bovine serum albumin (BSA): 1% 
Stock concentration of tween: 0.1% 
Bovine serum albumin (2.5ml) and tween (250µl) was dissolved in double distilled 
water. The solution were topped up to 250ml with double distilled water and stored 
at 4ºC. 
 
 
3. Phosphate buffer saline 
 
Stock concentration of potassium phosphate (Kh2PO4): 
Stock concentration of sodium phosphate (NA2HPO4): 
Stock concentration of sodium chloride (NACl2): 
Stock concentration of potassium chloride (KCl): 
Potassium phosphate (0.12g), sodium phosphate (0.72g), sodium chloride (4.0g) 
and potassium chloride (0.1g) was dissolved in double distilled water. The solution 
were topped up to 500ml with double distilled water and stored at 4ºC. 
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